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Thesis summary  
 
The blood-brain barrier (BBB) and the blood-tumour barrier (BTB) represent insidious 
obstacles for the delivery of anti-cancer agents to solid brain tumours, not only because 
of their morphological features, but also due to the presence of the drug efflux transporter 
breast cancer resistant protein (BCRP), localised at both the BBB and BTB. This efflux 
transporter restricts the permeation of anti-cancer agents across both barriers leading to 
suboptimal concentrations of drugs at the intended site of action.  
This work examined 13 naturally occurring phytochemicals, which were screened for 
their dual ability to modulate the efflux function of BCRP in addition to their anti-cancer 
properties in human LN229 glioblastoma cells, namely: (i) inhibition of cellular migration; 
(ii) activation of apoptosis; (iii) reactive oxygen species (ROS) production and (iv) 
activation of caspase pathways. Phytochemicals displayed minimal cytotoxicity, were 
able to modulate BCRP which led to enhancing the permeability of the fluorescent probe 
substrate H33342, in addition to inhibiting cellular migration. Hesperetin and baicalin 
displayed the optimal modulatory potential and demonstrated a similar ability to generate 
ROS and activate Caspase-3/7 when compared to the anti-cancer agents methotrexate 
and temozolomide. Subsequently, hesperetin was progressed as the optimal candidate, 
and its ability to permeate across the BBB was confirmed after conducting a permeability 
study using an in-vitro primary porcine brain microvascular endothelial cell (PBMEC) 
BBB model. We demonstrated that hesperetin was highly permeable across the BBB, 
can modulate the efflux function of BCRP and overall enhance the apparent permeability 
(Papp) of mitoxantrone and methotrexate. Thereafter, we assessed the impact of shear 
stress fashioned by laminal flow on the morphology of PBMEC using a Quasi Vivo 600® 
perfusion system. The results displayed a significant increase in Transepithelial 
Electrical Resistance (TEER) values, improved formation of zonula occludens-1 (ZO-1), 
and higher expression of efflux transporter proteins, suggesting the formation of a better 
in-vitro BBB model with hesperetin still being highly permeable across the barrier further 
confirming its ability to bypass the BBB and reach the BTB. This work highlights the anti-
cancer and BCRP modulatory capabilities of phytochemicals as well as the ability of 
hesperetin to bypass the BBB.  
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Introduction   
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 Cancer biology and pharmacology 
 
The term ‘cancer’ can be defined as a group of cells that grow at an uncontrollable 
rate disregarding tenets of cell division. In healthy mammals, cells are subjected 
to many signals that direct them to either divide, differentiate or die. Cancer cells, 
however, are immune to these signals and consequently grow and proliferate 
uncontrollably. If cancer cells are allowed to grow and spread uncontrolled, the 
consequences can be deadly. Approximately 90% of cancer related mortalities 
are due to the dispersion of cancerous cells across the body, a process termed 
metastasis (Emuss, 2006). Tumours can be benign or malignant with malignant 
tumours being larger in size (> 3 cm) and capable of spreading at a  greater rate 
than benign tumours (Shields et al., 2017).   
 
The cell cycle is normally stringently controlled by various regulatory pathways 
therefore, it is not surprising that genes responsible for cell cycle regulation are 
often found mis-regulated and mutated in cancers (Table 1.1) (Collins et al., 
1997, Malumbres and Barbacid, 2009, Kastan and Bartek, 2004). Genes where 
a mutation leads to a gain or an increased level in function which results in 
malignancies, are called protooncogenes and typically encode for growth 
promoting proteins. Genes that lead to a reduced or loss in function, typically 
result in malignancies and are termed tumour suppressor genes, encoding 
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Table 1.1 Examples of gene mutations in cancer 
Gene Protein Function Alteration in 
cancer 
CCND1,2,3 D cyclins Positive regulator of CDK4/6 Overexpressed 
CCNE1 Cyclin E1 Positive regulator for CDK2 Overexpressed, 
deregulated 
RB1 pRb Repress E2f transcription Mutated, deleted 
TP53 p53 Check points, apoptosis Mutated, deleted 
MTBP MDM-2 Inhibitor of p53 Overexpressed 
CDKN2A p14 Arf,a Activator of p53 Mutated, deleted 
ATM ATM Checkpoints, repair Mutated, deleted 
 
Table adapted from (De Vita and Lawrence, 2011) 
 
 
Hanahan and Weinberg (2000) suggested that there are six hallmarks of cancer 
that, when combined together, result in a malignant growth (Figure 1.1). These 
were updated a decade later to include 4 additional emerging hallmarks (Figure 
1.2). Each of these physiological deviations obtained during tumour development 
signifies a complication in the anti-cancer defence mechanism. While cancers 
arising from different tissues have some differences, it is assumed that most, if 
not all human cancers share these ten hallmarks (Hanahan and Weinberg, 2000, 
Hanahan and Weinberg, 2011). 
Cancer cells have a high rate of proliferation and cell growth, consequently, they 
require a high level of amino acids, lipids, nucleotides, and energy. To fulfil that 
high demand of energy levels, oxidative phosphorylation and glycolysis are 
promoted which leads to an increase in the production of ATP. This insures the 
survival of cancer cells (Tennant et al., 2009). 
Cancer cells not only need glucose to produce energy, but also utilise it under 
hypoxic conditions to regulate various pathways that affect cancer progression. 
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One of these pathways include metabolic adaptation. Cancer cells undergo 
metabolic adaptation when the tumour microenvironment is derived of any 
oxygen supply (hypoxic conditions), and therefore glucose transport genes such 
as GLUT1 and GLUT3 are promoted. As a result of metabolic adaption, an 
increase in reactive oxygen species (ROS) production occurs which can activate 
hypoxia inducible factors (HIFs), which play an essential role in cancer initiation, 
proliferation and growth (Dang et al., 2008, Bertout et al., 2008). This metabolic 
imbalance and the pro-oxidative state of cancer cells is supported and maintained 
by many changes in the cellular metabolic activity, oncogenic alteration and as a 
result, the loss of the functions of tumour suppressor genes such as p53 




Figure 1.1 Six hallmarks of cancer 
The six hallmarks are: (i) evading cell death (apoptosis); (ii) self-sufficiency in 
growth signals; (iii) insensitivity to anti-growth signals; (iv) tissue invasion and 
metastasis; (v) sustained angiogenesis and (vi) unlimited replicative power 
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Figure 1.2 Emerging cancer hallmarks  
The 4 additional hallmarks that were later updated are, (i) avoiding immune 
destruction, (ii) tumour promoting inflammation, (iii) genome instability and 






Persistent intrinsic oxidative stress is one of the main features of cancer cells. 
Excessive ROS generation was reported in in-vitro cancer models such as breast 
and ovarian cancer, melanoma, pancreatic carcinoma, and neuroblastoma, 
where an increase in hydrogen peroxide has been reported when compared to 
healthy tissue (Szatrowski and Nathan, 1991, Liou and Storz, 2010). 
Cellular ROS can be generally divided into two main categories: (i) ROS 
generation as a biproduct of biological processes such as mitochondrial oxidative 
metabolism (Finkel, 2011, Grivennikova and Vinogradov, 2013); (ii) intentional 
ROS generation as a cellular response or cell defence mechanism to xenobiotics, 
bacterial invasion and cytokines (Starkov, 2008, Zakki et al., 2018).   
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ROS at appropriate levels has been shown to play an integral role in the 
modulation of numerous physiologic responses as part of regulating cells 
signalling (Schieber and Chandel, 2014, Liu et al., 2008). Within the normal 
threshold of ROS in healthy cells, ROS acts as a signal for peroxide mediated 
oxidation of protein cysteine residues which can trigger cell proliferation 
(Schieber and Chandel, 2014). In addition, it mediates DNA repair by inducing 
p53 (Liu et al., 2008). However, if production of ROS exceeds that threshold and 
is no longer controlled by the redox homeostasis, oxidative DNA damage can 
occur which leads to cells death.  
 
An increase in intracellular ROS levels, in addition to a flawed antioxidant system, 
can lead to the rise of pathological conditions (Rhee, 2006) such as cancer 
(Dhillon et al., 2014), inflammation (Nijland et al., 2014) heart disease (Dhar and 
Prasad, 2014) and diabetes (Rehman et al., 2014). Increased ROS production 
within the cell leads to the depolarisation of the mitochondria which releases 
cytochrome C. Normally, cytochrome C contributes to the synthesis of ATP, 
however when the cell receives an apoptotic signal, cytochrome C is released 
into the cytosol which triggers cell death.  This process involves the induction of 
caspase-9 which stimulates nucleotide binding to APAF-1 (apoptotic protein 
activation factor 1), that results in the activation of caspase (NavaneethaKrishnan 
et al., 2018). Increased ROS levels have also been associated with the mediated 
cleavage of caspase-3 via triggering caspase-8 (Redza-Dutordoir and Averill-
Bates, 2016). In cancer cells, ROS generation elevates the rate of mutagenicity 
and leads to chromosomal instability, DNA base pairs damage and hence 
promotes cancer progression (Radisky et al., 2005, Samper et al., 2003). 
Oxidative stress also plays a role in inactivation of apoptotic proteins by 
upregulating anti-apoptotic genes such as BcL-2 (McCubrey et al., 2007). 
Additionally, ROS generation in cancer cells can participate in the metastatic 
process by stimulating the cells to invade surrounding healthy tissue, form new 
blood vessels (angiogenesis) and eventually migrate to new locations (Mori et al., 
2004, Coussens and Werb, 1996). 
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Apoptosis is an orchestrated and well organised process that occurs in 
pathological and physiological conditions (Wong, 2011). In cancer, there is an 
imbalance between cell proliferation and cell death, with cells that otherwise are 
due to undergo apoptosis, fail to receive an appropriate cascade signal and 
develop the ability to evade the apoptosis regulatory process (Wong, 2011). 
TP53, which codes for p53, is one of the most studied tumour suppressor genes 
due to its ability to regulate cellular metabolism, transcriptional processes, 
genomic stability, proliferation, autophagy, and apoptosis (McCubrey et al., 2007, 
Budanov, 2014). In normal cells, p53 can increase the expression of various 
antioxidant genes such as the tumour protein p53-inducible nuclear protein 1 
(TP53INP1), TP53-induced glycolysis and apoptosis regulator (TIGAR) (Cano et 
al., 2009, Sablina et al., 2005). In p53 depleted cancer cells, there is an absence 
of p53 dependant antioxidant regulators which leads to a surge in oxidative stress 
within the cells permitting ROS build-up. 
p53 mutation is one of the most common genetic abnormalities in cancer patients 
and is regarded as a hallmark of cancer (Kumar and Pandey, 2013), with a 
mutated p53 protein leading to triggering of apoptosis in addition to lack of cell 
proliferation control.  
Three key biochemical changes occur during apoptosis, namely: (i) DNA and 
protein break down, (ii) activation of caspases and (iii) membrane changes and 
recognition by phagocytic cells (Wong, 2011). Early in the apoptotic process, 
phosphatidylserine (PS), present in the inner layer of the cell membrane, 
undergoes reorientation to the outer layers of the cell membrane allowing for its 
recognition by macrophages which lead to phagocytosis. Thereafter, DNA break 
down takes places where 50-300 kilobase pieces are formed (Vaux and Silke, 
2003). Afterwards, endonucleases cleave the inter-nucleosomal DNA into 
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Morphologically, the presence of chromatin condensation and nuclear 
fragmentation are considered hallmarks of apoptosis. This is usually 
accompanied by rounding up of the cell, refutation of pseudopods and pyknosis 
(Kroemer et al., 2009). The cell membrane remains intact throughout the 
apoptotic process, however, in the later stages of apoptosis, loss of cell 
membrane integrity and membrane blebbing takes place; a process ending with 
phagocytes consuming the cell before apoptotic bodies emerge (Ziegler and 
Groscurth, 2004, Kroemer et al., 2009, Wong, 2011). 
 
 
 Caspases: the executioners of apoptosis  
 
 
Caspases are cysteine proteases that are synthetised as inactive proenzymes 
known as procaspases, with a pro-domain N-terminal and two subunits, one large 
and one small (Cohen, 1997). There are 14 members of the caspases family, 11 
of which are found in humans and are divided into 3 subfamilies (Table 1.2) 
(Friedlander, 2003). A process that is characteristic to apoptosis is the activation 
of caspases. Caspases are a group of cysteine protease enzymes when 
activated, the N-terminal is cleaved and a heterodimer is formed from the small 
and the large subunits (Fan et al., 2005). Active caspases cleave vital proteins 
and nuclear cytoskeleton as well as activating DNase which further breaks down 
nuclear DNA (Lavrik, 2005, Shalini et al., 2015). 
 
Table 1.2 Subfamily members of the caspase family 
Subfamily Role Caspase members 
I Apoptosis activator 2, 8, 9, 10 
II Apoptosis executioner 3, 6, 7 
III Inflammatory mediator 1, 4, 5, 11, 12, 13, 14 
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A feature of malignant tumours is their ability to initiate a unique, multi-stage 
biological phenomenon known as the “metastatic cascade” where cell invasion is 
a major trigger and a critical factor for additional cancer progression and 
metastasis in the surrounding and/or distant tissue and organs (Krakhmal et al., 
2015, van Zijl et al., 2011). 
 
Cellular migration requires the formation of cytoplasmatic lamellipodia and 
filopodia extensions which are controlled by actin filaments.  These are used to 
promote polarized morphology. At the ends of the lamellipodia, cells are 
connected to the extracellular matrix trough the actin cytoskeleton network and 
this allowed anchorage of the cytoplasmatic extensions. A consequence of this 
is the ability to drag the cell body (Le Clainche and Carlier, 2008).   
 
Metastasis is a term used to describe the spread of cancer cells form the 
originating or primary tumour site to neighbouring tissue and distant organs 
(Tarin, 2011, Chambers et al., 2002). Cancer metastases is considered the main 
cause of cancer related mortalities which is estimated to be at 90% (Chaffer and 
Weinberg, 2011). For metastasis to occur, cancer cells must first detach from the 
originating tumour site, enter the circulatory and lymphatic systems, avoid 
immune attack, extravasate at a distant capillary network and then invade and 
divide in new organs (Welch and Hurst, 2019, Bacac and Stamenkovic, 2008). 
Metastatic cancer cells have the ability to create a microenvironment that enables 
proliferation and angiogenesis, which results in the formation of malignant 




The National Cancer Institute (NCI) classifies cancers based on the type of tissue 
from which the cancer originates (histological) or by the site (organ) which the 
cancer first appears (NCI, 2021).  
 
There are six major histological origins: 
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i) Carcinomas are cancers that arise from epithelial tissue and can 
appear in the breast, prostate, lung, and colon. They account for more 
than 80% of reported cancer cases.  
 
ii) Sarcomas arise from connective tissue such as bones, cartilages, fat 
and muscles. Sarcomas usually occur in youngers individuals, 
examples include, fibrosarcoma, chondrosarcoma and osteogenic 
sarcoma. 
 
iii) Myeloma is a cancer that originates in plasma cells of bone marrow. 
 
iv) Leukaemia refers to liquid cancers and usually begins in the bone 
marrow.  
 
v) Lymphoma is the type of cancer that develops in the glands or nodules 
of the lymph system, lymphomas are known as solid cancers and can 
occur in specific organs such as the stomach or the brain. 
  
vi) Mixed origin cancers are those that arise from more than one tissue 




 Cancers of the central nervous system  
 
Worldwide, 250,000 cases of brain and CNS tumours are diagnosed every year, 
this makes up 3% of all cancer cases (Miranda-Filho et al., 2016). CNS cancers 
are ranked as the 8th overall cause of death in the UK (Parrish et al., 2015), and 
have had an increased incidence of 39% since the 1990s. They are the leading 
cause of cancer death in men under 40 years old and women under 20 years old 
(Siegel et al., 2020). In the UK, 30 cases of brain and other CNS tumours are 
diagnosed every day with a reported mortality rate of approximately 52% for 
malignant brain tumours.  
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Gliomas are divided into 4 grades: (i) Grade 1 are slow growing, unlikely to 
spread and can be cured with surgical removal; (ii) Grade 2 are less likely to 
metastasis but more likely to re-occur after treatment; (iii) Grade 3 have a rapid 
rate of proliferating cells and can rapidly grow; (iv) Grade 4 cells have a high 
proliferation rate as well as the presence of blood vessel growth and areas of 
necrotic cells, in addition to being highly likely to metastasise.  
The most aggressive and most common is grade 4, which is also known as 
glioblastoma multiforme (GBM). These tumours have garnered significant 
attention given that most patients with GBM die within 12 month of diagnosis 
(Holland, 2000).  
The main mode of treatment for GBM has remained unchanged for decades, 
commencing with surgical removal of the tumour mass, followed by radiotherapy 
and chemotherapy (Holland, 2000, Abbruzzese et al., 2017). Assuming all of the 
tumour tissue was surgically removed and followed up with radiation and 
chemotherapy, the survival rate of the patient can extends by up to 15 month and 
a 5-year survival rate from diagnosis of less than 5% (Abbruzzese et al., 2017). 
Variations exist in the types of gliomas, and this is dictated by the molecular 
phenotype (Table 1.3). CNS tumours exist and are location specific, for example, 
meningiomas (tumour of the meninges), schwannomas (benign tumours similar 
to meningiomas), medulloblastomas (found near the midline of the cerebellum) 
and craniopharyngiomas (benign tumours at the base of the brain) (Behin et al., 
2003, Cohen and Weller, 2007, Louis et al., 2016) (Figure 1.3). 
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Figure 1.3 Location of different types of brain tumour 





Table 1.3 Classification of CNS tumours grades I,II,III and IV based on the 
molecular phenotype (Louis et al., 2016) 
Grade  WHO grades of select CNS tumours 
I Pilocytic astrocytoma, subependymoma giant cell astrocytoma, 
subependymoma, myxopapillary ependymoma, angiocentric glioma, 
choroid plexus papilloma, gangliocytoma, ganglioglioma, schwannoma, 
neurofibroma, perineurioma, meningioma, spindle cell oncocytoma, 
pituicytoma, granular cell tumour, craniopharyngioma, pineocytoma and 
haemangioblastoma.  
II Ependymoma, pleomorphic xanthoastrocytoma, choroid glioma pf third 
ventricle, atypical choroid plexus papilloma, central neurocytoma, extra 
ventricular neurocytoma, cerebellar liponeurocytoma, atypical meningioma 
and papillary tumour of the pineal region.  
III Anaplastic pleomorphic xanthoastrocytoma, anaplastic ependymoma, 
choroid plexus carcinoma, anaplastic ganglioglioma, pineal parenchymal 
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tumour of the intermediate deafferentation, papillary tumour of the pineal 
region, anaplastic meningioma and haemangiopericytoma 
IV Glioblastoma IDH-wildtype, glioblastoma IDH-mutant, diffuse midline 
glioma H3K27M-mutant, pineoblastoma, medulloblastoma, 
medulloepithelioma, CNS embryonal tumour, atypical teratoid tumour and 
malignant peripheral nerve sheath tumour MPNST. 
 
 
The most common type of primary brain cancer originates from glial cells and are 
termed glioblastoma multiform (GBM). Glial cells include microglia, astrocytes 
and oligodendrocyte lineage cells and they make up a large portion of the human 
brain (Jäkel and Dimou, 2017). Similar to other cancers, GBM is thought to arise 
from stem cells, more precisely from precursor cells that otherwise create glia 
and neurons (Zong et al., 2012). The standard treatment for GBM is typically 
surgical resection, followed by radiotherapy and finally a treatment with an 
alkylating agent such as temozolomide.  
Furthermore, the highly malignant nature of glioblastomas is mainly a result of 
the excessive cell proliferation and invasion of surrounding brain tissue, in 
addition to suppression of any immune anti-tumour response. Tumour invasion 
to surrounding tissues occurs where neoplastic cells initiate migration while 
adhering to the extracellular matrix (ECM) starting at the primary tumour site. 
These cells then degrade the ECM through the secretion of proteolytic enzymes 
such as matrix metalloproteinases (MMPs) and then invade normal tissue 
(Demuth, T. and Berens, M.E. 2004; Singh, R.D. et al., 2010).  
 
 
 Drug delivery to brain tumours  
 
Generally, the number of hydrogen bond donors and the ability of a compound to 
form hydrogen bonds can significantly impact their ability to penetrate into the 
CNS. Moderately lipophilic molecules are thought to cross the BBB through 
passive diffusion (Pajouhesh and Lenz, 2005). Molecules with high polarity are 
poor CNS agents unless they undergo active transport to penetrate the CNS. The 
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size of molecules, ionisation and molecular flexibility are other factors that affect 
transport of compounds across the BBB (Mouritsen and Jørgensen, 1998). 
 
In 1997, Christopher Lipinski assessed the physicochemical characteristics of 
clinical drug candidates and proposed the ‘rule of 5’ that could predict the 
possibility of compounds to permeate through the BBB (Lipinski et al., 1997). The 
rule of five noted that in order for molecules to permeate across the BBB, they 
should possess the following key properties: (i) a molecular mass less than 500 
Da; (ii) high lipophilicity with octanol-water partition coefficient (log P) less than 5; 
(iii) 5 or less hydrogen donating bonds; (iv) 10 or less hydrogen accepting bonds 
(Mikitsh and Chacko, 2014). Unfortunately, some chemotherapeutic agents, do 
not fall within this category and so drug delivery of chemotherapeutic agents 
requires a strategy to overcome this problem and be able to achieve clinically 
relevant drug concentration levels at the tumour site.  
 
Since brain tumours are essentially located within the brain parenchyma, any 
systemically administered chemotherapeutic agents will have to permeate across 
the BBB and BTB in order to reach their target tumour site, hence limiting 
xenobiotic entry. The scarcity of effective CNS cancer therapeutics is often a 
result of poor delivery into CNS tissue as a result of the BBB and the BTB 




The BBB was first described in the late 19th century by Paul Ehrlich, a German 
scientist who injected mice with a trypan blue dye and identified that the dye had 
stained all tissues except for the spinal cord and the brain. Later Edwin Codman 
conducted an experiment where trypan blue was injected into the cerebrospinal 
fluid and observed brain tissue staining only (Goldmann, 1912, Haseloff et al., 
2005). These two experiments lead to the concept that the brain and other body 
organs were in distinct compartments separated by a barrier (Friedemann, 1942).  
 
The BBB consists of cerebral endothelial cells, astrocyte end feet, pericytes, 
neurons and extracellular matrix. These together make up the neurovascular unit 
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(NVU) (Bagchi et al., 2019). Each component of the NVU is mutually connected 
to each other forming a highly efficient system that regulates cerebral blood flow. 
Each element of the NVU plays a distinct active role to maintain brain 
homeostasis (Bagchi et al., 2019) (Figure 1.4).  
 
Neurons are known as the pacemaker of the neurovascular unit (Banerjee and 
Bhat, 2007), because of their highly sophisticated function where they are 
capable of detecting the smallest changes in nutrients and oxygen supply and in 
response send electrical and chemical messages to the vessels in order to return 
to normal physiological conditions, thus influencing the vasculature and blood 
supply to the adjoining areas (Figley and Stroman, 2011). 
 
At first, the role of astrocytes was unknown, however, it was later demonstrated 
that astrocytes are incredibly versatile within the NVU, and possess the ability to 
communicate with both the neurons and blood vessels simultaneously (López-
Bayghen and Ortega, 2011, Santello et al., 2012). It has been also reported that 
astrocytes have an effect on the formation of tight and adhesion junctions in the 
BBB and hence regulate the tightness of the barrier itself in addition to 
upregulating the expression of a range of transporters and enzymes within 
endothelial cells (Haseloff et al., 2005).  
Pericytes are embedded within the basement membrane that covers 30% of the 
endothelium, and given their close contact to endothelial cells, they play a 
significant role in their development and maturation (Sá-Pereira et al., 2012). 
Much like astrocytes, the role of pericytes was unknown as they were considered 
as simple support cells (Armulik et al., 2010). However, it was displayed that they 
secrete adhesion molecules and growth factors as a response to ATP increase 
(Kawamura et al., 2003). Pericytes are also essential in controlling blood vessel 
proliferation, formation and are able to control the diameter of blood vessels to 
help modulate cerebral blood flow (Di Pietro et al., 2002, Peppiatt et al., 2006). 
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Figure 1.4 The neurovascular unit 
The basement membrane surrounds the endothelial cells and embeds the 
pericytes. Endothelial cells are connected through tight junctions. Astrocyte end 




The BBB is formed primarily of microvascular endothelial cells that are tightly 
fused together and form a tight continuous lipid layer that heavily restricts free 
diffusion of drugs into the brain (Emanueli et al., 2003, Duchemin et al., 2012).  
Key to the barrier function of the BBB is the presence of proteins termed ‘tight-
junction’ proteins, which primarily serve to restrict paracellular diffusion of drugs 
between adjacent endothelial cells. Tight junctions (TJ) are formed by link zones 
between cells, in which the intercellular cleft is sealed. TJ are controlled and 
maintained by the expression of a range of proteins such as occludins, claudins 
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Figure 1.5 Endothelial tight junction and adhesion junction structure 
Occludins and claudin proteins are the main components of TJs, ZO-1, -2, and -
3 provide structural basis for the assembly of TJs. AJs and JAMS take part in the 







Under pathological conditions such as epilepsy, multiple sclerosis, AIDS, 
dementia and stroke, the performance and organisation of the BBB can be 
disturbed (de Vries et al., 2012, van Tellingen et al., 2015). This is also the case 
with brain cancers (Abbott et al., 2006). Changes in the barrier triggered by the 
presence of the tumour is not linked to tumour size, type or location and is 
different within every single neoplasm (van Tellingen et al., 2015). In low grade 
gliomas, the morphology and function of the BTB remains mostly intact and 
resemble that of the BBB. However, in high grade gliomas, as confirmed by MRI 
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The BTB is a visibly distinctive barrier from the BBB and is formed by tumour 
capillaries. It is composed of three separate microvessel populations: (i) non-
fenestrated and continuous much like normal brain capillaries; (ii) capillaries 
enclosing inter-endothelial gaps (iii) fenestrated and continues capillaries 
(Groothuis, 2000, Schlageter et al., 1999, van Tellingen et al., 2015). Much like 
the BBB, endothelial cells of the BTB express drug efflux transporters from the 
ABC family such as ABCG2/BCRP (Aronica et al., 2005, Iorio et al., 2016) and 
ABCB1/P-gp (Lin et al., 2014), as well as other ABC efflux transporters (Arvanitis 
et al., 2020a, Bronger et al., 2005). 
 
The BTB is considered a leaky barrier and is characterised by pericyte disruption, 
loss of neuronal connection and loss of astrocyte end feet (Dubois et al., 2014). 
In addition, tight junction proteins and stem cell derived pericytes are 
downregulated and pericyte cell coverage is disrupted (Dubois et al., 2014, 
Achrol et al., 2019, Cheng et al., 2013). This is indicated by the detection of 
peripheral monocytes and T-cell subpopulation in brain tumours suggesting the 
permeability of the neurovascular unit to circulating cells (Achrol et al., 2019). 
Moreover, the disruption in BBB permeability is evident by the detection of 
circulating  brain tumour markers and the higher drug accumulation within brain 
tumours in comparison with unaltered brains (Arvanitis et al., 2020a). Despite 
these observations, the BTB maintains critical features of the BBB including the 
expression of active efflux transporters in endothelial and tumour cells (van 
Tellingen et al., 2015). It is worth noting that an intact BBB can be present in 
advanced glioblastoma cases displaying a variety of efflux transporters that 
restrict permeation of anti-cancer agents (Arvanitis et al., 2020a, van Tellingen et 
al., 2015, Sarkaria et al., 2018). Consequently, in both low-grade and high-grade  
glioblastomas, the BBB and the BTB form an arduous obstacle in brain tumour 
treatment by preventing the delivery of appropriate quantities of possibly effective 
chemotherapeutic agents (Juillerat-Jeanneret, 2008, Korfel and Thiel, 2007). 
 
 
In order for adequate amounts of chemotherapeutic agents to reach the 
sight of the tumour, bypassing the BBB is a prerequisite (Kim et al., 2018). The 
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primary function of the BBB is maintaining the homeostasis of the CNS by 
restricting the permeation of ions, molecules, fluids and cells between the blood 
and the brain, in addition to providing the brain with nutrients. The BBB also acts 
as a xenobiotic barrier through the presence of a significant network of membrane 
localised uptake/efflux transporter proteins responsible for the carried-mediated 
transport of molecules (Abbott, 2005). 
 
Two key pathways exist through which molecules are able to permeate across 
the BBB, namely transcellular pathways and paracellular pathways (Figure 1.5), 
both of which are primarily passive diffusion pathways. The paracellular route 
refers to movement of molecular across the endothelium by passing through 
intercellular spaces located between adjacent cells. In the BBB, this route is 
considered an essential and unique phenotype for the BBB as molecular diffusion 
is strictly controlled by TJs, which play a key role in regulating permeability across 
the BBB, whilst also maintaining the polarity of receptors and enzymes on the 
luminal and abluminal membrane domains (Banik et al., 2010).   
In contrast, transcellular pathways allow passage of small lipophilic molecules 
across the lipid bilayer of the endothelial cells and is primarily a pathway for 
lipophilic, non-polar molecules (Pardridge, 2002). 
 
Transcytosis refers to the transport of macromolecules from the apical to the 
basolateral side of the cell. This process takes place in different cells including 
endothelial cells and neurons (Pulgar, 2019). There are two types of transcytosis 
in the brain, receptor mediated transcytosis and adsorptive mediated transcytosis 
(Figure 1.6). Receptor mediated transcytosis (RMT) are specific receptors in the 
lumen of endothelial cells and are responsible for the transport of specific ligands. 
This is the main mechanism through which molecules such as insulin and 
transferrin are transported across the BBB (Abbott, 2013).  
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Figure 1.6 Transport pathways in the blood-brain barrier 
(1) Paracellular aqueous pathway through which limited amount of water-soluble 
molecule can diffuse. (2) transcellular lipophilic pathway through which lipid 
soluble molecules diffuse across the BBB. (3) protein transporters pathway is 
responsible for diffusion of glucose, purine bases, amino acids, chlorine and other 
substances. (4) receptor mediated transcytosis that transport insulin, transferrin 
and certain proteins. (5) adsorptive transcytosis transports poorly absorbed 
proteins such as albumin. (6) Efflux transporters (Brazil, 2017) 
 
 
Adsorptive mediated transcytosis (AMT) is responsible for transport of molecules 
that are polycationic in nature such as neuropeptides, proteins, and large 
therapeutic molecules.  For these molecules,  binding to anionic molecules at the 
surface of the cell is critical for their resultant transportation and passage across 
the endothelia through vesicular systems (Patel and Patel, 2017).  
 
The BBB also contains an insidious network of membrane bound transporter 
proteins which are responsible for the active efflux or active uptake of molecules 
across the BBB through an energy-mediated (hydrolysis of ATP) process.  
Typical examples of these can be found in the membrane bound transporter 
proteins P-glycoprotein (P-gp/ABCB1), breast cancer resistant protein 
(BCRP/ABCG2), multi-drug resistant proteins (MRP-1, -4, -5 and -6) and organic 
anion transporting poly peptides (OATP2). For the transport of larger molecular, 
a carrier mediated transport pathway also exists for transport of nutrients into the 
brain such as amino acid large transporter LAT-1, glucose transporter GLUT-1, 
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monocarboxylic acid transporter MCT-1 and sodium coupled nucleoside 




Despite the BTB being a leakier barrier, studies have shown that it displays 
heterogonous drug permeability where, the centre of the tumour demonstrates 
higher leakiness in comparison with the adjoining brain microenvironment and 
the peritumoral area (Arvanitis et al., 2020b). This was shown in a malignant 
murine glioma model where dasatinib distribution was heterogeneous in the 
tumour lesion and was higher than that of the surround brain tissue (Agarwal et 
al., 2012). Further, low molecular weight compounds administered systemically 
in brain metastasis mouse models have shown irregular distribution within the 
tumour tissue (Lyle et al., 2016). Moreover, the permeability of 14C-paclitaxel and 
14C-doxorubicin was assessed across the BTB in brain tumour metastasis mice 
models and demonstrated that 89% of the lesions displayed a heterogeneous 
BTB permeability, with drug uptake generally greater than that in normal brain 
tissue yet, drug concentrations reached cytotoxic levels in less than 10% of the 
metastatic models examined (Lockman et al., 2010). 
 
Circulating drugs are exposed to multiple barriers imposed by the NVU, namely 
reduced transcytosis, reduced paracellular transport of hydrophilic compounds 
and efflux transporters that inhibit the passage of lipophilic molecules across the 
BTB (Banks, 2016). Many of these circulating drugs have an affinity to ABC 
transporters which are often responsible for reducing the uptake of drugs across 
the BBB (Seelig, 2007, Nałȩcz, 2016, Carmeliet and Jain, 2011). Evolving 
insights into the BBB/BTB structure and function, have granted novel approaches 
to overcome the limitations they impose and enhance drug delivery to brain 
tumours. Some invasive approaches include, intrathecal and intraventricular 
injections (Groothuis, 2000, Beauchesne, 2010), implantation of wafer and 
microchips (Bregy et al., 2013, Chowdhary et al., 2015) and convection enhanced 
delivery by direct injection (Zhou et al., 2017b, Lonser et al., 2015).  
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Another popular approach to overcome multi drug resistance MDR at the 
BBB/BTB is through overcoming efflux pumps. Studies conducted pre-clinically 
have focused on the co-administration of the chemotherapeutic agent with a 
transporter inhibitor. This approach has shown a significant enhancement in 
chemotherapeutic agent concentration within the brain. This was evident by a 
1.5-fold increase of temozolomide when co-administered with elacridar, a BCRP 
and P-gp inhibitor, in mice (de Gooijer et al., 2018). The increased recognition of 
the role ABC transporters play in BBB and brain tumour drug permeability 
suggests the need for more potent, more specific inhibitors that can target 
specific transporters and improve cancer cell drug uptake (Robey et al., 2018, 
Kim et al., 2018, Lin et al., 2014).  
 
  The ABC family of efflux transporters 
 
Active transport of molecules across barriers refers to the movement of 
molecules against a concentration gradient and often requires the energy 
released from ATP hydrolysis in order to shuttle molecules across the cell 
membrane.  Many therapeutic agents are transported into the brain and extruded 
out of the brain through active transport. Multiple efflux transporters such as ATP-
binding cassette (ABC) transporters and influx transporters such as peptide 
transports, nucleoside transporters, organic cation transporters and (Sanchez-




Table 1.4 Examples of influx transporters and substrates 
Transporter Substrate 




Amino acid transport system 
LAT-1 Large neutral amino acids 
CAT-1 Cationic amino acids 
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xCT L-Cystine/L-Glutamine 
Organic anion transport system  
Oatp14 Thyroid hormones 
OCTN2 Carnitine 
Nucleoside transport system 
CNT2 Nucleosides  
  
 




The ABC superfamily of drug transporters are amongst the largest and the most 
abundantly expressed transporter proteins found in prokaryotes (Sanchez-
Covarrubias et al., 2014). The ABC family is subdivided into 7 subfamilies (ABCA-
ABCG) and consists of 49 genes in total (Dréan et al., 2018). The ABC family has 
many functions which include, peptide transport and maintenance of the lipid 
bilayer. However, the most notable and widely studied role is their contribution in 
the development of the MDR phenotypes (Dean et al., 2001).  
 
ABC transporters are either expressed as ‘full’ (Figure 1.7) or ‘half’ (Figure 1.8) 
transporters with full transporters having two transmembrane domains (TMD) and 
two nucleotide binding domains (NBD) and half transporters having only one of 
each. The ABC transporters are thought to undergo homodimerization in order to 
become functional (Dréan et al., 2018, Hyde et al., 1990, Dean et al., 2001). 
 
All members of the ABC family exhibit two primary structural motifs, namely 
‘Walker A’, a phosphate binding loop and ‘Walker B’ magnesium binding loop. 
Besides these two motifs, three other motifs are found in the ABC cassette, the 
‘LSGGQ’ motif is specific to ABC transporters, ‘the switch region’ which attach to 
water molecules for hydrolysis and the Q-motif found between walker A and 
walker B and interacts with gamma phosphates through water bond formation. 
Walker A, walker B and the Q-motif make up the nucleotide binding site (Zhou, 
2008, Higgins, 2001). In order to transport molecules across a cell membrane, 
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ABC transporters utilise energy from ATP hydrolysis in order to function (You and 
Morris, 2006).   
 
The reasoning behind the ability of the ABC transporters to bind to a variety of 
structurally unrelated compounds and molecules is still unclear. However, two 
theories have come to light as possible explanations. The first theory claims that, 
when the transporter is facing inwards, the binding pocket of the transporter has 
a higher affinity to substrates. The binding of the transporter to the substrate leads 
to a conformational change leading the transporter to face outwards resulting in 
a reduced affinity to the substrate and hence the efflux of the substrate into the 
extracellular matrix. This theory is termed the “altering access model” (Clay, 
2013). The second theory describes how the dimerization of the NBD after ATP 
hydrolysis causes a switch in the binding pocket from facing inward to facing 
outward. This inversion leads to a conformational change in the transporter 
leading to a reduced affinity to the substrate and its efflux. This theory is known 
as the “ATP-switch model” (Higgins and Linton, 2004). 
 
Examples of members of the ABC family of transporters include:  
 
ABCA: plays an essential role in cholesterol transport across the plasma 
membrane. Mutations in ABCA1 leads to individuals developing dyslipidaemia 
(M. et al., 2001).  
 
ABCB: consists of 11 members and are known to transport many molecules such 
as drugs, peptides and intracellular heme/iron (Sanchez-Covarrubias et al., 
2014). ABCB11 also known as bile salt export pump (BSEP) is responsible for 
the production and transport of hydrophobic bile salts such as taurine which is 
located in the liver. Consequently, it plays a major role in homeostasis of hepatic 
bile acids and regulation of biliary lipid secretion (Hayashi and Sugiyama, 2013) 
mutations in ABCB11 are associated hepatomegaly and pruritus (Chiang, 2013). 
The most widely researched and reported on member of this family is ABCB1 or 
P-glycoprotein (P-gp) and is known to be a major contributor in MDR which 
responsible for efflux of drugs (Sanchez-Covarrubias et al., 2014). P-glycoprotein 
(P-gp) was the first member of the ABC transporter family to be identified in 
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Chinese hamster ovaries (Juliano and Ling, 1976), and since then many studies 
identified a wide range of other efflux transporters that play a critical role in drug 
delivery across the BBB (Löscher and Potschka, 2005, Amin, 2013, Chung et al., 
2016).  
 
ABCC: consists of 13 members. They play role in signal transduction, toxin 
secretion and ion transport (M. et al., 2001). Mutations in the members of the 
ABCC subfamily can result in a range of pathophysiological consists such as 
hypoglycaemia (Fournet et al., 2001), cystic fibrosis (Cohen and Prince, 2012) 
and Dubin-Johnson syndrome (Wada et al., 1998). A major contributor towards 
the MDR phenotype from the ABCC family is MRP-1 (Sanchez-Covarrubias et 
al., 2014).  
 
ABCD: has 4 members which are all half transporters. They function in the 
transport of very long chain fatty acids (Wanders et al., 2007). Mutations in this 
subfamily are linked with impairment in vision, cognition and hearing (Cappa et 
al., 2011).  
 
ABCE and ABCF: are the least characterised of all the subfamilies with one 
known member of the ABCE family known as OABP protein and is known to play 
a role in identifying oligodenylate synthesis that takes place due to viral infections 
(Tian et al., 2012).   
 
ABCG: subfamily has 6 members, ABCG1, ABCG5 and ABCG8 play a role in 
sterol transport (Tama and A., 2000).  ABCG2 also known as BCRP plays a key 
role in the MDR phenotype and takes part in the efflux of wide range of diverse 
therapeutic agents.   
 
The most pharmacologically relevant ABC transporters are P-gp, BCRP and 
MRP-1. These are expressed in the apical side of cells in the brain, liver and 
intestine (Alvarez et al., 2010). The action of the transporters is initiated by 
interaction of the binding site with a certain substrate, which induces a 
conformational change that is transmitted to the binding domain where ATP 
binding activates. ATP binding leads to changes in the positioning and affinity of 
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the substrate binding site and thereby the substrate is discharged at the 
extracellular side of the cell (Higgins, 2001).  
 





ABC transporters are often associated with the aggressive nature of cancer 
progression, in part due to their ability to efflux chemotherapeutic agents and 
hence imparting a MDR phenotype, however irregularities in ABC transporter 
expression and function can also play a role in cancer progression beyond MDR 
(Muriithi, 2020).  
 
Studies have reported that the dysregulated ABC protein expression is often 
linked to an aggressive tumour prototype as measured by tumour stage, size and 
the possibility of metastasis (Scotto, 2003). Even though the irregularities in ABC 
protein expression can merely be a consequence of genetic alterations that 
accompany tumour formation, the possibility that these proteins play a pro-
tumour role cannot be ignored (Muriithi, 2020).  
 
More commonly, ABC transporters have been implicated in MDR phenotypes, 
hindering intracellular accumulation of anti-cancer agents, and leading to tumour 
progression and growth. The overexpression of P-gp, BCRP and MRP-1 has 
been directly associated with poor prognosis in glioblastoma patients (Balça-Silva 
Structure of a typical ABC transporter includes transmembrane binding 
domains (TMD) and nucleotide binding domains (NBD). The functioning 
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et al., 2017, Balça-Silva et al., 2019, Matias et al., 2018). In breast cancer, 
overexpression of ABCC11 was associated with an aggressive tumour subtype 
(Yamada et al., 2013). It was also reported that overexpression of ABCC4 was 
associated with MYCN gene amplification which lead to the spread of the tumour, 
more importantly it was noted that its expression in primary untreated 
neuroblastomas was linked to reduced overall survival (Huynh et al., 2012). 
 
Cancer cells are known to propagate outside the original tumour site in a process 
termed “invasion”, with ABC transporters being partly implicated. A study 
reported that ABCB5 aided in the invasion of colorectal cancer in-vivo and in-vitro 
(Guo et al., 2018). It was also reported that in melanomas, MRP-1 was linked to 
the invasion and metastasis of the cancer when compared to tumours that didn’t 
express MRP-1 (Landreville et al., 2011). In the U251 glioblastoma cell line, it 
was shown that downregulation of BCRP was correlated with reduced invasion 
and metastasis (Gong et al., 2014). Likewise, when comparing the effect of P-gp 
on the progression of breast cancer, it was reported that expression of P-gp in 
breast cancer cells in axillary nodes resulted in an increase in metastasis when 
compared to cells that lacked P-gp (Schneider et al., 2001). 
 
The ability of cancer cells to evade apoptosis is essential to their persistent 
proliferation and survival (Hanahan and Weinberg, 2000), combined with the fact 
that majority of chemotherapeutic agents are cytostatic, cancer cells that evade 




Breast Cancer Resistance Protein was first identified in the breast cancer cell line 
MCF-7/AdrVp. Despite the absence of MRP and P-gp in these cells, the limited 
permeability of rhodamine 123 and adriamycin suggested the presence of a new 
transporter protein (Chen et al., 1990, Lee et al., 1997). This transporter was later 
termed as ‘breast cancer resistant protein’ (BCRP) (Doyle et al., 1998).  BCRP 
has a molecular weight of 72 KDa, 655 amino acids, and is a half transporter 
(Figure 1.7) with the C-terminal and N-terminal located on the intracellular side of 
plasma membrane (Doyle et al., 1998).  
 




Figure 1.8 The structure of breast cancer resistance protein (BCRP) 
BCRP a half transporter comprising of one transmembrane binding (TMD) and 
one nucleotide binding domain (NMD), comprised of 6 trans-membrane spanning 




In order for BCRP to act as an efflux transporter, it is believed that it undergoes 
homodimerization or heterodimerization (Graf et al., 2003, Austin Doyle and 
Ross, 2003, Shigeta et al., 2010). BCRP has been reported to be expressed in 
various tissue sanctuary sites, such as the placenta, gastrointestinal tract, 
testicles, heart, liver and brain (Sanchez-Covarrubias et al., 2014, Meissner et 
al., 2006, Cooray et al., 2004a).  
 
Within the brain, BCRP is expressed in the luminal region of the endothelial cells 
of the BBB in addition to astrocytes and microglia (Gloria et al., 2007). Based on 
mRNA analysis, BCRP was found to be expressed in higher quantities in the BBB 
than P-gp and MRP-1 (Eisenblätter et al., 2003). Later studies employing 
quantitative proteomics have reported an absolute protein abundance of 
transporter proteins at the BBB and have stated that BCRP (8.14 fmol/µg protein) 
and P-pg (6.06 fmol/µg protein) are the most abundant transporter proteins at the 
human BBB (Uchida et al., 2011).  
 
BCRP has a primary protective function in human physiology by restricting 
access of therapeutic agents as well as some endogenous substrate molecules 
(Oostendorp et al., 2009, Chen et al., 2003). The overexpression of certain ABC 
transporters was found to increase MDR, which significantly influences failure of 
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chemotherapy (Sun et al., 2012), with BCRP being prominent in accounting for 
the multidrug resistance phenotype in humans (Dean et al., 2001, Roundhill et 
al., 2015). 
BCRP has a wide range of chemotherapeutic substrates such as mitoxantrone, 
irinotecan, imatinib, doxorubicin, methotrexate and SN-38 (Cooray et al., 2004b). 
Mitoxantrone resistant colon cancer cell line was found to overexpress BCRP and 
hence its resistant to mitoxantrone (Miyata et al., 1999). Many other cell lines that 
overexpress BCRP, such as glioblastoma, fibrosarcoma, non-small cell lung 
cancer and gastric carcinoma were found to also be drug resistant (Ross et al., 
1999). In-vitro, it was reported that the resistance of human ovarian cancer cell 
line IGROV1 to type-1 topoisomerase inhibitor topotecan was a direct corelation 
to the over expression of BCRP in the cell line (Maliepaard et al., 1999), in 
addition, its overexpression in gastric carcinoma cell line (EPG85-257RNOV) and 
glioblastoma cell line (SF295/MX) rendered them refractory to mitoxantrone 
therapy (Robey et al., 2001a). Furthermore, in MCF7 cell line, over expression of 
BCRP lead to resistance to both methotrexate and mitoxantrone (Volk et al., 
2002).  
Within animal studies, a direct correlation has been demonstrated between 
methotrexate resistance and the expression of BCRP at the BBB (Li et al., 2013). 
In addition, the distribution of methotrexate when used in the treatment of CNS 
lymphoma was very limited, with only 5% of the drug crossing the BBB (Zhu et 
al., 2009). Also, in patients with high grade gliomas, cerebral penetration of 
methotrexate was shown to be very low (Blakeley et al., 2009). Furthermore, 
brain uptake for mitoxantrone was shown to increase by 3-fold when co-
administered with a BCRP and a P-gp inhibitor in mice, demonstrating that BCRP 
plays a critical role in limiting the permeability of mitoxantrone across the BBB 




Developing strategies to modulate efflux transporter activity have been promoted 
by the increasing awareness of the influence these transporters have on CNS 
drug delivery (Arvanitis et al., 2020a, Löscher and Potschka, 2005). Mechanisms 
to inhibit efflux transporters at the BBB/BTB include approaches such as the use 
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of direct inhibitors and transcriptional modulation (Banik et al., 2010).  Over the 
last two decades, developing agents that modulate the action of P-gp have been 
the primary focus of many studies attempting to reverse the MDR phenotype. 
First generation inhibitors of P-gp include verapamil, cyclosporine A, quinidine, 
yohimbine and tamoxifen. These agents failed to clinically translate to successful 
modulators due to their poor specificity and binding proprieties which required 
administering these agents in high doses which lead to non-specific binding and 
major systemic toxicities (Ferry et al., 1996)  
 
Second generation inhibitors include dexverapamil, valspodar and dexniguldipine 
(Fardel et al., 1993, Kolitz et al., 2010, Summers et al., 2004). These agents 
displayed a greater inhibitory effect on transporter proteins with reduced toxicity. 
However, these agents still demonstrated limitations, such as inhibition of the 
metabolism of chemotherapeutic agents when administered concurrently leading 
to accumulation of the chemotherapy in the blood and systemic toxicity. For 
instance, valspodar reduces the hepatic metabolism of vinblastine and paclitaxel 
through inhibition of CYP 3A4, leading to increased concentration of the cytotoxic 
agents in the blood (Bates et al., 2004). In a similar fashion, a study in patients 
with solid tumours demonstrated that combined administration of paclitaxel and 
biricodar resulted in a significant decrease in paclitaxel clearance, as a result of 
biricodar interfering with paclitaxel’s metabolism (Rowinsky et al., 1998).  
 
More recently third generation inhibitors such as tariquidar, mitotane, elacridar 
and zosuquidar were found to be clinically effective with less toxicity when 
compared to previous generations (Leitner et al., 2011). However, later clinical 
trials showed that these inhibitors possessed major toxicities and had low survival 
benefits (Dash et al., 2017).  
 
More recently, attention has turned towards modulation of BCRP. An extract from 
the fermentation broth of Aspergillus fumigatus, fumitremorgin C (FTC), was the 
first discovered BCRP inhibitor, but failed to translate clinically due to its severe 
neurotoxicity profile (Hirsch et al., 2009). Thereafter, 42 derivatives from FTC 
were later developed with only two of those (Ko143 and Ko132) showing 
promising results. These were however discontinued clinically due to their 
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cytotoxicity (Pick et al., 2011).  Many tyrosine kinase inhibitors (TKI) such as 
gefitinib has been reported as inhibitors of the efflux function of BCRP (Leggas 
et al., 2006, Stewart et al., 2004). However, exposing cells to gefitinib lead to an 
increase in the expression of BCRP, and an increased resistance to anti-cancer 
agent SN-38 when administered concurrently, proposing that gefitinib is a BCRP 
substrate (Azzariti et al., 2010).  Another TKI, sunitinib, was found to modulate 
BCRP mediated efflux function (Shukla et al., 2009a).  
 
Despite research highlighting some current inhibitors of BCRP, their poor 
specificity and cytotoxicity remain a major limiting factor in their clinical translation 
(Tang et al., 2012, Pick et al., 2011, Hirsch et al., 2009). There is still a need for 
effective BCRP inhibitors that are safe, effective and are able to modulate the 
efflux action of BCRP. 
 
More recently, a group of naturally occurring phytochemicals have come to light 
as BCRP modulators. These have garnered great attention due to their effectivity 
and safety as ABC transporter modulators in addition to their other health 
benefits.  
 
 Natural product phytochemicals  
 
Phytochemicals are naturally occurring chemicals in foods that are widely 
consumed within the diet of mammals. A major category of phytochemicals are 
flavonoids, which are found naturally in fruits, vegetables, and herbs (Table 1.5). 
flavonoids fall into the food category and are deemed tolerable with reported daily 
exposure through dietary intake  exceeding 1 gram (Pick et al., 2011, Perez-
Vizcaino and Fraga, 2018).  Over 6500 chemicals have been identified as 
belonging to the general category of flavonoids (Panche et al., 2016, Rashid et 
al., 2019).  
 
Flavonoids structurally consist of aromatic rings A and C and a heterocyclic 
benzene ring B (Figure 1.9). They are categorised into subgroups based on the 
position of the attached substitution (Rx).  
 
 
B.A.M. Elbakary, PhD Thesis, Aston University 2021. 47 
 
Figure 1.9 Basic structure of flavonoids 
Flavonoids consist of ring A and B which are aromatic rings and ring C which 
links rings A and B together. Based on the positions of substitutions (Rx) and 








Group Example Food source 
Flavonols Quercertin, Kaempferol, 
Myicetin, Querctagetin 
Blueberry, black tea, 
leek, yellow onion, 
cherry, apple, tomato, 
curly kale. 






Flavanones Hesperetin, naringenin, 
eridodicytol, 
dihydrofisten 
Orange juice, lemon 
juice, grapefruit juice. 









Beans, apricot, peach, 
red wine, grapes, 
cherry, chocolate 
Isoflavones Daidzein, Genisten, 
glycitein 
Soybean, tofu, legumes 
Anthocyanins Petunidin, malvidin, 
peonidin, cyanidin, 
delphinindin. 
Red berries, purple 
grapes, rhubarb plum, 
red cabbage, 
strawberries 
Some examples of flavonoids and their presence in food. Table adapted and 
modified from (Lakhanpal and Ral, 2007) 
 
 





Studying the structure and function of BCRP and its substrates have revealed 
insights into the mechanisms underlining BCRP-mediated multidrug resistance 
in cancer and healthy tissue. The interaction of flavonoids with BCRP appear to 
resemble those shown in the interaction of flavonoids with P-gp (Conseil et al., 
1998, Boumendjel et al., 2001) where flavonoids interact with the C-terminal 
region of the NBD. That said, two mechanisms of action have been proposed for 
the ability of flavonoids to inhibit BCRP, binding to either the nucleotide binding 
domain or the transmembrane domain substrate binding sites (Figure 1.8) 
(Alvarez et al., 2010, Pulido et al., 2006, Bock et al., 2000). 
 
Flavonoids such as quercetin, genistein, naringenin and kaempferol were shown 
to competitively inhibit the action of BCRP and bind with stronger affinity to the 
transporter (Katayama et al., 2007, Di Pietro et al., 2002, Zhang and Morris, 2003, 
Walgren et al., 2000). On the other hand, other studies have demonstrated that 
quercetin, benzo-a-pyrene and kaempferol are known to inhibit BCRP by binding 
to the ATP binding site and hence lead to the inactivation of the transporter (Yarla 
and Ganapaty, 2013b, Guohua et al., 2011, Wang, 2007). 
 
The known BCRP inhibitors Ko143 (Ozvegy-Laczka et al., 2005) and FTC 
(Özvegy et al., 2001, Robey et al., 2001b) were shown to modulate BCRP by 
inhibiting its ATPase activity, however, flavone derivatives were shown to 
increase the activity of ATPase much like mitoxantrone, suggesting the presence 
of a large poly-specific drug binding site in BCRP much akin to those 
demonstrated in P-gp and MRP-1 (Ozvegy-Laczka et al., 2005). 
 
Additionally, variation in the substitutions in flavonoids (Figure 1.8) play a key role 
in their ability to modulate BCRP. A study reported that the presence of hydroxyl 
and hydrophobic substitutions rendered flavones such as luteolin and apigenin 
more effective in the inhibition of drug efflux function of BCRP compared to other  
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classes of flavonoids, with a hydroxyl substitution at position 5 in ring-A resulting 
in the best inhibitory effect. In addition, the presence of hydrophobic substitutions 
at positions 6’ and 7’ correlated with a higher binding affinity with BCRP (Ahmed-
Belkacem et al., 2005a). 
 
Furthermore, pharmacophore calculations suggested hydrophobic groups in 
position 4’ in aromatic ring B and the presence of hydrogen bond acceptors in 
positions 5’ and 7’ play a critical role in the ability of flavonoids to modulate the 
action of BCRP (Fang et al., 2016). In addition, the occurrence of a 2,3-double 
bond in ring C, ring B branched at position 2, hydroxylation at position 5 and 
absence of hydroxylation at position 3 all seem to be critical for potent BCRP 
inhibition (Morris and Zhang, 2006). 
 
Genetic polymorphisms of BCRP play a major role in the ability for flavonoids and 
substrates to bind. Phenylalanine at position 439 (Phe 439), found in the internal 
cavity of BCRP in the NBD is a critical factor in the binding affinity of flavonoids 
to BCRP. Biochanin-a, chrysin, naringenin and diosimin modulate BCRP through 
the formation of a non-covalent bond between the aromatic ring in these 
flavonoids and Phe 439 which is present in the substrates binding pocket (Fan et 
al., 2019). Furthermore, arginine at position 482 (Arg 482) in BCRP has been 
shown to have a major role in the substrate selection process for BCRP (Noguchi 
et al., 2009). Arg 482 with a positive charge has an effect on the interaction 
between BCRP and its drug substrates and consequently the carboxyl group at 
the transmembrane binding site that is in close juxtaposition to Arg 482 seems to 
take part in the substrate binding pocket interface of BCRP (Ejendal et al., 2006, 
Hazai and Bikádi, 2008, Li et al., 2007).  
 
The most well studied mutations in BCRP occur when arginine 482 (R482), is 
replaced with threonine (R482T) or glycine (R482G) (Breedveld et al., 2006, 
Honjo et al., 2001, Robey et al., 2001b). The MCF7 and S1-M1-80 cell lines were 
identified to have mutation of the 482 amino acid, these mutations were 
associated with overexpression of BCRP. Furthermore, they were reported to be 
highly resistant to mitoxantrone and doxorubicin in addition to the efflux of 
rhodamine and anthracycline resistance (Volk et al., 2002, Honjo et al., 2001). 
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Additionally, variants of the amino acid 482 lead to lack of affinity to methotrexate 
in MCF cells and at the same time increased mitoxantrone resistance (Li et al., 
2007, Ozvegy et al., 2002, Volk et al., 2002).  
 
The inhibitory effect of BCRP by flavonoids was also suggested to be result of 
the parent compound rather than their metabolites. For example, genistein was 
shown to be transported unchanged by BCRP (Imai et al., 2004a) whilst naringin 
and phoridzin had no effect on the efflux action of BCRP. However, their aglycon 
counterparts were found to be strong inhibitors in MCF cells suggesting that the 
presence of the sugar moity significantly affects the BCRP inhibitory activity of 
flavonoids (Zhang et al., 2004b).  
 
 
Naturally occurring phytochemicals have been reported on as having numerous 
anti-cancer properties such as inhibiting cell migration and invasion, inducing 
apoptosis, and participating in cancer cell cycle arrest (Yahfoufi et al., 2018, 
Gorlach et al., 2015, Perez-Vizcaino and Fraga, 2018, Kopustinskiene et al., 
2020). In addition, studies have shown that conjugated metabolites of flavonoids 
possess anti-inflammatory activates (Zhang et al., 2004b, Perez-Vizcaino and 
Fraga, 2018), angiogenic properties and anti-oxidative action (Harada et al., 
1999, Xiao et al., 2011).  
 
Overproduction of reactive oxygen species (ROS) occurs when the homeostatic 
balance between anti-oxidant defence and pro-oxidant activities is compromised, 
thus leading to free radical accumulation (Rodríguez-García et al., 2019). 
Flavonoids have  dual abilities as anti-oxidants and pro-oxidants (Link et al., 
2010, Hadi et al., 2000), both of which are involved in their anti-cancer properties 
(Oliveira-Marques et al., 2009, Valko et al., 2007). In addition, they increase 
expression of tumour suppressor TP53 and cell death regulator protein Bax and 
downregulate apoptosis suppressor gene BcL-2 (Zhang et al., 2015b, Abotaleb 
et al., 2018). Subsequently, this supresses cancer cell proliferation, migration and 
activates apoptosis (Shen et al., 2010, Liskova et al., 2020). 
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Flavonoids are also able to exhibit their anti-oxidant ability by scavenging of free 
radicals through hydrogen atom donation which results in inactivation of the free 
radical (Nijveldt et al., 2001). The arrangement of the functional groups in the 
flavonoids’ structure can also influence their antioxidant ability (Heim et al., 2002). 
The presence of a hydroxyl substitution in ring B is crucial for ROS scavenging, 
however, A- and C- ring substitutions have small impact on the ROS scavenging 
rate (Procházková et al., 2011).  Flavonoids’ ability as anti-oxidants has also been 
proposed to be due to the redox activity of phenolic hydroxyl groups such as 
those found in catechol moieties which are easily oxidized (Chobot and Hadacek, 
2011).  
 
Furthermore, flavonoids can exhibit their antioxidant abilities by supressing pro-
oxidative enzymes and stimulating phase II detoxification enzymes (Youn et al., 
2006). In-vitro studies have also demonstrated that the glycosylation of the 3-OH 
group strongly inhibits the flavonoids ability to scavenge ROS (Burda and 
Oleszek, 2001, Taubert et al., 2003) where the aglycon hesperetin was a better 
anti-oxidant than its glycoside counterpart hesperidin  and baicalin was better 
than baicalein (Rice-Evans et al., 1996, Procházková et al., 2011).  
 
Additionally, flavonoids can exhibit their anti-oxidant abilities by activating anti-
oxidant enzymes (Ferrali et al., 1997), chelating metals such as copper and iron 
and thereby removing spontaneous factors available for the formation of free 
radicals (Ferrali et al., 1997). They also inhibit oxidases (Cos et al., 1998) such 
as xanthine oxidase  and protein kinase C (Hanasaki et al., 1994, Procházková 
et al., 2011) and enhance anti-oxidant proprieties of low molecular weight 
antioxidants (Yeh et al., 2005) 
 
Numerous reports have also demonstrated the pro-oxidants properties of 
flavonoids, under certain conditions, where the number of hydroxyl group 
substitution is directly proportional to their pro-oxidant abilities (Haenen et al., 
1997). More specifically, hydroxyl groups present in ring B where shown to 
significantly increase their ability to produce ROS (Heim et al., 2002, Hanasaki et 
al., 1994). Flavonoids are also able to reduce Cu2+  to Cu+ and induce  free 
radicals formation as a result (Cao et al., 1997). This is particularly important in 
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cancer cells, where Cu2+ has been reported to increase cancer cell proliferation 
and tumour growth (Wang et al., 2010a). In addition, the reduction of oxygen to 
a superoxide anion as well as reduction of Fe3+ to Fe2+  contributes to this 
phenomena (Procházková et al., 2011).  
 
Within cancer cells, reports have also demonstrated how flavonoids can act as 
pro-oxidants by inhibiting enzymes involved in cell growth, proliferation and 
mobility, such as phosphatidylinositol 3-kinase PI3K (Abotaleb et al., 2018), 
protein kinase B (Neagu et al., 2019) as well as inhibiting epidermal growth factor 
receptor proteins (Rodríguez-García et al., 2019).The pro-oxidant ability of 
flavonoids can be associated with their anti-oxidant feature where, the formed 
compound after flavonoids ROS scavenging is a highly reactive flavonoid 
phenoxyl (Bayrakçeken et al., 2003) which is subjected to additional oxidation 
yielding more stable compounds such as quinones (Hernández et al., 2009, 
Awad et al., 2002). The pro-oxidant proprieties of naringenin, naringin and 
apigenin were attributed to the formation of phenoxyl radicals which oxidize 
NADPH that leads to increase in oxygen uptake and formation of a highly reactive 
superoxide (Chan et al., 1999, Galati et al., 2002, Galati et al., 1999). 
 
  Cellular models of the glioblastoma  
 
As researchers begin to better understand the complex interaction between 
gliomas and their surrounding micro-environment, a transition away from 
xenograft tumour models towards nonimmunogenic in-vitro models is now at the 
forefront of preliminary GBM research. This is a result of their ability to mimic 
many in-vivo GBM characteristics as well as the high throughput nature of in-vitro 
models. A variety of in-vitro cellular models exist that replicate GBM in-vitro. The 





This malignant glioma cell line was established by Ponten and collages in 1975 
(Ponten, 1975) from a 75 year old patient. This cell line has been extensively 
used over the last 40 years in in-vitro and xenograft models (Radaelli et al., 2009, 
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Husain et al., 1998). It is capable of mimicking many immunohistochemical and 
histological features of human GBM as well as mimicking changes in tumour 
suppressor genes and oncogenic pathways (Wen and Kesari, 2008, Candolfi et 
al., 2007). Moreover, the tumour cells showed high level of cellular proliferation 
and expression, with 19 of the known ABC transporters reported to be expressed. 
It is also suggested that high passages after the establishment of the cell line 




This model was established from a 44 year old female by Ponten in 1975 (Ponten, 
1975). Despite major differences that exist between human GBM and the U87 
cell model such as having more homogenous, leaky vessels and less invasive 
non-diffusive growth pattern (de Vries et al., 2009), the U87 model has been 
utilised in assessing GBM angiogenesis and tumour angiogenic therapy (Radaelli 
et al., 2009). U87 cell line was reported to express P-gp and BCRP (Wijaya et al., 




The C6 rat glioma model is the one most commonly used in neuro-oncology in 
the study of low grade and high grade gliomas (Giakoumettis et al., 2018).  
This model was established by injecting adult Wistar-Furth rats with a 
carcinogenic chemical known was methylnitrosourea  (Benda et al., 1968). C6 
display a similar diffusive infiltrating invasion pattern to human GBM such as 
nuclear polymorphism, foci of tumour necrosis and high miotic index (Chicoine 
and Silbergeld, 1995, Doblas et al., 2010, Gieryng et al., 2017). As well as having 
the ability to invade and migrate in a similar fashion to that of human xenografts 
(Giakoumettis et al., 2018). 
 
However, a key histological difference when compared to human GBM is the lack 
of expression of glial fibrillary acidic protein GFAP which is a main component of 
astrocytes within the CNS (Chou et al., 2003). The expression of the tumour 
suppressor genes p53 and PTEN are also reported to be minimal compared to 
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human GBM (Asai et al., 1994). In addition, the cells were reported to loss their 
invasive nature and grow in an encapsulated mode when transplanted in Wister 




The LN229 model was established from a 60 year old female in 1979 (Diserens 
et al., 1981). The cells are reported to express mutated p53 and PTEN in a similar 
fashion to human GBM (Ishii et al., 1999). LN229 cells were reported to have the 
highest migration speed when compared to U251 and U87 models (Diao et al., 
2019). Immunoblot studies confirmed a 2-fold higher expression of BCRP in the 
nucleus of the cells compared to cytoplasmic extract, which suggested a possible 
secondary efflux site (Bhatia, 2013). P-gp, MRP-1 and MRP-2 were reportedly 
expressed in LN229 although in a lesser amount than BCRP (Bhatia, 2013, 
Bhatia et al., 2012). The LN229 model has been used to study apoptosis in 
addition to cellular migration and invasion (Zhang et al., 2009, Liu et al., 2014, 
Wang et al., 2018).  
 
 
 In-vitro models of the blood-brain barrier 
Many models for in-vitro BBB research have been developed and characterised 
over the last four decades to study BBB biology and drug transport. However, 
none of the models used behave exactly the same and hence irregularities in the 
outcome and the lack of a consciences on a gold standard model (Helms et al., 
2016). Small variabilities such as different laboratory condition and different 
providers impose a challenge in obtaining a well-defined view of the benefits and 
drawback of BBB in-vitro models. The following sections highlight some 
commonly used in-vitro BBB models. 
 
 
 Human origin models 
 
Human BBB models have been used in in-vitro research for over 15 years. The 
most widely used immortalised human BBB model is the hCMEC/D3 cell line 
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(Poller et al., 2008, Ohtsuki et al., 2013). This cell line has been extensively 
characterised compared to other models. hCMEC/D3 possess essential 
endothelial markers such as CD34, CD31, CD40 and von Willenbrand factor. In 
addition, this cell line expresses TJ proteins and efflux transporters such as P-gp 
and BCRP (Weksler et al., 2013, Poller et al., 2008, Vu et al., 2009). 
 
However, the expression of claudin-5, an important member of tight junction 
protein, has been reported to be low when compared to microvessels in-vivo 
(Urich et al., 2012). In addition, hCMEC/D3 monolayers demonstrated low 
transepithelial electrical resistance (TEER) values of 30-50 Ω.cm2, which is 
significantly below the in-vivo TEER of approximately 1000 Ω.cm2 and making 
them less suited for drug transporter studies (Weksler et al., 2005, Weksler et al., 
2013, Biemans et al., 2017).  
Another human cell line used in BBB research is the endothelial progenitor cells 
(EPC) which is derived from bone marrow or the umbilical cord. These cells were 
shown to express tight junction proteins ZO-1 and claudin-5. In addition, they 
expressed transporters such as GLUT-1, P-gp and BCRP. Much like hCMEC/D3 
cells, the limitation of the model is their low TEER values < 60 Ω.cm2. However, 
an elevation In TEER values was reported when cocultured with Bovine pericytes 
(Helms et al., 2016, Ponio et al., 2014).  
 
  Rodent origin models 
 
Rat brain endothelial cell lines were first isolated and established in 1994 (Roux 
et al., 1994). Rat endothelial cells express many drug efflux transporters such as 
P-gp and BCRP (Qosa et al., 2015) and proteins that are specific to BBB 
characteristics, such as tight junction proteins ZO-1 and occludin (Watanabe et 
al., 2013). Extensively used rat cell lines in BBB drug permeability studies include 
bEND.3, bEND.5, GP8 and GPNT (Olesen and Leonardi, 2003).  A further widely 
used rat model is the TR-CSFB model, which was optimised for permeability and 
transport studies. However, these cells are known to form leaky barriers (TEER: 
~90 Ω.cm2) and require growth at lower temperatures (Kitazawa et al., 2001, 
Hosoya et al., 2004). 
 
 
B.A.M. Elbakary, PhD Thesis, Aston University 2021. 56 
  Bovine based models 
 
Bovine endothelial models such as the BBEC-117 (Sobue et al., 1999) and SV-
BEC (Durieu-Trautmann et al., 1991) have been widely used as in-vitro BBB 
models. Bovine monolayers have a reported TEER value of 120-130 Ω.cm2 
(Gaillard and de Boer, 2000) and  have been used in drug transport and 
permeability studies (Ahmed-Belkacem et al., 2005a, Valdameri et al., 2011). 
Bovine models have been reported to being subpar in regards to transport activity 
and barrier tightness as well as lack of functional activity of ABC transporters 
(Hakkarainen et al., 2014, Anfuso et al., 2014). Bovine models are not frequently 
used in BBB models due to labour intensive extraction of primary cells and 
irregularities in reproducibility (Helms et al., 2016) as well as risk of infection of 
the cells with Creutzfeldt-Jakob or obtaining cells from a cow infected with mad 
cow disease. 
 
 Porcine based models 
 
The immortalised porcine brain endothelial cell line PBMEC/C12 was developed 
in 1996 (Teifel and Friedl, 1996) and has been successfully used in numerous 
studies to assess small molecular transport, gene/protein expression and 
endothelial cell surface receptor studies (Kaur and Badhan, 2017, Helms et al., 
2016, Torok et al., 2003, Franke, 2000, Lauer et al., 2004). 
 
PBMEC/C12 cells demonstrated key BBB characteristics such as restrictive 
paracellular pathways, expression of tight junctions such as ZO-1, and 
expression of efflux transporters such as BCRP and P-gp. The reported TEER 
values were in the region of 80-100 W.cm2 and are enhanced by supplementing 
the cells with fibronectin (Patabendige et al., 2013, Neuhaus et al., 2006). 
 
Immortalised cell lines have been an integral part of in-vitro research since the 
20th century, providing a powerful tool for applications such as studying 
cytotoxicity, drug metabolism, drug permeability, gene functions and producing 
vaccines and antibodies (Kaur and Dufour, 2012). However, there are limitations 
associated with using immortalised cell lines such as genetic and phenotypic 
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alterations from the originating tissue  with an increase passage number (Pan et 
al., 2009). Furthermore, following prolonged periods of time, immortalised cell 
lines are prone to contamination (Lorsch et al., 2014). In contrast to primary 
porcine cells, the PBMEC/C12 cell line lose their morphological and phenotypical 
features as well as important biological in-vivo markers compared to  the 
originating primary cells (Pan et al., 2009).  
 
Although immortalised BBB models are broadly used for in-vitro studies, they lack 
many BBB features and demonstrated comparatively low TEER values to human 
BBB cellular monolayer resistance. However, a novel BBB in-vitro model has 
gained traction from the isolation of brain microvascular endothelial cells directly 
from recently slaughtered pigs, resulting in high yield of endothelial cells with 
excellent monolayer formation and high resistance to drug permeation 




The first complete reported method for the isolation of primary porcine brain 
microvascular endothelial cells (PBMEC) was based on an isolation and 
extraction method used for extracting primary rat endothelial cells (Bowman et 
al., 1981, Franke, 2000). This method was later modified to provide a detailed 
method for isolation (Patabendige et al., 2013). The primary PBMEC model was 
developed due to the ease and convenience of obtaining pigs brains, higher yield 
of cells when compared to rat brain hemispheres and the ability of endothelial 
cells to retain their BBB phenotype characteristics when compared to primary 
bovine and rat cells. It has been reported that PBMEC grown in non-contact co-
cultures with astrocytes was critical for the development of BBB characteristics 
(Rubin et al., 1991).  However it was later demonstrated that growing the cells in 
an astrocyte conditioned media (ACM) in addition to adding BBB forming 
additives such as hydrocortisone and cAMP would yield a robust BBB in-vitro 
model suitable for drug permeability studies (Skinner et al., 2009, Gaillard et al., 
2001, Patabendige et al., 2013, Hoheisel et al., 1998, Thomsen et al., 2015). The 
high TEER values reported for PBMEC, in excess of 800 W.cm2, correspond to a 
restrictive model and reported low permeability of small molecules with sucrose 
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permeability ranging between 0.2-8 x10-6 cm/s (Patabendige et al., 2013, 
Lohmann et al., 2002, Franke et al., 1999) 
 
PBMEC were confirmed by western blot and PCR to express tight junction such 
as ZO-1 and ZO-2 (Huwyler et al., 1996, Matthes et al., 2011, Schulze et al., 
1997), Claudin-5 (Rempe et al., 2014, Kröll et al., 2009) and occludin (Rempe et 
al., 2014, Malina et al., 2009). Furthermore, a range of ABC efflux transporters 
have been identified within the model, which includes P-gp, BCRP, MRP-1 and 
MRP-4 (Lemmen et al., 2013, Parlow et al., 2009, Matthes et al., 2011).  
 
The well-defined expression of tight junctions and efflux transporters makes this 
an excellent model for drug permeation studies across the BBB (Helms et al., 
2016) as well as the model of choice to introduce continuous impedance TEER 
analysis due to the consistency of reported TEER values (Benson et al., 2013). 
 
  Limitations of current BBB cell culture models  
 
The endothelial microenvironment is coordinated through a variety of complicated 
chemical and mechanical signalling which makes the accomplishment of 
physiological endothelial phenotype in the laboratory a challenging task (Abaci et 
al., 2015, James and Allen, 2018). Systematic explorations of complex biological 
operations entail in-vitro models that mimic in-vivo interactions such as interstitial 
blood flow and intracellular communication, A feature that is missing in many in-
vitro BBB models. Many of the main elements of the in-vivo vasculature are 
relevant for tissue engineering, regenerative medicine, and vascular biology, 
these include hemodynamic shear stress, the extracellular matrix and 
interactions between multiple cell types (Srigunapalan et al., 2011).  
 
Modern in-vitro BBB models do not account for the role of shear stress, as a result 
of it being considered to have a negligible effect to the extracellular 
microenvironment, cellular morphology, and characteristics. An argument was 
made by Di and Kerns (Di and Kerns, 2015) which suggested that shear stress 
is insignificant since blood flow in the brain capillaries is very low, additionally, 
Difficulties in determining optimal cell culture conditions, conceptualising,  
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developing and scaling up flow-based cell models, has made them an 
unattractive option of in-vitro BBB research. These claims were later contested 
by studies that illustrated the importance of shear stress in replicating the in-vivo 
microenvironment as well as providing easy to set up flow models that replicate 
the homeostatic state of the brain and other organs (Elbakary and Badhan, 2020, 




Shear stress is a mechanical force that cells experience due to blood flow and 
interstitial fluid flow which produces frictional potencies. It plays essential roles in 
maintaining homeostasis and cellular remodelling (Chiu and Chien, 2011). 
Moreover, shear stress caused by laminal flow, is one of the key regulators of the 
endothelial phenotype and barrier integrity exhibited to have a fundamental role 
in the formation of distinctive phenotypes (Abaci et al., 2015). 
 
Endothelial cells act in response to shear stress by altering intracellular signalling, 
gene and protein expression (Chien, 2007). Mechanical forces acting on the 
vessel wall incorporate those of normal and circumferential stresses, both of 
which are caused by the activity of pressure and shear stress that acts parallel to 
the luminal surface of the vessels due to flow (Figure 1.10) (Nerem, 1993). 
Circumference pressure acts along the vessel wall boundary to cause stretching, 
while shear stress acts parallel to the cell surface and is a consequence of fluid 
viscosity and the velocity gradient amid adjacent layers of flowing fluid (Nerem, 
1993, Chien, 2007). 
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Figure 1.10 Normal stress compared to shear stress 
Schematic illustration showing the generation of shear stress by blood flow 
(parallel) and the generation of normal stress (perpendicular) (Chien, 2006). 
 
In the brain, microvascular capillaries typically are 10 µm in diameter and 
experience a flow rate of 6-12 nL/min which equates to 10-20 dynes/cm2 (Wong 
et al., 2013). In the local endothelium, normal and abnormal (disturbed) blood 
flow patterns induce different responses (Kaisar et al., 2017).  Shear stress is 
determined using (Equation 1) which illustrates that shear stress is directly 
proportional to flow and indirectly proportion to the radius of capillaries i.e. 





where SS is shear stress, µ is viscosity (mPa.s), Q is flow rate (mL/s), R is 
capillary radius (cm). 
 
Areas where flow has been disturbed become pathological, in that the balance 
between pro- and anti-angiogenic/pro- and anti-inflammatory states is no longer 
present leading to the occurrences of pathophysiological states such as ischemic 
stroke (Balaguru et al., 2016). Studies have demonstrated that intraluminal flow 
has a vital part in the development and maintenance of BBB in-vitro and in-vivo 
phenotypes (Desai  et al., 2002, Stanness et al., 2020). 
 
SS=4µQ/pr3     
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 Hollow fibre models  
 
Tissue culture on hollow fibres were first developed by Kanazek et al (Knazek et 
al., 1972). The model was later modified by Janirgo et al. and there after by 
Cucullo et al  (Janigro et al., 1999, Cucullo et al., 2002). The hollow fibre system 
consists of a polycarbonate hollow fibre chamber which is sealed by a glass 
bottom and a removable acrylic top (Figure 1.11). The hollow fibre is connected 
to a media reservoir through gas permeable tubing which allows the exchange of 
O2 and CO2. This is connected to a pumping system that can generate a media 
flow rate of up to 50 mL/min (Cucullo et al., 2002).  
An advantage of this system is the negligible extravasation of proteins, 
expression of ion channels and efflux transporters. However, drawbacks of this 
model include the requirement for a high seeding density during the initial set up 
of the system and the lack of visual observation of the intraluminal compartments 
to evaluate morphological and phenotypical changes in the endothelium. In 
addition, the system is not designed for high throughput screening and is 
technically challenging (Naik and Cucullo. L, 2012, Sivandzade and Cucullo, 
2018) 
 
The only BBB cell model to have been studied using this system is the PBMEC1/2 
system. Cells grown in this system demonstrated higher viability compared to 
models grown under static conditions and was less permeable to FITC-dextran 
compared to that in a non-flow model. The highest flow rate the cells were 
subjected to was reported to be 14 mL/min. No TEER values were reported in  
this study (Neuhaus et al., 2006), however, another study reported TEER values 
of < 250 Ω.cm2 (Cucullo et al., 2013). 
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Figure 1.11 Hollow fibre BBB model using PBMEC1/2 
The hollow fibre cartridge where PBMEC1/2 cells are seeded is connected by 
gas permeable tubing to a reservoir media bottle. Media is circulated by a 
pumping system with a maximum flow rate of 50 mL/min. Rat C6 cells were 




 Microfluidic platforms  
 
Microfluidic systems are a type of three dimensional in-vitro models consisting of 
an ‘organ-on-a chip’ device constructed from polydimethylsiloxane (PDMS) 
channels moulded using a photo-defined master mould and a porous tissue 
culture substrate which is then sealed between two channel networks (Figure 
1.12) (Esch et al., 2012). The benefits of this system in BBB modelling is having 
realistic dimensions and allows for the observing the cells in a 3D engineered 
physiological microenvironment by exposing the endothelium to physiological 
flow (Griep et al., 2013, Booth and Kim. H, 2012). Drawbacks of this model 
involve limited scalability, requiring high technical skills and equipment to achieve 
the model, in addition to the lack of quantification of critical BBB parameters such 
as TEER and selective permeability (Gastfriend et al., 2018). 
A study using bEND.3 mouse brain cells showed a significant improvement in 
TEER values when cells were exposed to 0.0223 dynes/cm2 with a reported 
TEER value of 140 Ω.cm2 in comparison to 15 Ω.cm2 when cells were grown 
under static conditions (Booth and Kim. H, 2012). Another study using human 
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hCMEC/D3 cells were exposed for 3 days to flow rate of 5.8 dynes/cm2 and 
demonstrated 3 fold increase in TEER values from 37 Ω.cm2 to 120 Ω.cm2 (Griep 
et al., 2013). 
 
 
Figure 1.12 Schematic representation of a microfluidic based model 
A microfluidic model made up of, a pump connected to the inlet of the channel to 
allow for the passage of media beneath the cells. The cells are seeded on a 
porous cell culture substrate and is sandwiched between two PDMS channels 
(Sivandzade and Cucullo, 2018). 
 
 Perfusion based interconnected chamber 
 
Recently, a novel cell culture flow-based chamber technology was developed and 
commercialised (Vozz, 2008, Iori et al., 2012), the QuasiVivoâ system (Kirstall, 
Sheffield, UK).  The QuasiVivoâ system utilises a flow model that is able to 
simulate blood flow between different cell culture chambers which represent 
tissues (Elbakary and Badhan, 2020, Haycock, 2014). There are 3 QuasiVivoâ 
models, the QV 500, 600 and 900.  
 
The QV500 system consists of 10 mm deep, 15 mm in width and can hold up to  
2 mL in volume (Figure 1.13). The chambers are suitable for surface culture 
models such as cells grown on coverslips but cannot house cell culture insert 
systems. The QV500 system was used by other groups to assess the benefit of  
dynamic media flow within an interconnected systems of chambers with differing 
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Figure 1.13 The Quasi vivo® 500 system 
An experimental set up of the QV500 system inside an incubator displaying a 





The QV600 system has chambers that are 22 mm deep, 15 mm in width and can 
hold up to 4 mL in volume (Figure 1.14). This system can be utilised using 
coverslips and 24-well inserts and can be used to establish a liquid/liquid 
interface (LLI) and air/liquid interface (ALI) (Sbrana and Ahluwalia, 2012). The 
system has a reservoir bottle where media exchange takes place and a peristatic 
pump that can be housed in an incubator. The QV600 has been utilised with 
permeable insert systems. For example an increase in barrier tightness 
(measured by TEER) was noted when using the QV600 ALI to develop an in-vitro 
pulmonary model cultured using NHBE on semi-permeable inserts (Chandorkar 
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Figure 1.14 The Quasi vivo® 600 system 
The QV600 model showing a peristatic pump, a reservoir bottle, an outlet for 
O2/CO2 exchange with a filter attached, a 2 mL chamber and connectors.  
 
 
Recently, a number of groups have utilised the QV600 system with cellular barrier 
models such as the intestinal epithelial cells (Caco-2) and pulmonary cells 
(NHBE, SAE) to assess the impact of shear stress produced by laminal flow on 
cellular viability, barrier proprieties and increased barrier tightness to better 
enhance in-vitro models and their suitability for drug permeability and toxicity 
testing by optimizing the microenvironment (Elbakary and Badhan, 2020, Giusti 
et al., 2014, Chandorkar et al., 2017). 
 
 
 Thesis aims and objectives  
 
The overall aim of this thesis is to enhance drug delivery to brain tumours by 
overcoming MDR resulting due to the presence of BCRP in the BBB and the BTB 
as well as assess the duality of phytocompounds as BCRP modulators and anti-
cancer agents. For this we commenced with the tumour site rather than the BBB, 
where we aimed to assess the dual ability of phytochemicals to modulate the 
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efflux action of BCRP and the anti-cancer proprieties they might exhibit in LN229 
human glioblastoma cells. Upon completing the first stage we then assessed the 
ability of optimal flavonoids to modulate the action of BCRP at the BBB. Once 
this stage was accomplished, we then utilised shear stress in the form of laminal 
flow to enhance BBB characteristics and increase barrier tightness that is to 
assess the permeability of optimal flavonoids across a more restrictive barrier.  
To realise those aims, the overall objectives were: 
 
 Chapter 2: 
 
• To assess the cytotoxicity of phytochemicals and anti-cancer agents 
• To assess the ability of phytochemicals to modulate the efflux action of 
BCRP  
• To assess the effect of phytochemicals to modulate the expression of 
BCRP  
• To assess the effect of phytochemicals on cellular migration  
• To assess the effect of flavonoids and anti-cancer agents on reactive 
oxygen species generation  
• To assess the effect of flavonoids and anti-cancer agents on the activation 
of caspases  
 
Chapter 3:  
 
• To optimise collagen culture surface coating using PBMEC/C12 cells  
• To develop and characterise an in-vitro BBB model using primary porcine 
brain cells 
• To assess the cytotoxicity of hesperetin, methotrexate and mitoxantrone 
within primary porcine brain cells 
• To demonstrate the efflux function of BCRP using the substrates 
methotrexate and mitoxantrone  
• To assess the permeability of hesperetin across the BBB model 
• To demonstrate the ability of hesperetin to modulate the efflux action of 
BCRP and enhance drug permeation across the BBB  
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Chapter 4:  
 
• To create a blood brain barrier model using PBMEC grown in 24-well 
inserts for use in the QV600 chamber 
• To determine the optimal flow rate suitable for PBMEC growth   
• To examine the effect of shear stress on cell proliferation  
• To examine the effect of shear stress on TEER values  
• To examine the effect of shear stress on ZO-1 tight junction protein 
expression 
• To assess the permeability of mitoxantrone and hesperetin across the 
BBB model, following exposure to shear stress    
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Chapter 2  
 
Phytochemical mediated 
modulation of breast cancer 
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 Background  
Gliomas are a common type of tumour occurring in the brain and spinal column 
and can be classified by their originating cell location. Gliomas contribute to about 
78% of all malignant tumours (Louis et al., 2007), with glioblastoma multiforme 
being the most frequent and malignant type. According to the World Health 
Organisation (Gaillard, 2021), 80% of these tumours are grade 4 and 5 which is 
considered  high grade tumours. Glioblastomas are a form of aggressive brain 
tumour which often presents with poor prognosis and a median survival time of 
less than 1.5 years (Rock et al., 2012, Ohka et al., 2012, Thakkar et al., 2014, 
Santos et al., 2011).  
Brain tumours among other CNS illnesses remain difficult to treat due to the 
inability of many therapeutic agents to obtain efficacious concentrations in the 
brain. Partly that’s because of active efflux transporters that limit blood to brain 
drug uptake. The impact of the limitations imposed by BBB and BTB on CNS 
indicated drug discovery/development pathways is clearly illustrated by the fact 
that it takes longer to develop CNS-indicated drugs (15 years) compared to non-
CNS indicated drugs (7-9 years) with a higher failure rate in clinical sitting 
(Alvarez et al., 2010). 
Glioblastoma, much like other malignancies, occur due to the uncontrollable cell 
proliferation, cell migration, invasion and infiltration to neighbouring tissue (Achrol 
et al., 2019, Demuth and Berens, 2004, Singh et al., 2010). 
Furthermore, the presence of active efflux transporters on the apical and 
basolateral membrane of the BBB and the BTB can significantly hinder drug 
transport into the brain (Stieger and Gao, 2015, On and Miller, 2014).  
The overexpression of ABC transporters, primarily BCRP and P-gp, has been 
reported in solid tumours and in drug-naïve tumours, where the originating tissue 
showed little to no expression of the transporters, with irregularities in the 
expression of ABC transporters related to more aggressive tumour phenotype 
(Scotto, 2003, Muriithi, 2020). This suggests that ABC transporters play a vital 
role in cancer progression beyond MDR and is contributor towards poor 
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prognosis (Wijaya et al., 2017, Ginguené et al., 2010).  In some cases, the tumour 
compromises the integrity of the BBB and forms a heterogenous vasculature 
known as the blood tumour barrier (BTB). The BTB has numerous distinct 
characteristics such as non-fenestrated capillaries, ununiform permeability and 
expression of efflux transporters  (Arvanitis et al., 2020a) These impose major 
obstacles for drug delivery targeting GBM (Groothuis, 2000, Schlageter et al., 
1999). 
 
Current chemotherapeutics routinely used for treatment of GBM alone or in 
combination with radiotherapy (Stupp et al., 2007) have low efficacy because 
most tumours are resistant to multimodality approaches and multiple anti-cancer 
agents, none of which are considered curative (Weller et al., 2015, van Tellingen 
et al., 2015, Gomez-Zepeda et al., 2019). Despite agents such as temozolomide 
being widely used clinically, it has been reported that at least 50% of patients are 
refractory to it as a solo agent, with the remaining requiring additional modes of 
therapy such as temozolomide with radiotherapy, resulting in an improved overall 
mean survival rates (Johnson and O'Neill, 2012).  There is an urgent need to 
improve the efficacy of anti-cancer agents rather than devising new ones. One 
recent approach to overcome the limited permeability of anti-cancer agents at the 
BBB and the BTB is to modulate the efflux functions of members of the ABC 
family of transporters that take part in the MDR phenotype such as BCRP (Mao 
and Unadkat, 2015, Ni et al., 2010, M. F. Gonçalves et al., 2020) 
 
A common concern with more recent transporter inhibitors has been their toxicity 
profile and poor specificity which have resulted in clinical failure (Gimenez-
Bonafe et al., 2008).  Therefore, there is a need to identity and develop newer 
inhibitors or modulators of both drug transporters and their regulatory elements, 
to enable a broad approach to the modulation of the transport function at CNS 
barriers. 
 
One potential group of candidate compounds which are often perceived as being 
‘safe’ are natural product derived phytochemicals, commonly from the flavonoids 
group, which have demonstrated an ability to modulate the expression and 
 
B.A.M. Elbakary, PhD Thesis, Aston University 2021. 71 
function of xenobiotic clearance pathways (Cooray et al., 2004b, Imai et al., 
2004a, Ahmed-Belkacem et al., 2007, Pick et al., 2011, Valdameri et al., 2012). 
 
Several flavones, flavonols and flavanones were reported to possess potent anti-
tumour activity (Edenharder et al., 1993), with these properties being associated 
with their ability to induce ROS production (Hadi et al., 2000), induce apoptosis 
(Abotaleb et al., 2018), participate in cell cycle arrest and supress cancer invasion 
(Rodríguez-García et al., 2019). Similar activities have been demonstrated with 
all flavonoid groups (Braganhol et al., 2006, Nguyen et al., 2004, Santos et al., 
2011, Lin et al., 2008, Shen et al., 2010, Wang et al., 2010c). Furthermore, a 
variety of flavonoids demonstrate pro-oxidative properties, in contrast to their 
activity as antioxidants, inducing cancer cell death often by increasing ROS 
production (Gibellini et al., 2010, Sharma et al., 2007b, Kachadourian and Day, 
2006, Jeong et al., 2009, Lee et al., 2010, Hattori et al., 2009, Matsuzawa and 
Ichijo, 2008).  
 
Combining phytochemicals with well-known anticancer agents in-vitro and in-vivo 
has been shown to exhibit promising results. For example, combining genistein 
with cisplatin was able to significantly reduce cancer cell proliferation and induce 
apoptosis in BxPC-3 pancreatic tumour xerographs (Mohammad et al., 2006). In 
laryngeal cancer cells HeP-2 using a combination of cisplatin and quercetin lead 
to an increased induction of apoptosis within the cells via ROS production and 
activation of caspases-8 and 9 (Sharma et al., 2005). Similarly, in MCF-7 breast 
cancer cells, combining doxorubicin with quercetin distinctly reduced cancer cell 
migration, and reduced cancer cell proliferation. In addition, quercetin was able 
to reduce unwanted cytotoxic effects to healthy normal cells (Staedler et al., 
2011).  
 
Moreover, current clinical trials have displayed the safety and efficacy of 
phytochemicals either solely as anti-cancer agents (Fantini et al., 2015) or in 
combination with a chemotherapeutic agent (Saldanha and Tollefsbol, 2011, 
Gupta et al., 2013, Kanwar et al., 2012). Breast cancer patients undergoing 
radiotherapy were administered ECGC 400 mg orally three times a day. 
Compared to patients undergoing radiotherapy alone, the results showed 
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reduced serum level of VEGF and HGF, in addition to supressed activation of 
MMP-9 and MMP-3 (Zhang et al., 2012). Indeed, within the in-vitro glioblastoma 
cell models such as LN229, flavonoids have been shown to modulate BCRP 
functional transporter activity and trigger apoptosis pathways (Sharma et al., 
2007a, Siegelin et al., 2009, Gibellini et al., 2010, Kachadourian and Day, 2006, 
Jeong et al., 2009, Lee et al., 2010, Hattori et al., 2009, Matsuzawa and Ichijo, 
2008).   
 
The phytocompounds were selected for this experimental study based on reports 
that demonstrated the compounds’ anti-cancer properties and/or modulatory 
action of ABC efflux transporters and/or ability to permeate across in-vitro BBB 
models since chemotherapeutic agents must first bypass the BBB in order to 
reach the tumour site (Table 2.1). In addition, previous work by our group have 
demonstrated the potential for flavonoids to modulate BCRP functional 
transporter activity at the BBB and blood-CSF-barrier (Kaur and Badhan, 2017). 
These compounds were not reported to have been screened in the LN229 human 
glioblastoma cell line pervious nor did their effect on the expression of ABC efflux 
transports in that cell line. Further, availability and affordability of the 
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Table 2.1 phytochemicals reported anti-cancer proprieties, blood brain barrier permeability and   interaction with members 











Interaction with ABC 
transporters 
Hesperetin Induce cell cycle 
arrest,  
 Apoptosis 
(Sambantham et al., 
2013),  inhibit 




C6 (Ersoz et al., 2019) 
PC-3 (Sambantham et 
al., 2013) 
SiHa (Alshatwi, 2012) 
 
J 5.75 ± 0.4 nmol/min/mg 
protein in Caco-2 
monolayer using 500 µM of 
the compound (Kobayashi 
et al., 2008) 
BCRP substrate (Brand et 
al., 2011) 
BCRP inhibitor (Morris and 
Zhang, 2006) 
P-gp inhibitor (Morris and 
Zhang, 2006) 
Rutin Reduce tumour 
growth, 
Induce apoptosis and 
cell cycle arrest (Chen 
et al., 2013, 
Ganeshpurkar and 
Saluja, 2017, Caparica 
et al., 2020) 
LAN-5 (Chen et al., 
2013) 
C6 (da Silva et al., 
2020) 
786-O (Caparica et al., 
2020) 
 
Papp 0.05 x 10-6  ± 0.03 
cm/s in Caco-2 monolayer 
using 100 µM of the 
compound (Yang et al., 
2014) 
P-gp inhibitor (Mohana et 
al., 2016) 
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Quercetin Reduces cell 
proliferation and 
Induces of Cell death 
(Lu et al., 2006, Chen 
et al., 2004) 
HL-60 (Kang and 
Liang, 1997) 
HT-29, HepG2,PC-3 
(Pan et al., 2018) 
65.54% permeable across 
BMVEC monolayer model 
(Ren et al., 2010) 
Papp 147.7 ±20.8 nm/s 
across ECV304 monolayer 
(Youdim et al., 2004a) 
Papp  2.02 x 10-6 ± 0.38 cm/s 
in Caco-2 monolayer using 
100 µM  of the compound 
(Yang et al., 2014) 
P-gp Substrate (Wang et 
al., 2005b) 
BCRP substrate (Sesink et 
al., 2005) 
BCRP inhibitor (Yoshikawa 
et al., 2004, Cooray et al., 
2004a) 
BCRP inducer (Ebert et al., 
2006) 
Estrone NR NR NR BCRP inhibitor (Kaur and 
Badhan, 2017) 
Baicalin Induces Apoptosis 
(Chen et al., 2001, Yu 
et al., 2015, Shieh et 
al., 2006), reduces 
migration (Gao et al., 
2017a, Duan et al., 
2019) 
Inhibits metastasis 
(Zhou et al., 2017a)  
LNCaP, JCA-1 (Chen 
et al., 2001) 
HePG2, SMMC-7721 
(Yu et al., 2015) 
 
Pe 0.0455 x 10-6  cm/s 
when tested in artificial 
PAMPA BBB model using 
200 µM of the compound 
(Tarragó et al., 2008) 
Papp 3.89 x 10-6  ± 0.48 
cm/s in Caco-2 monolayer 
using 23.7 µM of the 
compound (Li et al., 2012) 
BCRP inhibitor (Kalapos-
Kovács et al., 2015a) 
MRP-2 inhibitor (Akao et 
al., 2007, Li et al., 2012) 
 
Curcumin Apoptosis, 
suppression of cell 
proliferation, invasion, 
and migration (Anand 
et al., 2008, 
HepG2 (Fan et al., 
2014, Cao et al., 2008) 
A549 (Liu et al., 2017, 
Chen, 2009) 
HT29 (Sharma, 2009) 
NR BCRP inhibitor (Shukla et 
al., 2009b) 
MDR-3 inhibitor (Wen et al., 
2019) 
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Kunnumakkara et al., 
2017) 
HeLa (Cai et al., 2012, 
Shang et al., 2016) 




(Erdogan et al., 2018, 
Memariani et al., 2020, 
Ghanbari-Movahed et 
al., 2021, Camargo et 
al., 2012) 
HT-29 (Krajka-Kuźniak 
et al., 2017) 
PC-3 (Erdogan et al., 
2018) 
 
NR P-gp inhibitor (Mohana et 
al., 2016) 
Naringenin reduce Cell migration,  
Induce Apoptosis 
(Chang et al., 2017, 
Shi et al., 2021, 
Memariani et al., 
2020) 
A549 (Chang et al., 
2017) 
TCC (Ghanbari-
Movahed et al., 2021) 
NR P-gp inhibitor (de Castro et 
al., 2007, de Castro et al., 
2008) 
BCRP inhibitor (Ahmed-
Belkacem et al., 2005b, 
Takahata et al., 2008) 








(Banjerdpongchai et al., 
2016) 
HeLa (Wang et al., 
2015) 
Papp 3.78 x 10-6  ± 0.32 
cm/s in Caco-2 monolayer 
using 50 µM of the 
compound (Yang et al., 
2014) 
P-gp inhibitor (Mohana et 
al., 2016) 
α -Naphthoflavone Induces apoptosis (Yu 
et al., 2019) 
MCF-7 (Merchant et al., 
1993) 
NR P-gp inhibitor  (Datta et al., 
2015) 
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Chemosensitizer 
(Datta et al., 2015) 
Biochanin A Induce apoptosis, 
inhibit cell migration (Li 
et al., 2018b, 
Bhardwaj et al., 2014, 
Szliszka et al., 2013, 
Jain et al., 2015) 
PANC1(Bhardwaj et al., 
2014) 
A549 (Li et al., 2018b) 
NR P-gp inhibitor (Zhang and 
Morris, 2003) 
BCRP inhibitor (Zhang et 
al., 2004a, Pick et al., 2011) 
Benzo (a) pyrene Carcinogenic  
Tumorigenic (Gelboin, 
1980, Goyal et al., 
2010) 
WHCO-1 (Dzobo et al., 
2018) 
MCF-7, HePG2 
(Hockley et al., 2006) 
NR NR 
Fisetin Induce apoptosis 
Inhibit invasion and 
migration and cell 
proliferation (Imran et 
al., 2021, Mukhtar et 
al., 2016, Mukhtar et 
al., 2015) 
HT-29 (Suh et al., 
2009) 
U266 (Jang et al., 
2012) 
BT549 (Li et al., 2018a) 
PANC1 (Jia et al., 
2019) 
NR BCRP inhibitor (Yarla and 
Ganapaty, 2013a) 
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 Aims and objectives 
 
Given the ability of flavonoids to initiate apoptosis and attenuate the functional 
activity of BCRP at the BBB and within glioblastoma cells, our aim for this chapter 
was to examine the impact of flavonoids on BCRP functional transporter activity 
and expression in LN229 cells and their dual role as apoptosis and reactive 
oxygen species inducing agents. To achieve the aims for this chapter, the overall 
objectives were to utilise the LN229 GBM cellular model: 
 
• To assess the cytotoxicity of phytochemicals and anti-cancer agents 
• To assess the ability of phytochemicals to modulate the efflux action of 
BCRP  
• To assess the effect of phytochemicals to modulate the expression of 
BCRP  
• To assess the effect of phytochemicals on cellular migration  
• To assess the effect of flavonoids and anti-cancer agents on reactive 
oxygen species generation  
• To assess the effect of flavonoids and anti-cancer agents on the activation 
of caspases  
 
B.A.M. Elbakary, PhD Thesis, Aston University 2021. 78 
  Materials  
Dulbecco's modified essential media with 4.5 g/L glucose (DMEM),  Antibiotic-
Antimycotic® were obtained from Biosera (Sussex, UK); Ko143, RIPA lysis buffer 
system, Tris Buffered Saline with Tween 20 (TBST) 20X were obtained from 
Santa Cruz Biotechnology (Texas, USA);  TruPAGE TM Precast gels 4-8%; 
TruPAGE™ TEA-Tricine SDS Running Buffer, TruPAGE™ TEA-Tricine SDS 
transfer buffer were obtained from Sigma-Aldrich (UK); monoclonal ABCG2 
antibody (BXP-21) (#sc-58222) and β-actin C4 HRP (#sc-47778) were obtained 
from  Santa Cruz Biotechnology (Texas, USA), goat anti-mouse IgG (H+L) 
secondary antibody (#62-6520) was obtained from Thermofisher (Oxford, UK); 
curcumin was obtained from Cayman Chemicals (Cambridge, UK); and all other 
chemicals were sourced from Sigma (Dorset, UK) and are HPLC grade. 
For this chapter, the following modulators/flavonoids were considered α-
naphthoflavone; baicalin; benzo-a-pyrene; biochanin A; curcumin; estrone; 
fisetin; hesperidin; hesperetin; naringin; naringenin; quercetin and rutin.  Stock 
solutions of all test compounds were prepared in dimethyl sulfoxide (DMSO) and 






The immortalised human glioblastoma cell line LN229 (ATCC: CRL-2611) were 
cultured in media containing 1% FBS, 1% v/v antibiotic-antimycotic and DMEM. 
Cells were seeded in an uncoated T75 flask and grown for 4-5 days until 
confluency. Thereafter, 1 mL 0.25% w/v trypsin-EDTA was added to the flask for 
3 minutes and then neutralised with an equal amount of growth media.  The cell 
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In order to assess the impact of the phytochemicals of interest on cellular viability 
and determine the 50% cellular growth inhibitory concentration (IC50), a MTT 
assay was conducted.  A sterile stock solution of MTT was prepared by dissolving 
5 mg/mL MTT powder in DMSO and stored at -20 °C. This was diluted to a 
working concentration (1:10) in sterile serum free growth media on the day of 
experiment. In each well of the 96-well plates, 50,000 LN229 cells were seeded 
and incubated for 24 hours at 37 °C, 5% CO2. The cells were treated with a 6-
fold concentration range of modulators (0.001-100 µM) and were incubated for 
an additional 24 hours. The media was subsequently removed, and the cells were 
washed with pre-warmed PBS. The cells were incubated with MTT working 
solution (0.5 mg/mL) in the dark for 4 hours. Thereafter, the MTT solution was 
removed, and the formed purple formazan crystals were dissolved using 100 
µL/well DMSO. After gentle shaking for 15 minutes, the absorbance was 
measured at 362 nm and the percentage viability calculated according to 
equation (2). 
 
%	#$%%&%'(	)*'+*%*,- = !"	$%&'(%$)*+	,)	-(+$-+.	*+//&!"	$%&'(%$)*+	,)	*')-('/	*+//& 	× 	100       (2)     
 
 
To assess the impact of modulators on BCRP functional activity, changes in the 
intracellular accumulation of the BCRP fluorescent substrate, Hoescht-33342 
(H33342), were assessed in the presence and absence of the modulators (Kaur 
and Badhan, 2015, Kaur and Badhan, 2017). Into each well of 96-well plates, 
50,000 LN229 cells were seeded and incubated for 24 hours at 37 °C and 5% 
CO2.  Cells were then pre-incubated with phytochemicals over a 6-fold 
concentration range of flavonoids, 0.001-100 µM, for 1 hour. Thereafter the cells 
were incubated for an additional 1 hour with identical phytochemicals 
concentrations in addition to 10 µM H33342. The media was then removed, and 
the cells were washed twice with ice cold PBS, 20 µL of PBS was added to each 
well before being frozen at -80 °C for 20 minutes. The cells were then removed 
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from the clear plate into a black 96-well plate by scraping. The fluorescence of 
H33342 was measured (Tecan Spark 10M®) at an excitation and emission 
wavelength of 360 nm and 489 nm respectively.  
 
 
This assay was conducted to examine the effect of the flavonoids on the cellular 
migration properties of LN229 cells (Sharma et al., 2007b, Jonkman et al., 2014). 
Into each well of a 24-well plate, 70,000 LN229 cells were seeded and incubated 
for 24 hours (at least 90% confluence). The cells were subsequently incubated 
for an additional 24 hours in serum free growth media (Sharma et al., 2007b, 
Jonkman et al., 2014). Thereafter, vertical and horizontal scratches were made 
in the middle of each well using a 20 µL pipette tip. The cells were then washed 
with pre-warmed PBS to remove any cell debris. Based on the results of the MTT 
assay, a non-toxic concentration of each flavonoid was incubated in addition to 
untreated wells within the incubation chamber of an optimal imaging microscope 
capable of automated looped imagery of each well (Cell-IQ®) (CM Technologies, 
Finland). Images were captured every 30 minutes for a 24-hour period. The 
percentage of wound closure was calculated using the Cell-IQ® analyser™ 
software according to the differences between initially scratched area and new 
closure area following the incubation period.  In order to compare effectiveness, 




Western blotting was carried to the assess the effect of the phytochemicals on 
the expression of BCRP in LN229 cells. LN229 cells were seeded into T25 flasks 
at a density of 50,000 cells/flask to achieve 80% confluence. The cells were then 
incubated with the phytochemicals at a concentration of 50 µM for a further 24 
hours. Thereafter, the flasks were washed with ice cold PBS and removed from 
the surface of the flask using a cell scraper. The cells suspension was centrifuged 
at 3000 rpm (Hettich MIKRO 200) for 5 minutes at 4 °C. The supernatant was 
then discarded, and the pellet was resuspended with 50 µL of RIPA buffer and 
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homogenised three times by passing through a 29G needle at 4 °C. The lysed 
cell suspension was centrifugated at 13,500 rpm for 25 minutes at 4 °C.  The total 
protein in each sample was determined using Thermo scientific Pierce® 
Microplate BCA Protein Assay Kit.  Thereafter, 40 µg of protein from each 
flavonoid exposed sample was prepared for SDS-PAGE by the addition of 2.5 µL 
LDS 4X sample buffer, 1 µL DTT 10X sample reducer to a final total volume of 
30 µL with sterile filtered water. The samples were heated at 70 °C for 10 minutes 
before being transferred into wells of a TruPAGE TM Precast SDS-PAGE gel (4-8 
%). 
 
A Bio-Rad Mini Trans-Blot® system was used for electrophoresis and run using a 
TruPAGE™ TEA-Tricine SDS Running Buffer (1:50) at 180 V for at least 40 
minutes or until the blue dye approached the end of the cassette. Thereafter, the 
gel was washed with ultrapure water and placed on to a PVDF membrane for 
protein blotting. The PVDF membrane was pre-activated prior to use, in methanol 
for 10 minutes and soaked in transfer TruPAGE™ TEA-Tricine SDS 
transfer Buffer 20X (1:50 dilution) with 20% methanol. The membrane was then 
submerged within the cassette into the gel tank with ice cold transfer buffer and 
blotting commenced at 50 V for 2 hours and 45 minutes. The membrane was 
then washed with ultrapure water and exposed to Ponceau stain (0.1% w/v 
Ponceau S in 5% v/v acetic acid) for one minute to allow for the visualisation of 
the transferred proteins on the membrane. The membrane was then washed with 
TBST for 15 minutes until the dye was removed, followed by blocking in 5% w/v 
skimmed powdered milk blocking buffer for 6 hours. 
 
Thereafter, the membrane was incubated with the monoclonal ABCG2 antibody 
(BXP-21) (1:200 dilution) overnight at 4 °C.  The blots were then washed three 
times for 5 minutes each in TBST, before being incubated with goat anti-mouse 
IgG (H+L) secondary antibody (1:15000 dilution) for 2 hours. The membrane was 
subsequently washed three times in TBST buffer for 5 minutes each time, before 
being incubated with Clarity™ Western ECL Substrate for 1 minute. Thereafter, 
the membrane was placed on transparent film and transferred to a developing 
cassette then developed using a CL-X PosureTM X-ray film. Following 
visualisation, membranes were stripped using a mild stripping agent (glycine  
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15 g, SDS 1 g, Tween-20 10 mL, ultrapure water up to 1 L) (Abcam, 2020) and 
subsequently blocked for 3 hours at room temperature in 10% w/v skimmed 
powdered milk blocking buffer before being incubated with β-actin C4 HRP 
(1:8000 dilution) for 1 hour at room temperature and developed and visualised as 




To assess the potential for optimal flavonoids to activate ROS pathways in LN229 
cells, 25,000 cells/well were seeded into a 96-well black clear bottom plates and 
allowed to attach for 24 hours. To detect intracellular ROS production, a 
fluorescent probe 2',7’-dichlorofluorescin diacetate (DCF-DA) cellular ROS 
Detection assay kit (Ab113851, Abcam Cambridge, UK) was utilised.  Once DCF-
DA diffuses into the cell, it undergoes deacetylated by esterase to a non-
fluorescent compound. ROS has the ability to oxidize this non-fluorescent 
compound to a highly fluorescent 2’ 7’ dicholoroflouresciene (DCF).  
 
The cells were washed with 1X buffer and treated with 25 µM DCF-DA and 
incubated for 45 minutes at 37 °C, 5% CO2. Thereafter, the cells were treated 
with the selected optimal flavonoids and control anti-cancer agents methotrexate 
and temozolomide all at 10 µM, 100 µM and 500 µM, for 2 hours. The 
fluorescence of DCF was then detected (Tecan Spark 10M®) at an excitation and 
emission wavelengths of 485 nm and 535 nm respectively. The increase in 
fluorescence intensity was used to assess the generation of net intracellular ROS 
when compared to control (un-treated cells). 
 
 
In order to assess the ability of the flavonoids to activate apoptosis in LN229 cells, 
the detection of caspase activity was assessed using a fluorescence Caspase-
3/7 assay kit (Cayman Chemicals, 10009135, USA). This assay kit utilises a 
specific substrate, N-Ac-DEVD-N’-MC-R110, which can be cleaved by active 
caspase-3 or caspase-7, to generates a product which is highly fluorescent, and 
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can be detected at an excitation and emission wavelengths of 485 and 535 nm, 
respectively.  
 
LN229 cells were seeded at a 40,000 cells/well into a 96-well plate and incubated 
for 24 hours.  Thereafter the cells were treated with selected optimal flavonoids 
and control anti-cancer agents methotrexate and temozolomide, all at 10 µM and 
100 µM for 4 hours. The plate was subsequently centrifuged at 800 g for 5 
minutes and the media was aspirated, followed by addition of 200 µL/well of 
assay buffer.  The plate was then centrifuged for further 5 minutes at 800 g, 
before the supernatant was removed and 100 µL/well of cell lysis buffer was 
added and then incubated under gentle shaking at room temperature for 30 
minutes. Thereafter, the plate was centrifuge for an additional 10 minutes at 800 
g followed by the transfer of 90 µL into the corresponding wells of a black 96-well 
plate. Into each well, 10 µL of assay buffer and 100µL of the caspase-3/7 
substrate solution were also added. The plate was then incubated for 90 minutes 
at 37 °C, 5% CO2. The resulting florescence of the cleaved DEVD substrate was 
measured at an excitation and emission wavelengths of 485 nm and 535 nm 
respectively (Tecan Spark 10M®). 
 
 Statistical Analysis 
All data is presented as mean ± standard deviation, with experiments being 
conducted in at least 3 replicate independent experiment unless otherwise stated. 
Where appropriate, statistical analyses was performed in GraphPad Prism 9 (La 
Jolla, California, USA), with t-tests and one-way ANOVA used to determine 
differences between the mean values. A significance p-value of <0.05 was 













In order to investigate the cellular toxicity towards LN229 cells, a MTT cytotoxicity 
assay was conducted across a 6-fold concentration (0.001-100 µM) range of the 
modulators for 24 hours. All the modulators displayed limited toxicity up to 100 
µM, with an IC50 determined only for biochanin A (113.4 µM [CI: 64.39-199.8 µM]) 
and benzo-a-pyrene (40.2 µM [CI: 18.03-87.94 µM]) (Figure 2.1).  
 
 
To further investigate the cytotoxicity of the anti-cancer agents methotrexate and 
temozolomide as a baselines for comparison, LN229 cells were exposed to a 6- 
fold concentration range, 0.001-100 μM, of anti-cancer agents for 24 hours 
(Figure 2.2). Temozolomide demonstrated an IC50, 302.3 μM [CI: 165.9-708.6 
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Figure 2.1 Cellular 
cytotoxicity of modulators 
of BCRP in LN229 cells. 
Cells were seeded and grown 
on 96 well plate for 24 hrs prior 
to exposure to modulators 
over a concentration range of 
0.001-100 µM for 24 hours. 
Thereafter, 20 µL/well (0.5 
mg/mL) of MTT was added 
into each well and the plate 
was incubated for 4 hours. The 
media was aspired and a 100 
µL/well of DMSO was added 
before absorbance was 








Figure 2.1 Cellular 
cytotoxicity of modulators 
of BCRP in LN229 cells 
(Cont.) 
Cells were seeded and grown 
on 96 well plate for 24 hrs 
prior to exposure to 
modulators over a 
concentration range of 0.001-
100 µM for 24 hours. 
Thereafter, 20 µL/well (0.5 
mg/mL) of MTT was added 
into each well and the plate 
was incubated for 4 hours. 
The media was aspired and a 
100 µL/well of DMSO was 
added before absorbance 
was measured for each well 
at 570 nm. 
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Figure 2.2 Cellular cytotoxicity of methotrexate and temozolomide in 
LN229  
Cells were seeded and grown on 96 well plate for 24 hours prior to exposure to 
anti-cancer agents over concentration range of 0.001-1000 µM for 24 hours. 
subsequently, 20 µl/ well (0.5 mg/mL) of MTT was added and the plates were 
incubated for 24 hours. The media was aspired and 100 µL/well of DMSO was 





To assess the ability of the modulators to inhibit BCRP efflux function in LN229 
cells, the intracellular accumulation of H33342, a fluorescent BCRP probe 
substrate, was assessed in the absence and presence of modulators across 6 
fold concentration range, (0.001-100 µM) (Figure 2.3). Estrone, naringin, α-
naphthoflavone demonstrated no significant increase in intracellular H33342 at 
all concentrations studied. Biochanin-a and the non-flavonoid carcinogen benzo-
a-pyrene demonstrated statistically significant increases at 100 µM only (P ≤ 
0.001). Using the commercially available BCRP modulator Ko143 demonstrated 
a statically significant increase (1.5-1.55-fold) in intracellular accumulation of 
H33342 over concentration range (1,10 µM). The greatest increase in H33342 
intracellular accumulation was demonstrated with baicalin (1.8-2.2-fold) and 
hesperetin (2.5-2.8-fold) over the range of (1-100 µM) (Figure 2.3).  
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Figure 2.3 H33342 accumulation assay for BCRP function in LN229 cells. 
Cells were grown in 96-well plates for 24 hours prior to incubation and 
subsequently washed with pre-warmed PBS prior to being pre-incubated for 1 
hour with BCRP modulators over a concentration range of 0.001- 100 µM in blank 
media. Thereafter the cells were incubated with the same modulator 
concentrations in addition to 10 µM H33342  for 1 hour. The cells were washed 
with cold PBS and stored in -80°C for 20 minutes. Thereafter, the cells were 
moved to an opaque bottom plate and fluorescence was measured on a multi-
plate reader at excitation and emission wavelengths 355 nm and 460 nm 
respectively. Statistical significance was conducted relative to control.  * P≤ 0.05, 
** P ≤ 0.01, *** P ≤ 0.001 and **** P ≤ 0.0001. 
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H33342 accumulation assay for BCRP function in LN229 cells (cont). 
Cells were grown in 96-well plates for 24 hours prior to incubation and 
subsequently washed with pre-warmed PBS prior to being pre-incubated for 1 
hour with BCRP modulators over a concentration range of 0.001- 100 µM in blank 
media. Thereafter the cells were incubated with the same modulator 
concentrations in addition to 10 µM H33342  for 1 hour. The cells were washed 
with cold PBS and stored in -80°C for 20 minutes. Thereafter, the cells were 
moved to an opaque bottom plate and fluorescence was measured on a multi-
plate reader at excitation and emission wavelengths 355 nm and 460 nm 
respectively. Statistical significance was conducted relative to control.  * P≤ 0.05, 
** P ≤ 0.01, *** P ≤ 0.001 and **** P ≤ 0.0001. 
 





H33342 accumulation assay for BCRP function in LN229 cells (cont). 
Cells were grown in 96-well plates for 24 hours prior to incubation and 
subsequently washed with pre-warmed PBS prior to being pre-incubated for 1 
hour with BCRP modulators over a concentration range of 0.001- 100 µM in blank 
media. Thereafter the cells were incubated with the same modulator 
concentrations in addition to 10 µM H33342  for 1 hour. The cells were washed 
with cold PBS and stored in -80°C for 20 minutes. Thereafter, the cells were 
moved to an opaque bottom plate and fluorescence was measured on a multi-
plate reader at excitation and emission wavelengths 355 nm and 460 nm 
respectively. Statistical significance was conducted relative to control.  * P≤ 0.05, 
** P ≤ 0.01, *** P ≤ 0.001 and **** P ≤ 0.0001. 
 
 





H33342 accumulation assay for BCRP function in LN229 cells (cont). 
Cells were grown in 96-well plates for 24 hours prior to incubation and 
subsequently washed with pre-warmed PBS prior to being pre-incubated for 1 
hour with BCRP modulators over a concentration range of 0.001- 100 µM in blank 
media. Thereafter the cells were incubated with the same modulator 
concentrations in addition to 10 µM H33342  for 1 hour. The cells were washed 
with cold PBS and stored in -80°C for 20 minutes. Thereafter, the cells were 
moved to an opaque bottom plate and fluorescence was measured on a multi-
plate reader at excitation and emission wavelengths 355 nm and 460 nm 
respectively. Statistical significance was conducted relative to control.  * P≤ 0.05, 





In order to examine the ability of the modulators to inhibit cellular migration of 
human glioblastoma cells LN229, a wound healing assay was conducted where 
the migration of cells within a scratch was quantified over 24 hours in the 
presence of 50 µM of the modulators (Figure 2.4). Incubation with all modulators 
resulted in a statistically significant decreases in cellular migration compared to 
control (P ≤ 0.0001), except for naringin, naringenin and rutin (Figure 2.4A).  
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Biochanin-a and curcumin demonstrated < 2% migration following 24 hours with 
the overall order of migration (Figure 2.4A) being: untreated > naringin > rutin > 
naringenin > hesperidin > quercetin > fisetin > estrone > benzo-a-pyrene > 
baicalin > α-naphthoflavone >  hesperetin >curcumin > biochanin-a (Figure 2.4 A 
and B).  
 
Figure 2.4 Cellular migration assay 
(A) percentage closure of LN229 cells following scratches made to the plate 
surface.  Cells were incubated with serum free media containing 50 µM of the 
modulators for 24 hours within a Cell-IQ incubator. Automated looped images 
were taken prior to incubation and after 24 hours of incubation with the horizonal 
dashed line represent a 50% closure cut-off. A: untreated; B: α-naphthoflavone; 
C: baicalin; D: benzo-a-pyrene; E: biochanin A; F: curcumin; G: estrone; H: 
fisetin; I: hesperidin; J: hesperetin; K: naringin; L: naringenin; M: quercetin; N: 
rutin. Statistical significance was conducted relative to control (A). ** P ≤ 0.01 and 
**** P ≤ 0.0001.  
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Cellular migration assay(cont.) 
(B) images of the wound at 0 and 24 hours of LN229 cells following scratches 
made to the plate surface.  Cells were incubated with serum free media 
containing 50 µM of the modulators for 24 hours within a Cell-IQ incubator. 
Automated looped images were taken prior to incubation A: untreated; B: α-
naphthoflavone; C: baicalin; D: benzo-a-pyrene; E: biochanin A; F: curcumin; G: 
estrone; H: fisetin; I: hesperidin; J: hesperetin; K: naringin; L: naringenin; M: 
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To assess the impact of modulators on BCRP protein expression, LN229 cells 
were incubated with 50 µM modulators for 24 hours and western blot analysis 
was conducted (Figure 2.5). Hesperetin demonstrated the highest statistically 
significant downregulation in BCRP protein expression, -2.56 ± 0.45-fold (P ≤ 
0.0001), followed by curcumin -0.65 ± 0.1-fold (P ≤ 0.01) and biochanin A -1.4 ±  
0.01-fold (Figure 2.6). All the other modulators lead to an increase in the 
expression of BCRP in the following order: rutin > quercetin > benzo-a-pyrene > 
fisetin > naringenin > baicalin > naringin > α-naphthoflavone > estrone > 
hesperidin (Figure 2.6). 
 
Based upon the studies so far, baicalin and hesperetin were selected as optimal 
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Figure 2.5 Changes on BCRP expression after 24-hour incubation with the modulators 
Cells were seeded in T25 flasks and incubated with 50 µM of the modulators once confluent for 24 hours. cells protein extraction was 
conducted using RIPA buffer. 40 µg of the protein was loaded on a 4%-8% SDS PAGE gel to separate the bands, the gel was then 
transferred to a PVDF membrane and incubated with BXP21 (Santa Cruz,USA) for 24 hours at 4 C, then incubated with mouse anti-







Figure 2.6 Fold change in BCRP expression 
Cells were seeded in T25 flasks and incubated with 50 µM of the modulators 
once confluent for 24 hours. cells protein extraction was conducted using RIPA 
buffer. 40 µg of the protein was loaded on a 4%-8% SDS PAGE gel to separate 
the bands, the gel was then transferred to a PVDF membrane and incubated with 
BXP21 (Santa Cruz,USA) for 24 hours at 4 °C, then incubated with mouse anti-
rabbit IgG (Themofisher,UK). ECL (Bio-RAD, UK) detection was conducted. 
Significant difference in protein expression is shown relative to control. * P ≤ 0.05; 












In order to assess the ability of baicalin and hesperetin, and current therapeutic 
anti-cancer agents methotrexate and temozolomide to activate ROS pathways in 
human glioblastoma LN229 cells, a ROS assay was conducted at 10 µM, 100 µM 
and 500 µM of each compound.  Methotrexate 10 µM resulted in the largest ROS 
detection, 5.16 ± 2.44-fold with both modulators demonstrated at least a 3-fold 
increase (all statistically significant) in ROS production when compared to 
untreated cells (Figure 2.7). 
 
 
Figure 2.7 Radical oxygen species detection assay 
LN229 cells were grown in 96-well plates for 24 hours prior to being washed with 
1X buffer. The cells were treated with 25 µM DCF-DA and incubated for 45 
minutes. Thereafter, the cells were treated with baicalin, hesperetin, 
methotrexate and temozolomide (10 µM, 100 µM, 500 µM) for 1 hour. DCF-DA 
fluorescence was measured at excitation and emission 485 nm and 535 nm. 
Results are presented normalised against untreated cells. * P ≤ 0.05; ** P ≤ 0.01; 








The activation of caspase 3 and 7 is known to be the functional endpoint of the 
apoptotic cascade and hence are used as a marker for apoptosis. A caspase-3/7 
fluorometric assay was utilised to assess activation of apoptosis pathways 
through the cleavage of N-Ac-DEVD-N’-MC-R11 to a fluorescent product. 
Flavonoid modulators resulted in an excess of a 9-fold increase in caspase 
activity compared to control at both 10 µM and 100 µM (Figure 2.8).  Furthermore, 
temozolomide demonstrated an approximately 8-fold increase and methotrexate 
10.5-12 fold increase at both 10 µM and 100 µM (Figure 2.8).   
 
Both flavonoids demonstrated a statistically significant increase in caspase 
activity when compared to untreated cells (P < 0.0001). Furthermore, a 
statistically significant (P < 0.01) higher caspase activity (compared to untreated 
control), was noted for hesperetin 100 µM (10.23 ± 0.37 fold) and baicalin 10 µM 
(11.12 ± 1.51 fold) than temozolomide at 10 µM (7.91 ± 0.53 fold) and 100 µM 






















Figure 2.8 Caspase-3/7 assay 
LN229 cells were seeded in 96 well plates for 24 hours followed by incubation 
with 10 µM and 100 µM of each compound (baicalin, hesperetin, methotrexate 
and temozolomide) for 4 hours. The resulting N-Ac-DEVD-N’-MC-R110 parent 
was cleaved by cellular Caspases to a fluorescent product, detected at an 
excitation and emission 485 nm and 535 nm. Results are presented normalised 







Increasing evidence now suggests that flavonoids may play a role as modulators 
of BCRP, potentially leading to an enhancing intracellular accumulation of 
substrate molecules (Dei et al., 2019, Fan et al., 2019, Imai et al., 2004b, 
Kalapos-Kovács et al., 2015b, Kaur and Badhan, 2015, Kaur and Badhan, 2017, 
Mao and Unadkat, 2015, Peña-Solórzano et al., 2017, Pick et al., 2011, Santos 
et al., 2015, Sowndhararajan et al., 2017, Tiwari et al., 2011, Toyoda et al., 2019, 
Xu et al., 2018). In the context of brain cancers, the localisation of BCRP and 
other ABC transporters at the BBB and BTB offer a novel target to enhance 
intracellular accumulation of anti-cancer agents. Previously, we demonstrated 
the impact of flavonoids on the modulation of BCRP at the BBB (Kaur and 
Badhan, 2017) and blood-CSF-barrier (Kaur and Badhan, 2015).  In this chapter 
we examined the potential of flavonoids to modulate BCRP function in human 
glioblastoma LN229 cells, in addition to examining the role of flavonoids in 
initiating ROS-production, activation of Caspase apoptosis cascade and 




13 modulators were screened for their cytotoxicity towards LN229 across a 6-fold 
log-concentration range.  The majority of modulators displayed limited toxicity up 
to 150 µM, with biochanin-a and the non-flavonoid carcinogen benzo-a-pyrene 
displaying a cell viability IC50 of ≤ 150 µM (Figure 2.1). Previous studies have 
utilised biochanin-a at concentrations below the calculated IC50 in LN229 cells 
(Habicht et al., 2014). Furthermore, benzo-a-pyrene is a known polyaromatic 
carcinogen and used as a positive control and has been reported to demonstrate 
an IC50 of ~10 µM in human brain microvascular endothelial cells (Jeong et al., 
2019). The lack of significant cellular toxicity for most flavonoids concurs with the 
typical concentrations reported for many flavonoids within the brain, namely ~50 
µM (Peng et al., 1998, Youdim et al., 2003, Youdim et al., 2004b). Toxicity of the 
anti-cancer compounds towards the LN229 cells, were not what was expected. 
With reported IC50 values (Figure 2.2) slightly higher than those reported in other 
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cancer cell lines. This might be due mutated p53 and PTEN that is resembles 
human GBM reported to be expressed in the LN229 cells line (Ishii et al., 1999). 
This would suggest that the LN229 cells might have been obtained from a high-
grade glioblastoma However, there are no reports or additional information from 




The fluorescent BCRP probe substrate H33342 was used as a tool to assess 
BCRP efflux function in the presence of modulators.  Our results demonstrated a 
range of responses over a phytochemical concentration range of 0.001-100 µM, 
with the greatest increase in H33342 intracellular accumulation demonstrated 
with baicalin (1.8-2.2-fold) and hesperetin (2.5-2.8-fold) over the range of 1-100 
µM which was more than that demonstrated by the commercially available BCRP 
modulator Ko143 (1.5-fold) across 1-10 µM (Figure 2.3). Both baicalin and 
hesperetin have been previously demonstrated to inhibit BCRP efflux at a low 
IC50 of < 50 µM (Cooray et al., 2004b, Kalapos-Kovács et al., 2015b, 
Sowndhararajan et al., 2017).  The exact mechanism of this interaction is thought 
to occur at the level of the cytosolic ATPase element of the transporter (Peña-
Solórzano et al., 2017) or the transmembrane binding sites (Fan et al., 2019). 
 
 
A main feature of glioblastomas are their ability to invade their surrounding 
microenvironment, migrate and metastasise (Johansen et al., 2016). 
Moreover, BCRP plays a role In the ability of cancer cells to migrate where, BCRP 
was reported to regulate the transport of active substrates such as extracellular 
matrix adhesion molecules which are critical for the ability of cancer cells’ 
migration and invasion  (Lye et al., 2019). It has been demonstrated that 
pharmacological modulation BCRP reduces migration in U251 stem cells glioma 
(Gong et al., 2014) and PANC-1 pancreatic cancer cells (Wang et al., 2010b). 
 
The majority of modulators demonstrated an ability to hinder cellular migration 
with fisetin, estrone, benzo-a-pyrene, baicalin, hesperetin, curcumin and 
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biochanin-A demonstrating a 50% or greater inhibition of migration at 
concentration 50 µM (Figure 2.4). Previous reports have highlighted a similar 
ability to modulate metastasis in different tumour cell lines for fisetin and curcumin 
(Ham et al., 2015), baicalin (Gao et al., 2017b, Zhu et al., 2018a), hesperetin 
(Zhang et al., 2017) and biochanin A (Zhao et al., 2018). This inhibitory 
mechanism is thought to occurs through inhibition of the activity of 
metalloproteases such as MMP-2 and MMP-9, previously elucidated for baicalin 
(Wang et al., 2010c, Zhu et al., 2018b) and hesperetin (Mao et al., 2017, Demuth 
and Berens, 2004, Singh et al., 2010, Santos et al., 2015).  
 
 
In order to further assess the effect of the modulators on the expression of BCRP 
in LN229 cells, western blot was conducted following incubating LN229 cells for 
24 hours with 50 µM flavonoids (Figure 2.5). Hesperetin demonstrated the largest 
down regulation in BCRP expression, -2.56 ± 0.45-fold (P ≤ 0.0001), followed by 
curcumin and biochanin-A (Figure 2.6). The remaining modulators increased the 
expression of BCRP.  
The transcriptional regulation of BCRP, as with many ABC transporters, is 
thought to be governed by a range of nuclear hormone receptors (Wang and 
Negishi, 2003, Xu et al., 2005) and the interference of these signalling pathways 
under physiological and pathophysiological conditions provides a new approach 
to modulate BCRP function at the CNS barriers (Mahringer and Fricker, 2010, 
Hartz and Bauer, 2011, Bauer et al., 2006). Many members of the nuclear 
receptor superfamily are known to regulate drug transporters this includes the 
pregnane-X-receptor (PXR), the constitutive androstane receptor (CAR) and the 
aryl hydrocarbon receptor (AhR) (Jacob et al., 2011, Xu et al., 2005, Dauchy et 
al., 2008b, Granberg et al., 2003). The regulation of many of the transporter 
proteins is controlled by endogenous and exogenous compounds, some of which 
are thought to be flavonoids, which act to activate the receptors and subsequently 
leads to changes in transporter gene and protein expression (Mahringer and 




Based on the cellular toxicity, accumulation, migration assay, and Western blot, 
baicalin and hesperetin were selected as two candidates to take forward, in part 
due to their lower cellular toxicity, significant increase in intracellular H33342 
accumulation, inhibition effects on cellular migration and downregulation of 




Whilst many flavonoids are known to modulate ABC transporter function, their 
role as potential anti-cancer agents, namely metastatic inhibitors and apoptosis 
inducers were further investigated using a ROS production assay and caspase- 
activation assay. Flavonoids are well known as free radical scavengers, but also 
demonstrated to function as pro-oxidatives leading to cytotoxicity, possibly due 
to the generation of ROS and leading to induction of apoptosis (Miura et al., 1998, 
Kuntz et al., 1999). With a disproportional increase in intracellular ROS, cancer 
cell cycle arrest, senescence and apoptosis will often follow. This often is a result 
of opening of mitochondrial permeability transition pores which releases 
cytochrome-c and thereby causing the activation of caspase. The switch to pro-
oxidant behaviour can often occurs under certain conditions, such as high 
concentrations of transition metal ions, an alkali pH environment and the 
presence of oxygen molecules (Blokhina et al., 2003). When assessing the 
impact of flavonoids and anti-cancer agents to enhance intracellular ROS, we 
demonstrated that methotrexate 10 µM caused a significant increase in ROS 
(5.16 ± 2.44-fold) with all other modulators demonstrated at least a 3-fold 
increase (all statistically significant) in ROS production when compared to 
untreated cells (Figure 2.7). 
 
Reports have indicated baicalin as possessing pro-oxidant properties in both 
human glioma and breast cancer cells (Gao et al., 2016, Zhu et al., 2018b), 
possibly with a role for endogenous copper (or other transition metals), controlling 
its pro-oxidant properties and modulation of cell growth (Liu et al., 2019).  It has 
been reported that  baicalin is capable of forming a complex with intracellular 
copper which is then able to initiate the redox cycling to increase ROS production 
and mitochondrial-dependent apoptosis cell death (Liu et al., 2019).  Additionally, 
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it has been demonstrated that flavonoids which include a structural phenol B ring 
are capable of forming phenoxyl radicals which can then oxidise NADH and 
leading to free radical oxygen activation (Chan et al., 1999). 
 
 Ability of hesperetin and baicalin to activate caspase pathways 
 
Programmed cell death (apoptosis) is responsible for vital biological functions 
such as elimination of unwanted damaged cells and maintenance of 
homeostasis. Irregularities in occurrence of apoptosis plays a part in tumour 
formation, progression and developing anticancer drug resistance (Ziegler and 
Groscurth, 2004, Ghobrial et al., 2005). Subsequently, triggering apoptosis  has 
emerged a primary means in cancer drug development (Goldar et al., 2015). One 
of the mechanisms through which cellular apoptosis can be mediated is through 
the caspase’s family of specific cysteine proteases, which are otherwise inactive 
within the cytosol. Upon activation, they play a primary role in the cellular 
apoptosis process and are an attractive target for glioblastoma treatments (Fulda, 
2018). Flavonoids have been demonstrated to activate the caspase molecular 
pathways in human glioblastoma cells (Das et al., 2009, Kong et al., 2019, Souza 
et al., 2018, Ghobrial et al., 2005) 
 
The active caspase-3/7 substrate, N-Ac-DEVD-N’-MC-R110, was utilised given 
its ability, upon cleavage by caspase enzymes, to yield a fluorescent compound 
capable of being detected. Different caspases have distinctive but overlapping 
cleavage sights, for example caspase -3/7 have the same cleavage sight where 
cleavage occurs after the second Asp (Asp-Glu-Val-Asp). The cleavage of 
caspase-3/7 is a functional end point for the apoptosis process (Ghavami et al., 
2009). Baicalin and hesperetin were subsequently assessed for the impact on 
this pathway at 10 µM and 100 µM (Figure 2.8). At both concentrations, a 9-fold 
increase in caspase activity was observed compared to control at both 10 µM 
and 100 µM (Figure 2.8) in addition to increases in activity for both temozolomide 




Flavonoids have been reported on as having pro-apoptotic properties in-vitro 
(Braganhol et al., 2006, Nguyen et al., 2004) as well as temozolomide in U251 
cells (Li et al., 2015) and methotrexate in RIE-1 (Papaconstantinou et al., 2001).  
 
In-vitro, baicalin has been shown to reduce cell proliferation of myeloma cell lines 
(NCI-H929 and U266), lymphoma cell lines (NCEB1) and lymphatic leukaemia 
cell lines (HL-60 and THP-1) (Kumagai et al., 2007). In addition, studies have 
reported its apoptotic effects in T24 human bladder cancer (Lin et al., 2013) A549 
lung cancer cell line (JJ et al., 2017) and HeLa cervical cancer cells (Yong et al., 
2015). Moreover, baicalin was shown to activate caspase-3 in U937 lymphoma 
cell line, however, the study showed that the baicalin’s effect was concentration 
dependent where, a high dose of baicalin has to be used in order to produce the 
desired apoptotic effect (Zakki et al., 2018), the same study also reported that 
baicalin was able to supress anti-oxidant enzymes and increase ROS generation 
(Zakki et al., 2018). In a further study, conducted in human osteosarcoma cells, 
baicalin was able to initiate substantial generation of ROS and was able to induce 
apoptosis through the activation of caspase -3 and -9 and inhibition of BcL-2 
proteins responsible for regulation of cell death (Wan and Ouyang, 2017). 
 
Previous research reported that hesperetin can induce apoptosis in rats with 
colon cancer (Aranganathan and Nalini, 2013), as well as in in-vitro cancer 
models such as  HT-29 colorectal adenocarcinoma cells (Rajamanickam et al., 
2012), gastric cancer  (Zhang et al., 2015a), MCF-7 breast cancer cell line (Palit 
et al., 2015), PC-3 prostate cancer cell line (Sambantham et al., 2013) and SiHa 
cervical tumour  cell lines (Alshatwi, 2012). Furthermore, hesperetin was shown 
to trigger apoptosis by increasing ROS generation in SGC-7901human gastric 
cancer cell lines (Zhang et al., 2015b).   
 
Much like baicalin, hesperetin also inhibited BcL-2 and induced caspase-3, 
caspase-9 (Green and Kroemer, 2004, Chen and Lesnefsky, 2011) and caspase-
7 (Palit et al., 2015). The apoptotic action of hesperetin in various cell lines 
involves the formation of an oxidant/antioxidant imbalance as hesperetin possess 
both pro-oxidative and anti-oxidant proprieties (Haidari et al., 2009), such that it 
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is able to reduce activities of anti-oxidants such as superoxide dismutase (SOD) 




To conclude, the expression of the efflux transporter BCRP at the BTB in 
glioblastoma is a major contributor in MDR, which results in sub-optimal 
concentration of anti-cancer drugs at the tumour site. In this study, we screened 
13 phytochemicals in human glioblastoma cells LN229 for their cytotoxicity, ability 
to modulate the efflux function and expression of BCRP and reduce cancer cell 
migration.  
 
Based on the results obtained, we have identified two optimal flavonoids 
hesperetin and baicalin and have demonstrated their ability to modulate the 
action and expression of BCRP as well as pro-oxidant and apoptosis inducing 
proprieties within LN229 glioblastoma cell line.  
 
This chapter highlights the potential for these two flavonoids to be further 
investigated as pro-oxidant agents alone or in combination with existing 
anticancer agents susceptible to BCRP efflux at the BBB and/or BTB. In the 
following chapter, hesperetin was selected as the optimal flavonoid to assess its 
ability to permeate across an in-vitro BBB model and modulate the efflux action 
of BCRP at the BBB and therefore enhance the permeability of anti-cancer 
















Chapter 3  
 
Enhancing the permeability of anti-
cancer agents across an in-vitro 























Elements of this chapter have been published in the following 
manuscripts: 
 
Elbakary, B. and R. K. S. Badhan (2020). "A dynamic perfusion based blood-
brain barrier model for cytotoxicity testing and drug permeation." Scientific 
Reports 10(1): 1-12. 
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The blood brain barrier (BBB) constitutes a significant obstacle to drug delivery 
for brain tumours, primarily as a result of the presence of tight junctions localised 
between the cells of the BBB endothelium which renders the intercellular 
endothelial space shut (Gomez-Zepeda et al., 2019, Brazil, 2017).  
This is further augmented by the presence of ABC efflux transporters, such as 
BCRP, which plays a major role in the MDR phenotype (Tiwari et al., 2011). 
BCRP has been shown to play a significant role in limiting the penetration of many 
structurally unrelated anti-cancer agents such as methotrexate, mitoxantrone, 
doxorubicin and topotecan amongst others (Ni et al., 2010, Wijnholds et al., 2000, 
Cisternino et al., 2004, Breedveld et al., 2005, Toyoda et al., 2019). With 
glioblastoma reported to be the deadliest form of brain cancer (Tan et al., 2020), 
permeation of anti-cancer drugs across the BBB becomes a critical pre-requisite 
for successful drug delivery to gliomas. 
 
The role of BCRP in limiting brain delivery of anticancer agents has been 
extensively demonstrated. For example, the correlation between the expression 
of BCRP and poor response to 5-fluorouracil has been reported in breast cancer 
patients (Burger et al., 2003, Yuan et al., 2008). In non-small cell lung cancer 
patients, the expression of BCRP was also reported to be linked with resistance 
to platinum-based chemotherapeutic agent vinorelbine and poor survival (Yoh et 
al., 2004).  
 
Regarding glioblastoma, the expression of BCRP at the BTB as well as the BBB 
has been reported to corelate with poor response to GBM therapy  (Mao and 
Unadkat, 2005, Wang et al., 2019). Wild type BCRP knockout mice with 
oncogene induced glioblastoma were found to demonstrate an up to 3-fold 
increase in the concentration of dasatinib in the core of the tumour upon its 
dissection (Agarwal et al., 2012). Moreover, gefitinib permeability across the BBB 
was found to be hindered by the presence of BCRP in-vitro in MDCK II cells as 
well as in-vivo in mice (Agarwal et al., 2010). Furthermore, vandetanib 
penetration across the BBB and into mice brains was shown to be limited by the 




Modulation and inhibition of BCRP was proposed to overcome its efflux function 
and increase permeability of substrates across the BBB (Mao and Unadkat, 2015, 
Ni et al., 2010). Many BCRP modulators have come to light as inhibitors of BCRP 
efflux function. These include fumitremorgin C (FTC) (Rabindran and LM, 2000), 
GF120918 (Duan and You, 2009, Suzuki and Watanabe, 2019) and Ko143 (Giri 
et al., 2008). However, their cytotoxicity and lack of selectivity limits their 
widespread clinical use (Zhang et al., 2004b).  
 
Interest in naturally occurring phytochemicals has increased over the past 
decade, due to their potent anti-cancer activities (Prakash et al., 2013) and ability 
to modulate the efflux function of BCRP (Zhang et al., 2004c, Gao et al., 2017b, 
An and Morris, 2010). Studies have demonstrated the effect of various 
phytochemicals in modulating BCRP (Kaur and Badhan, 2017). This is 
achievable at low concentrations, such as biochanin-a, benzoflavone, and 
chrysin at 30 µM, were able to inhibit BCRP in breast cancer cell line MCF-7 and 
increase influx of mitoxantrone. In the same cell line, hesperetin, quercetin and 
resveratrol were also able to increase intracellular accumulation of mitoxantrone 
by inhibiting BCRP (Cooray et al., 2004b, Pick et al., 2011). In human leukaemia 
cells line K-562, naringenin and genistein have also shown to modulate efflux 
function of BCRP (Imai et al., 2004a). Moreover, quercetin and curcumin where 
found to modulate the function of BCRP and down regulate its expression in 
porcine microvascular endothelial cell line (Kaur and Badhan, 2017) 
 
Methotrexate is used in treating primary CNS lymphoma and glioblastoma (Zhu 
et al., 2009, Sane et al., 2014). Methotrexate formally known as amethopterin is 
a folate derivative that is used in lower doses to manage autoimmune diseases 
such as rheumatoid arthritis and psoriasis. It is administered at higher doses to 
treat a number cancers such as  head and neck, brain, breast, lung and bladder 
cancer (Sane et al., 2014). Studies have shown that methotrexate has limited 
distribution into the brain where rodent brain interstitial fluid was assessed for 
accumulation using brain micro-dialysis with a brain-to-plasma ratio of 0.051 ± 
0.32 (Devineni et al., 1996). A similar study was performed in humans which 
displayed an even lower brain-to-plasma methotrexate ratio, 0.032 ±0.094 
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(Blakeley et al., 2009). A primary cause of the limited distribution into the brain is 
the role of BCRP in effluxing methotrexate (Sane et al., 2014, Agarwal et al., 
2010). An additional often used treatment for tumours is mitoxantrone. 
Mitoxantrone is a type II topoisomerase inhibitor that is used in regiments to treat 
acute myeloid leukaemia, breast cancer, non-Hodgkin’s lymphoma, and liver 
cancer. In addition, its used as a TRAIL sensitising agent in glioblastoma cell 
lines (Senbabaoglu et al., 2016, Taylor et al., 2011). Mitoxantrone is a known  be 
a BCRP substrate (Nakanishi and Ross, 2012, Özvegy et al., 2001) and 
resistance to mitoxantrone has been strongly corelated to the efflux function of 
BCRP (Doyle et al., 1998, Higgins, 1995, Miyata et al., 1999). 
 
In this chapter, temozolomide was replaced with mitoxantrone due to conflicting 
studies reporting on the effect of BCRP as a contributor to MDR towards 
temozolomide where, knockdown of BCRP did not have an effect on the 
sensitivity of temozolomide (Wijaya et al., 2017), while others stated that BCRP 
was a contributor in reducing temozolomides sensitivity in treating glioblastoma 
(Chua et al., 2008, Bleau et al., 2009). In addition, HPLC detection issue were 
encountered during the method development for temozolomide which is 
suspected to be due to compound degradation (Kapçak and Şatana Kara, 2018). 
Further, it was decided to focus on one optimal flavonoid, hesperetin, as it 
displayed stronger abilities in modulating the expression of BCRP at the BTB.  
 
 Aims and objectives 
 
Utilising results from the previous chapter, the focus of this study was on 
hesperetin and its ability to modulate BCRP efflux function in a BBB in-vitro 
model.  The aims were to assess the ability of hesperetin to permeate across the 
BBB, in addition to modulating the efflux function of BCRP in an in-vitro BBB 
model. Subsequently, our goal was to enhance the transport of methotrexate and 
mitoxantrone across the BBB. 
  
In order to achieve those aims, the objectives were to: 
 
• Optimise collagen culture surface coating using PBMEC/C12 cells  
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• Develop and characterise an in-vitro BBB model using primary porcine brain 
cells 
• Assess the cytotoxicity of hesperetin, methotrexate and mitoxantrone within 
primary porcine brain cells 
• Demonstrate the efflux function of BCRP using the substrates methotrexate 
and mitoxantrone  
• Assess the permeability of hesperetin across the BBB model 
• Demonstrate the ability of hesperetin to modulate the efflux action of BCRP 




Dulbecco's modified essential media with 4.5 g/L glucose (DMEM), minimum 
essential media (MEM), phenol red free DMEM 4.5 g/L, new born calf serum 
(NCS), foetal bovine serum (FBS), Leibovitz-15 (L-15), Hams F12, Antibiotic-
Antimycotic® were obtained from Biosera (Sussex, UK); Rat tail-1 collagen 1 g 
solution and plasma derived bovine serum (PDBS) (Firstlink, UK); Ko143 was 
obtained from Santa Cruz Biotechnology (Texas, USA); HEPES buffer solution 
and 0.25% trypsin-EDTA were obtained from (Gibco, UK); bovine collagen type-
1 50 µg/mL was obtained from (Thermo fisher, UK); ZO-1 1A12 monoclonal anti-
body, goat anti-mouse IgG H+L: super clonal secondary antibody were obtained 
from (Thermofisher, UK); Phalloidin-iFluor 488 reagent (ab176753) was obtained 
from (Abcam, UK); Thincerts® were obtained from Greiner Bio-One (Stonehouse, 
UK); all other chemicals were sourced from Sigma (Dorset, UK) and are HPLC 
grade. Stock solutions of all test compounds were prepared in dimethyl sulfoxide 





 Culture of C6 rat astrocytes 
C6 rat astrocytes are typically used to obtain astrocyte conditioned media (ACM) 
utilised in the development of the PBMEC system (Patabendige et al., 2013).  C6 
cells were obtained from Cell Line Services (Germany). Cryopreserved cells were 
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thawed and resuspended in a T75 flask containing media prepared from Hams 
F12:DMEM (50:50), 7.5% v/v new-born calf serum, 5 µg/mL transferrin, 0.5 U/mL 
heparin, 0.5% v/v antibiotic/antimycotic and 7 mM L-glutamine.  
The cells were grown in an uncoated T75 flask at 37 °C, 5% CO2 for 3 days. At 
80% confluency, the cells were washed with calcium and magnesium free PBS, 
followed by the addition of 2 mL 0.25% w/v trypsin-EDTA for 5 minutes. 
Thereafter, the cell suspension was resuspended in 10 mL C6 media and 
centrifuged for 5 minutes at 1500 rpm, 4 °C. The resultant cell pellet was then 
resuspended in C6 media and split into two T75 flasks. The used media  from the 
C6 cells was aspirated, changed daily and filtered through a 0.22 µm filter and 
stored at 4 °C and used within one week of collection. The media obtained is 
termed astrocyte conditioned media (ACM). 
 
 Culture of immortalised PBMEC/C12 
 
 
Cells, in-vivo, are not packed tightly together to form tissues, rather the majority 
of the tissue volume is made up of a meshwork of proteins called the extracellular 
matrix (ECM). The ECM is made up of proteins such as collagen, fibronectin, 
elastin and laminin which are secreted by fibroblasts (Lodish et al., 2000). These 
function to support the cellular cytoskeleton and facilitate cellular communication 
as well as regulate cell growth and proliferation (Frantz et al., 2010). Collagen is 
the most abundant protein in mammals making up 25% of the total protein mass 
(Alberts et al., 2002) and its use in tissue culture pertains to its function to support 
cellular growth, proliferation and differentiation (Heino, 2007, Kleinman et al., 
1981). The type of culture surface coating greatly affects cell behaviour and the 
response observed is reliant on both cell culture type and coating used as a 
substrate (Kleinman et al., 1987, Frantz et al., 2010).  
 
Herein, we aimed to assess the impact of species-specific collagen to develop 
an optimal in-vitro BBB model, using the rapidly growing immortalised 
PBMEC/C12 model, prior to utilising primary cells. PBMEC/C12 cells were 
obtained from Dr. M. Teifel  (institute  fur  Biochnemie, Tenchische Hochschule 
Darmstadt, Germany). A T75 flask was coated with 1% w/v gelatine and cells 
seeded and grown in C6 growth media: ACM media (1:1). Cells achieved 
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confluency within 3-5 days post seeding. At 90% confluency, cells were washed 
with calcium and magnesium  free  PBS  and  2  mL  0.25% w/v trypsin-EDTA  
was added  to  the  flask  and  placed  in  the  incubator  for  5  minutes  thereafter  
the  cell suspension was placed in 10 mL fresh media and centrifuged for 5 
minutes at 1500 rpm, 4 °C. The formed cell pellet was then resuspended in 1 mL 
media and counted using a haemocytometer for seeding in 24-well inserts.  
 
 
 The impact of species-specific collagen on the formation of a 
robust BBB model 
 
 
In order to assess the impact of species-specific collagen on barrier formation, 
50,000 PBMEC/C1-2 were seeded into 24-well inserts coated with a combination 
of bovine collagen (50 µg/mL) and fibronectin (7.5 µg/ml) or rat tail collagen (200 
µL/mL) and fibronectin (7.5 µg/mL).  PBMEC/C12 media is made up of a 50:50 
C6 media and ACM was supplemented with 1 µg/mL fibronectin to enhance 
attachment. The transepithelial electrical resistance (TEER) was measured for 5 
days using a chopstick electrode (STX2) and voltmeter (EVOM) (World  Precision  
Instrument).  The TEER was calculated according to equation (3): 
 
TEER Values (Ω. cm2) = (R Cell monolayer – R Blank insert) x SA   (3) 
 
Where SA  is the surface  area  of  the  permeable  insert  (cm2),  R Cell  monolayer 
is  the resistance across  permeable  insert  with  cells (Ω) and R Blank insert is the 




Porcine brain endothelial cells were isolated according to the methods reported 
by (Cantrill et al., 2012, Patabendige et al., 2013) with adaptations (Elbakary and 
Badhan, 2020, Kaur and Badhan, 2017). Porcine brain hemispheres were 
obtained from a local abattoir (Long Compton, Oxford, UK) within 30 minutes of 
slaughter and transported on ice cold Leibovitz-15 (L-15) media supplemented 
with 1% v/v penicillin and streptomycin. Hemispheres were placed into a sterile 
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beaker containing PBS with 1% v/v penicillin and streptomycin and washed to 
remove the meninges, blood vessels, choroid plexus and capillaries. The white 
matter was removed, and the grey matter excised and placed into a sterile beaker 
containing MEM supplemented with 10 mM HEPES and 1% v/v penicillin and 
streptomycin. The grey matter was chopped into smaller pieces using a sterile 
scalpel and passed through a 50 mL syringe into a T75 flask containing 50 mL 
MEM supplemented with 10 mM HEPES and 1% v/v penicillin and streptomycin.  
 
Thereafter 15 mL of the tissue suspension was transferred into a 40 mL Dounce 
tissue homogeniser containing 25 mL MEM supplemented with 10 mM HEPES 
and 1% v/v penicillin and streptomycin. The tissue suspension was homogenised 
with a loose (“A”) pestle gently for 15 strokes, followed by 15 strokes using the 
tight (“B”) pestle. Thereafter, tissue homogenates were transferred into a sterile 
T175 flask and the process was repeated for the remaining tissue suspension.  
The collected tissue homogenate was subsequently filtered through a 150 μm 
nylon mesh (Plastok Limited, UK), the collected filtrate was then filtered again 
through a 60 μm nylon mesh and filters were kept separately.  The filters were 
placed into a petri dish containing 80 mL of digest mix consisting of M199 media 
containing DNase I (2108 U/mg); trypsin (211 U/mg); collagenase (223 U/mg) 
(Worthington Biochemical, NJ, USA); 10% v/v FCS and 1% v/v penicillin and 
streptomycin. Petri dishes were labelled as 150s and 60s and incubated at 37 °C 
for 1 hour on an orbital shaker at 150 rpm. Thereafter the filters were carefully 
washed, and the digest mix moved to 50 mL centrifuge tubes and centrifuged at 
4 °C for 5 minutes at 5000 rpm, before being suspended in fresh MEM 
supplemented with 1% v/v penicillin and streptomycin and 10 mM HEPES. This 
process was repeated three times before the pellets were resuspended in 
cryopreservation media (10% v/v DMSO and 90% v/v FCS) for long-term storage 
in liquid nitrogen and labelled as ‘150s’, suitable for gene/protein 




A T75 flask was coated with bovine collagen (50 μg/mL) prior to addition of cells 
from a thawed ‘150s or 60s’. Thawed cells were suspended in full PBMEC media: 
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phenol red free DMEM, 10% v/v plasma derived bovine serum (PBDS), 1% v/v 
antibiotic-antimycotic, 125 μg/mL heparin and  1% v/v L-glutamine. Cells were 
grown for 2 days before the addition of 4 μg/mL puromycin for 2 days, to eradicate 
pericyte contamination. Thereafter, PBMEC cells were maintained in ACM 
collected from the growth of rat C6 astrocytes (See Section 3.4.1.1), in a 1:1 
(PBMEC:ACM), until confluence (8–10 days post seeding) and are referred to as 
passage 0. Following trypsinisation, PBMEC cells were subsequently seeded on 





Following trypsinisation, PBMEC cells were subsequently seeded at a density of 
80 x103 cells/cm2 into 1.12 cm2 permeable inserts (Greiner BioOne transparent 
ThinCerts® 12 well) coated with bovine collagen (50 μg/mL) and fibronectin (7.5 
μg/ mL) and maintained in PBMEC:ACM and considered as passage 1.  
Barrier integrity and formation was assessed through the determination of TEER, 
which was measured every 2 days using a chop-stick electrode (World Precision 
Instruments STX2). Tight-junction formation was enhanced through the addition 
of 250 μM cAMP, 17.5 μM RO 20–1724 and 550 nM hydrocortisone 24-hours 
prior to the initiation of an assay, with TEER values used to assess barrier 
integrity (Patabendige et al., 2013). The media was changed on the day a TEER 
measurement was carried out and measured every two days up to 10 days post 
seeding. Monolayer formation was monitored by measuring the TEER using a 
chopstick electrode (STX2) and voltammeter (EVOM) (World Precision 
Instrument) TEER was calculated according to equation (3).  
 
Control measurements were made using filters without cells (blank filter). The 
PBMEC model is considered suitable for transport/permeability assays when  
TEER > 400 Ω.cm2 is achieved (Patabendige et al., 2013, Yang et al., 2017, 





 Immunostaining detection of ZO-1 and F-actin in PBMECs in-vitro 
BBB model 
 
On the day peak TEER value was recorded typically 24 hours following the 
addition of barrier additives, the bottoms of the inserts were carefully pealed and 
washed with cold PBS and fixed in cold paraformaldehyde 4% w/v for 10 minutes. 
Thereafter the inserts were prepared for ZO-1 or F-actin visualisation.  
Zona oclaudin-1 (ZO-1) is a tight junction protein used to determine the integrity 
of BBB in-vitro models (Cantrill et al., 2012, Patabendige et al., 2013). In addition 
to using TEER measurements and lucifer yellow leakage in order to assess the 
barrier integrity, tight junction protein ZO-1 was visualised when peak TEER 
values were observed.  
 
Following fixing, the cells were washed three times with cold PBS and 
permeabilised using 0.02% w/v saponin for 10 minutes, followed by an additional 
cycle of washing with PBS. The cells were then blocked in 6% v/v goat serum 
overnight. Thereafter, inserts were incubated with ZO-1 primary antibody (ZO-1 
1A12 monoclonal) prepared in blocking buffer of 1% v/v goat serum (1:100 PBS) 
and incubated overnight at 4 ºC. The inserts were then washed with cold PBS 
three times prior to being incubated with secondary antibody (0.5 µg/mL goat 
anti-mouse IgG H+L super clonal secondary Alexa 488) for 2 hours on an orbital 
shaker (150 rpm) at room temperature. Cells were then washed with PBS and 
mounted on a coverslip using Flouroshield (containing DAPI). ZO-1 Tight junction 
formation was assessed using an upright confocal microscope Leica SP5 TCS II 
MP (Leica microscope systems (UK) Ltd, Milton Keynes, UK) using a 40x oil 
immersion lens. The images were obtained with an argon laser at 494 nm and a 
helium neon laser for DAPI visualisation at 461 nm.  
 
F-actin was visualised to ensure that the in-vitro model possessed an appropriate  
cytoskeleton formation which is essential for cell stability, cell proliferation and 
morphogenesis  (Dominguez and Holmes, 2011). Following fixing, the cells were 
washed with cold PBS three times and permeabilised for 10 minutes using 0.2% 
w/v saponin. Thereafter, the inserts were washed with ice cold PBS 3 times; the 
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inserts were then blocked in 1% w/v BSA for 1 hour then washed three times with 
ice cold PBS. The cells were then incubated with Phallodin-iFluor 488 (1:50) for 
20 minutes. The inserts where then washed and mounted on microscope slides 
using Flouroshield (containing DAPI). F-actin filaments were assessed using 
upright confocal microscope Leica SP5 TCS II MP (Leica microscope systems 
(UK) Ltd, Milton Keynes, UK) using a 40x oil immersion lens. The images were 
obtained with an argon laser at 517 nm and a helium neon laser for DAPI 




The cellular toxicity of hesperetin, methotrexate and mitoxantrone were assed 
using a MTT assay, as previously detailed in Section 2.4.2.  
 
 
24 hours following the addition of barrier forming additives (See Section 3.4.4), a 
transport assay was conducted to determine the ability of methotrexate, 
mitoxantrone and hesperetin to permeate across the developed in-vitro BBB 
model. 50 μM methotrexate was prepared in serum free PBMEC media 
containing 25 mM HEPES and added to the apical (for AB flux) or basolateral (for 
BA flux) compartments with sampling taking place from the opposite 
compartment. Samples (100 μL) were withdrawn at intervals between 15–90 
minutes and replaced with an equal amount fresh pre-warmed serum free 
PBMEC media containing 25 mM HEPES. Each sample was placed in a 2 mL 
HPLC autosampler amber vial and stored at 4 ºC until the end of the assay. 
Methotrexate concentrations were analysed using HPLC-UV detection (Agilent 
1200 series) (detailed in the subsequent section). The apparent permeability 
(Papp) was calculated using equation (4):  
Papp = !"/!$ %!	'	()         (4) 
where dQ/dt represents the amount of drug permeated per unit time, calculated 
from the regression line of time points of sampling; C0 the initial drug 
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concentration in the donor compartment; A (cm2) is the insert surface area (1.12 




.            (5) 
where Papp BA is the apparent permeability form basolateral to apical, and Papp AB 
is the apparent permeability form apical to basolateral.  
This method was used to assess the permeability of 50 μM mitoxantrone and 50 
μM hesperetin: 
(i) Mitoxantrone: samples detected using a fluorescent plate reader (Tecan Spark 
10M®) with an excitation wavelength of 488 nm and an emission wavelength of 
670 nm.  
(ii) Hesperetin: samples detected using UV-HPLC detection (Agilent 1200 series). 
 Lucifer yellow permeability assay  
 
Lucifer yellow (LY) is a fluorescent dye routinely used  as a marker to assess the 
formation of monolayers and barrier integrity since it is transported paracellularly 
(Zhao et al., 2019b, Yang et al., 2017). PBEMC were grown on inserts and were 
incubated with 100 μM Lucifer yellow (LY) prepared in serum free media with 
added 25mM HEPES. Samples for LY measurements were transferred into an 
opaque plate and fluorescence was measured at excitation and emission 
wavelength 428 nm and 540 nm respectively using fluorescent multiplate reader 
(Tecan spark 10M®). The percentage transfer of LY was determined using 
equation (6): 
%	Lucifer	yellow	transported	 = 	100	x	(1 −	+FG	HIJKLI$MNIL +FG	IOPQIL) )  (6) 
where RFU basolateral is the relative fluorescence measurements of the sample 
taken from the basolateral side, RFU apical is the relative fluorescence 
measurement taken from the apical side.  




 HPLC-UV detection of hesperetin   
 
An isocratic HPLC method was utilised for the HPLC-UV detection of hesperetin 
(Arya et al., 2015). HPLC analysis was conducting using a 1200 Infinity II LC 
Agilent system. Analysis of hesperetin was performed using a reversed phase 
C18 column 150 x 4.6 mm (Phenomenex, UK) with a mobile phase consisting of 
(45:55:0.1) acetonitrile: water: acetic acid with a flowrate of 1 mL/min at 25 ºC, 
injection sample volume 20 µL/sample and UV detection wavelength of 288 nm. 
Samples were examined over a concentration range of 0.1-50 µM. The method 
was validated by evaluating limit of detection (LOD) (Equation 7) and limit of 
quantification (LOQ) (Equation 8). A calibration curve for hesperetin was 
developed over the concentration range of 0.1-50 µM, which was used to 
determine linearity. The standards were prepared in quadruplicate and r2 was 
determined using the calibration curve generated from running this standard.  
 
RST = 3.3	(σS)    (7) 
RS" = 10	(σS)   (8) 
 
where σ is the standard deviation and S is the slope of the calibration curve.  
 
A linear regression analysis was conducted with the standards to calculate the 
standard deviation and the slope.  
 
 HPLC-UV detection for methotrexate  
 
An isocratic HPLC method was utilised for the HPLC-UV detection of 
methotrexate (Karami et al., 2019). Analysis of methotrexate was conducted 
using reversed phase C18 column 150 x 4.6 mm (Phenomenex, UK) with a 
mobile phase consisting of 89:11 50 mM acetate buffer: acetonitrile.  The mobile 
phase was acidified using HCl to obtain a final pH of 3.6 before it was filtered 
using a 0.4 µm filter. The flow rate was fixed at 1.5 mL/min, with an injection 
volume of 40 µL/sample and UV-detection spectrum at 307 nm. Samples were 
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examined over a concentration range of 0.1-50 µM. The method was validated 
by evaluating limit of detection (LOD) (Equation 7) and limit of quantification 
(LOQ) (Equation 8). A calibration curve for methotrexate was developed over the 
concentration range of 0.1-50 µM, which was used to determine linearity. The 
standards were prepared in quadruplicate and r2 was determined using the 
calibration curve generated from running this standard.  
 
 
A fluorescent multi-plate reader was used for detection of mitoxantrone due to 
the unavailability of a UV-visible light detector (over 400 nm). Mitoxantrone was 
detected using a fluorescent multi-plate reader (Tecan spark 10 M®) at an 
excitation wavelength of 607 nm and emission wavelength of 684 nm. A 
calibration curve for mitoxantrone was developed over the concentration range 
of 0.1- 50 µM, which was used to determine linearity. The standards were 
prepared in quadruplicates and r2 was determined from the calibration curve 
obtained from running the standard.  
 
 Statistical analysis  
 
All data is presented as mean and standard deviation, with experiments being 
conducted in at least 3 replicate independent experiment unless otherwise stated. 
Where appropriate, statistical analyses were performed in GraphPad Prism 9 (La 
Jolla, California, USA), with t-tests used to determine differences between the 






To assess the impact of species-specific ECM (rat or bovine collagen) on barrier 
formation, PBMEC/C12 cells were grown on permeable inserts coated with either 
rat or bovine collagen and their effect on TEER values determined.  
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The use of bovine collagen coated inserts resulted in higher TEER values 
throughout the study when compared to rat tail collagen coated inserts (Figure 
3.1). The peak TEER occurring on day 3 post seeding, with a 1.8-fold higher 
mean TEER for cells grown on bovine collagen (Bovine: 46.5 Ω.cm2 ± 2.1 Ω.cm2; 
Rat: 26 Ω.cm2± 5.6 Ω.cm2) (P < 0.0001). 
 
Figure 3.1 TEER measurements following growth of PBMEC1/2 on 
permeable cell culture inserts 
50,000 PBMEC C1/2 cells were seeded on either bovine 50 µg/mL and 
fibronectin 7.5 µg/mL coated inserts (black) or rat tail collagen 200 µg/mL and 
fibronectin 7.5 µg/mL coated inserts (red). TEER values were measured every 
day for five days. Symbols represent the mean measurement for each day (n=12 
inserts in 4 independent experiments for each day). Vertical lines indicate the 
standard deviation (SD). Statistical analysis compared the TEER at day 3 (peak) 





Based on the results obtained from the previous section, the culturing method for 
PBMECs was adapted to grow cells on bovine coated (50 µg/mL) plastic 
surfaces. Following addition of puromycin (4 µg/mL) to the culturing media to 
remove pericyte contamination (Figure 3.2A), a confluent robust layer formed by 






Figure 3.2 Morphology of PBEMC cultured on bovine collagen coated 
plasticware 
PBEMCs were grown in a T75 flask coated with 50 µg/mL bovine collagen and 
incubated for 10 days at 37 °C, 5% CO2. (A) PBMECs on day 2 using x10 prior 





The formation of a PBMEC monolayers, when grown on 12-well permeable 
inserts, was assessed by measuring TEER values every other day post-seeding. 
TEER values demonstrated a steady increase after the addition of barrier forming 
additives on day 2 post seeding (Figure 3.3). TEER values peaked to a maximum 
of 1428.56 ± 270.4 Ω.cm2 on day 4  (P ≤ 0.0001) when compared to TEER values 
on day 2 (61.89 ± 6.8 Ω.cm2). Transport studies were conducted on the day of 




Figure 3.3 TEER measurement of PBMECs on 12 well permeable insert 
80,000 cells were seeded on permeable cell culture inserts (12-well, 1.12 cm2) 
coated with bovine collagen (50 μg/mL) and fibronectin (7.5 μg/mL). The arrow 
indicates the day barrier forming agents (250 μM cAMP, 17.5 μM RO 20–1724 
and 550 nM hydrocortisone) were added. Statistical analysis compares TEER 
at day 2 to all other data points. ****P ≤ 0.0001. Red circles indicate the mean 
measurement for each day (n=12 inserts in 4 independent experiments for each 
day). Black lines indicate the standard deviation (SD).  
 
 
 Lucifer yellow permeability assay  
 
To assess the formation of a suitable cellular monolayer, the paracellular 
permeability marker lucifer yellow (LY) was used. Coated inserts lacking cells 
displayed a lucifer yellow permeability of 97% ± 2.6% (P < 0.0001), while insets 
seeded with PBMEC displayed an average of  0.88% ± 0.17% LY permeation 




Figure 3.4 Lucifer yellow permeability assay 
80,000 PMBECs were seeded in 12-well inserts. On day 4 post seeding, LY 
assay was conducted. Leakage of 100 µM LY across PBMEC was assessed over 
15-90 minutes assay. LY fluorescence was detected in the samples using Tecan 
spark 10M®). Vertical black lines represent the standard deviation.  
Unpaired t-test analysis was conducted between the mean measurements of the 




 Immunocytochemistry of tight junction protein ZO-1 and F-actin 
 
The expression of the tight junction protein ZO-1 was assessed using 
immunostaining of PBMEC grown on permeable inserts (Figure 3.5). Confocal 
laser microscopy was used to validate clear presence of ZO-1 in PBMEC in-vitro 
BBB model. Furthermore, to assess the integrity of PBMEC cytoskeleton, the 
expression of filamentous F-actin was validated using immunostaining of PBMEC 








Figure 3.5 ZO1 Immunocytochemistry images for PBMEC 
PBMECs were grown on permeable inserts, following adding the barrier enhancing additives on day 4, the pealed inserts were 
stained for (A) ZO-1, (B) DAPI, and (C) merged. Images were taken using Lecia SP5TCS II MP confocal microscope 
 




Figure 3.6 F-Actin Immunocytochemistry images for PBMEC 
PBMECs were grown on permeable inserts, following adding the barrier enhancing additives on day 4, the pealed inserts were 
stained for (A) F-actin, (B) DAPI, and (C) merged. Images were taken using Lecia SP5TCS II MP confocal microscope 




 Cellular toxicity of methotrexate towards PBMEC 
 
In order to determine the level of cytotoxicity of methotrexate and determine IC50 
for further studies, a MTT cytotoxicity assay was conducted in PBMEC across a 
6-fold concentration range, 0.001-100 µM. The IC50 was calculated to be 138.6 
µM (CI: 99.47-193.1) (Figure 3.7). 
 
Figure 3.7 Cellular toxicity of methotrexate 
50,000 cells were seeded in a 96 well plate and incubated until confluent. PBMEC 
were then incubated with methotrexate, 0.001-100 μM, for 24 hours. PBMEC 
were washed with PBS and incubated with MTT (0.5 mg/mL) for 4 hours. 
Thereafter, DMSO (100 μL/well) was added and absorbance was measured at 
570 nm. Data is presented from 8 replicates per experiment repeated in three 
independent experiments. Vertical black lines indicate the standard deviation. 
Shaded dashed lines indicate confidence interval of regression line. 
 
 
 Cellular cytotoxicity of mitoxantrone 
 
In order to determine the level of cytotoxicity of mitoxantrone and determine IC50 
for further studies, a MTT toxicity assay was conducted using PBMEC across a 
6-fold concentration range, 0.001-100 µM.  The IC50 was  determined to be 243.3 





Figure 3.8 Cellular toxicity of mitoxantrone 
50,000 cells were seeded in a 96 well plate and incubated until confluent. PBMEC 
were then incubated with mitoxantrone, 0.001-100 μM, for 24 hours. PBMEC 
were washed with PBS and incubated with MTT (0.5 mg/mL) for 4 hours. 
Thereafter, DMSO (100 μL/well) was added and absorbance was measured at 
570 nm. Data is presented from 8 replicates per experiment repeated in three 
independent experiments. Vertical black lines indicate the standard deviation. 
Shaded dashed lines indicate confidence interval of regression line. 
 
 
 Cellular cytotoxicity of hesperetin  
 
In order to determine the level of cytotoxicity of hesperetin and determine IC50 for 
further studies, a MTT toxicity assay was conducted using PBMEC across a 6-
fold concentration range, 0.001-100 µM.  The IC50 was  determined to be 298.9 





Figure 3.9 Cellular toxicity of hesperetin 
50,000 cells were seeded in a 96 well plate and incubated until confluent. PBMEC 
were then incubated with hesperetin, 0.001-100 μM, for 24 hours. PBMEC were 
washed with PBS and incubated with MTT (0.5 mg/mL) for 4 hours. Thereafter, 
DMSO (100 μL/well) was added and absorbance was measured at 570 nm. Data 
is presented from 8 replicates per experiment repeated in three independent 
experiments. Vertical black lines indicate the standard deviation. Shaded dashed 
lines indicate confidence interval of regression line. 
 
 Cellular toxicity of methotrexate in the presence of hesperetin  
 
In order to assess the impact of hesperetin on altering the cellular toxicity of 
methotrexate at the BBB, using the PBMEC model, cellular toxicity was 
determined using this combination. A MTT assay was conducted using a fixed 
hesperetin concentration 50 μM, with 3 concentrations of methotrexate (1, 10 and 
100 μM) (Figure 3.10). The percentage cellular viability obtained for each 
concentration was high,  97.5% ± 1.4% (1 μM), 90.01% ± 1.3% (10 μM) and 







Figure 3.10 Cellular cytotoxicity of methotrexate in combination with 
hesperetin 
Methotrexate (1, 10, 100 μM) was added to the cells, in combination with 50 μM 
hesperetin per each concentration and incubated with 24 hours at 37 ºC, 5% CO2.  
PBMECs were washed with PBS and incubated with MTT (0.5 mg/mL) for 4 
hours. Thereafter, DMSO (100 μL/well) was added and absorbance was 
measured at 570 nm. Black vertical lines indicate the standard deviation. ns: no 
significant difference between samples (One-way ANOVA) and no significant 




 Cytotoxicity of mitoxantrone in combination with hesperetin  
 
In order to assess the impact of hesperetin on altering the cellular toxicity of 
mitoxantrone at the BBB, using the PBMEC model, cellular toxicity was 
determined using this combination. A MTT assay was conducted using a fixed 
hesperetin concentration 50 μM, with 3 concentrations of mitoxantrone (1, 10 and 
100 μM) (Figure 3.11). The percentage cellular viability obtained for each 
concentration was high,  90.5% ± 1.1%, (1 μM), 87.4% ± 1.3 (10 μM) and 80.3% 





Figure 3.11 Cellular cytotoxicity mitoxantrone in combination with 
hesperetin 
Mitoxantrone (1, 10, 100 μM) was added to the cells, in combination with 50 μM 
hesperetin per each concentration and incubated with 24 hours at 37 ºC, 5% CO2.  
PBMECs were washed with PBS and incubated with MTT (0.5 mg/mL) for 4 
hours. Thereafter, DMSO (100 μL/well) was added and absorbance was 
measured at 570 nm. Black vertical lines indicate the standard deviation. ns: no 
significant difference between samples (One-way ANOVA) and no significant 




An isocratic HPLC method was utilised in order to allow the detection of 
hesperetin during cellular permeability assays. Samples were prepared from a 
hesperetin stock solution (10 mM) in PBS containing 25 mM HEPES. Hesperetin 
was detected at a constant retention time of 3.4 minutes (Figure 3.12) with a 





Figure 3.12 HPLC chromatogram for hesperetin 
Hesperetin was detected with a retention time 3.4 minutes using reversed 
phase C18 column and a mobile phase containing 45:44:0.1 acetonitrile: water: 
acetic acid at 1 mL/min flow rate.  
 
In order to account for system precision, 6 injections from the same hesperetin 
stock solution were analysed and the peak area was calculated (Table 3.1). The 
standard deviation was 0.19 and the relative standard deviation was less than 
1% indicating that the system precision is within an acceptable range.  For 
method precision, 6 samples were prepared from the same stock solution and 
analysed (Table 3.1).  The relative standard deviation was less than 1% indicating 
that the method precision is within an acceptable range.  
 
Table 3.1 System precision and method precision for UV-HPLC detection 
of hesperetin 
System precision Method precision 
Injection number AUC (mAU) Vial number AUC (mAU) 
1 110.7 1 111.4 
2 110.6 2 111.5 
3 110.5 3 111.2 
4 110.5 4 111.4 
5 110.6 5 111.4 
6 110.1 6 109.9 
Mean 110.55 Mean 111.4 
SD 0.19 SD 0.61 







The linearity of the HPLC method used for detection of hesperetin was 
determined by formulating a calibration curve using concentration range 0.09 µM- 
50 µM (Figure 3.13). The area under the curve (AUC) was linearly regressed 
under the concentration range used. The correlation coefficient (r2) was 0.9995, 
the slope and intercept were 0.2772 mAU.µM and 5.334 mAU respectively. The 
LOD and LOQ were found to be 0.91 µM and 0.93 µM respectively. 
 
Figure 3.13 HPLC linearity calibration plot for hesperetin 
A HPLC calibration curve for the detection of hesperetin. A concentration range 
of 0.09-50 µM was prepared in PBS containing 25 mM HEPES. The HPLC was 
injected with a volume of 20 µL of each concentration and the AUC was obtained. 
LOD and LOQ were calculated using regression analysis. 
 
 
An isocratic HPLC method was utilised for the detection of methotrexate. 
Samples were prepared in PBS containing 25 mM HEPES from a 5 mM stock 
solution. Methotrexate was detected at a constant retention time of 5.7 minutes 





Figure 3.14 HPLC chromatogram for methotrexate 
Methotrexate was detected with a retention time 5.7 minutes using reversed 
phase C18 column and a mobile phase containing 89:11 acetate buffer: water 
(pH= 3.6) at a constant 1.5 mL/min flow rate. 
 
In order to account for system precision, 6 injections from the same methotrexate 
stock solution were analysed and the peak area was calculated (Table 3.2). The 
relative standard deviation was less than 1% indicating that the system precision 
is within an acceptable range. For method precision, 6 samples were prepared 
from the same stock solution and analysed (Table 3.2).  the standard deviation 
was 0.3 and the relative standard deviation was less than 1% indicating that the 
method precision is within an acceptable range.  
Table 3.2 System precision and method precision for UV-HPLC detection 
of methotrexate 
System precision Method precision 
Injection number AUC (mAU) Vial number AUC (mAU) 
1 68 1 67.8 
2 68.1 2 68 
3 67.9 3 68 
4 67.8 4 68.4 
5 68 5 68.6 
6 68 6 68 
Mean 68 Mean 68 
SD 0.10 SD 0.30 





Acq. Operator   : Carlo                          Seq. Line :   1
Acq. Instrument : Instrument 1                    Location : Vial 1
Injection Date  : 22/11/2018 11:22:49                  Inj :   1
                                                Inj Volume : 50.000 µl
Acq. Method     : C:\CHEM32\1\TEMP\AESEQ\MTX_CALBRATION_1 2018-11-22 11-21-21\METHOTREXATE_
                  BASMA.M
Last changed    : 22/11/2018 11:21:21 by Carlo
Analysis Method : C:\CARLO HPLC\METHODS\CC_END.M
Last changed    : 05/11/2020 19:58:11 by Carlo Curti








 FLD1 A, Ex=230, Em=460 (MTX_CALBRATION_1 2018-11-22 11-21-21\001-0101.D)



















                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier:                   :      1.0000
Dilution:                     :      1.0000
Use Multiplier & Dilution Factor with ISTDs
 
 
Signal 1: FLD1 A, Ex=230, Em=460
 
 
Signal 2: VWD1 A, Wavelength=307 nm
 
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   1.370 VV    0.1217   24.22555    2.78027   1.0440
   2   5.713 BB    0.1757 2296.26099  201.93509  98.9560
 




                          *** End of Report ***
Data File C:\CHEM32\1\TEMP\AESEQ\MTX_CALBRATION_1 2018-11-22 11-21-21\001-0101.D
Sample Name: 50





The linearity of the HPLC method used for detection of methotrexate was 
determined by formulating a calibration curve using concentration range 0.09 µM- 
50 µM (Figure 3.15). The area under the curve (AUC) was linearly regressed 
under the concentration range used. The correlation coefficient (r2) was 0.9998, 
the slope and intercept were 0.2178 mAU.µM and 3.976 mAU respectively. The 
LOD and LOQ were found to be 2.03 µM and 2.7 µM respectively (Figure 3.15). 
 
 
Figure 3.15 HPLC linearity calibration plot for methotrexate 
A HPLC calibration curve for the detection of methotrexate. A concentration 
range of 0.09-50 µM was prepared in PBS containing 25 mM HEPES. The HPLC 
was injected with a volume of 40 µL of each concentration was and the AUC was 




Mitoxantrone was detected in the samples using a fluorescence multiplate reader 
at excitation and emission 607 nm and 684 nm respectively. Mitoxantrone 
samples, 0.09–50 µM, were prepared in PBS containing 5 mM HESPES from a 
10 mM stock. The correlation coefficient (r2) was 0.9880, the slope and intercept 
were 14.61 RFU.µM and 266.8 RFU respectively. LOD is and LOQ were 





Figure 3.16 Fluorescence detection linearity calibration plot for 
mitoxantrone 
A fluorescence detection calibration curve for the detection of mitoxantrone, 0.09-
50 µM, prepared in PBS  containing 25 mM HEPES. 100 µL samples were placed 
into a well sample of a black 96-well plate and the fluorescence measured at an 
excitation wavelength of 607 nm and emission wavelength of 684 using Tecan 




The results obtained from the previous chapter demonstrated the ability of 
hesperetin to modulate the efflux action of BCRP in LN229 cells. Herein, the 
ability of hesperetin to permeate through the BBB was first assessed. Secondly, 
its ability to modulate the efflux function of BCRP in a PBMECs in-vitro BBB 
model was evaluated and subsequently compared the permeability of 




 Methotrexate permeability across an in-vitro BBB model 
 
The permeability of methotrexate was assessed across an in-vitro PBMEC BBB 
model (Figure 3.17). The flux of methotrexate from the apical to basolateral 
direction (AB) Papp AB was determined with an apparent permeability of  
1.05 x10-6 cm/s ± 2.72x10-6 cm/s with a basolateral to apical (BA) Papp BA apparent 




Figure 3.17 The permeability of methotrexate across an in-vitro BBB 
model established with PBMEC grown on permeable inserts 
80,000 PBMECs were seeded onto 12-well permeable inserts. On day 3 post 
seeding, barrier forming additives were added to the media. Transport of 
methotrexate, 50 µM, across the formed monolayer was evaluated by 
determining the flux from apical to basolateral (AB) (black) and basolateral to 
apical (BA) (red). Methotrexate was detected using UV-HPLC.  Each data point 
represents the mean measurement for each day (n=16 inserts in 4 independent 
experiments for each day).  
 
 138 
 Hesperetin permeability across an in-vitro BBB model 
 
The permeability of hesperetin was assessed across an in-vitro PBMEC BBB 
model (Figure 3.18). The flux of methotrexate from the apical to basolateral 
direction (AB) (Papp AB) was determined with an apparent permeability of  
4.68 x10-6 cm/s ± 5.6 x10-7 cm/s with a basolateral to apical (BA) (Papp BA) 
apparent permeability of 4.59 x10-6 cm/s ± 4.73 x10-7 cm/s, resulting in an efflux 
ratio of 0.98. 
 
 
Figure 3.18 The permeability of hesperetin across an in-vitro BBB model 
established with PBMEC grown on permeable inserts 
80,000 PBMECs were seeded onto 12-well permeable inserts. On day 3 post 
seeding, barrier forming additives were added to the media. Transport of 
hesperetin, 50 µM, across the formed monolayer was evaluated by determining 
the flux from apical to basolateral (AB) (black) and basolateral to apical (BA) (red). 
Hesperetin was detected using UV-HPLC.  Each data point represents the mean 






 Assessing the impact of hesperetin on the modulating the 
permeability of methotrexate across an in-vitro BBB model. 
 
In order to assess the ability of hesperetin to modulate the flux of methotrexate 
across an in-vitro BBB model, PBMECs were incubated with 50 µM hesperetin 
30 minutes prior to incubation with methotrexate. The inclusion of hesperetin 
resulted in an increased AB flux of methotrexate with an apparent permeability 
(Papp AB) of 2.85 x 10-6 cm/s ± 1.35 x10-7 cm/s and basolateral to apical flux (Papp 
BA) of 2.43 x10-6 cm/s ± 5.5 x10-7 cm/s (Figure 3.19). The efflux ratio for the 
transport of methotrexate in the presence of hesperetin was 0.85.  
 
 
Figure 3.19 The permeability of methotrexate across an in-vitro BBB 
model established with PBMEC grown on permeable inserts 
80,000 PBMECs were seeded onto 12-well permeable inserts. On day 3 post 
seeding, barrier forming additives were added to the media. Transport of 
methotrexate, 50 µM, across the formed monolayer was evaluated by 
determining the flux from apical to basolateral (AB) (black) and basolateral to 
apical (BA) (red).  Inserts were pre-incubated with hesperetin 50 µM prior to the 
addition of methotrexate. The study was conducted in the presence of both 
methotrexate and hesperetin.  Methotrexate was detected using HPLC-UV.  Each 
data point represents the mean measurement for each day (n=16 inserts in 4 
independent experiments for each day). 
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 Mitoxantrone permeability across an in-vitro BBB model 
 
The permeability of mitoxantrone was assessed across an in-vitro PBMEC BBB 
model (Figure 3.20). The flux of mitoxantrone from the apical to basolateral 
direction (AB) Papp AB was determined with an apparent permeability of  
1.59 x10-7 cm/s ± 3.5 x10-8 cm/s with a basolateral to apical (BA) Papp BA apparent 




Figure 3.20 The permeability of mitoxantrone across an in-vitro BBB 
model established with PBMEC grown on permeable inserts 
80,000 PBMECs were seeded onto 12-well permeable inserts. On day 3 post 
seeding, barrier forming additives were added to the media. Transport of 
mitoxantrone, 50 µM, across the formed monolayer was evaluated by 
determining the flux from apical to basolateral (AB) (black) and basolateral to 
apical (BA) (red). Mitoxantrone was detected using fluorescence detection.  Each 
data point represents the mean measurement for each day (n=12 inserts in 4 
independent experiments for each day). * P < 0.05; *** P < 0.001. 
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 Assessing the impact of hesperetin on the modulating the 
permeability of mitoxantrone across an in-vitro BBB model 
 
In order to assess the ability of hesperetin to modulate the flux of mitoxantrone 
across an in-vitro BBB model, PBMECs were incubated with 50 µM hesperetin 
30 minutes prior to incubation with mitoxantrone. The inclusion of hesperetin 
resulted in an increased AB flux of mitoxantrone with an apparent permeability 
(Papp AB) of 3.7 x10-7 cm/s ± 3.36 x10-8 cm/s and basolateral to apical flux (Papp BA) 
of 4.79 x10-7 cm/s  ± 2.3 x 10-8 cm/s. (Figure 3.21). The efflux ratio for the 
transport of mitoxantrone in the presence of hesperetin was 1.29.  
 
 
Figure 3.21 The permeability of mitoxantrone across an in-vitro BBB 
model established with PBMEC grown on permeable insert, in the 
presence of hesperetin 
80,000 PBMECs were seeded onto 12-well permeable inserts. On day 3 post 
seeding, barrier forming additives were added to the media. Transport of 
mitoxantrone, 50 µM, across the formed monolayer was evaluated by 
determining the flux from apical to basolateral (AB) (black) and basolateral to 
apical (BA) (red).  Inserts were pre-incubated with hesperetin 50 µM prior to the 
addition of mitoxantrone. The study was conducted in the presence of both 
mitoxantrone and hesperetin.  Mitoxantrone was detected using fluorescence 
detection.  Each data point represents the mean measurement for each day 
(n=12 inserts in 4 independent experiments for each day). 
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 Changes in the basolateral to apical flux of anti-cancer agents in 
the presence of hesperetin 
 
In the presence of hesperetin, methotrexate Papp BA was 2.43 x10-6 ± 5.5 x10-6  
cm/s and in absence of hesperetin the reported Papp BA was 1.64 x10-6 ±  
2.05 x10-7 cm/s, resulting in the demonstrated increase in Papp BA for methotrexate 
was 48% (Figure 3.22A). However, the reported ER of methotrexate in the 
presence and absence of hesperetin were 0.85 and 1.6 respectively (* P ≤ 0.05) 
(Figure 3.22.B), an overall reduction in ER by 46.9%.  
 
In the presence and absence of hesperetin, the reported Papp BA of mitoxantrone 
was 0.5 x 10-6 ± 2.3 x 10-8 cm/s and 0.7 x 10-6 ± 1.8 x 10-8 cm/s (*P ≤ 0.05) 
respectively (Figure 3.22A). The demonstrated reduction in Papp BA was 32.6%. 
The reported ER in the presence and absence of hesperetin were 1.29 and 4.47 




Figure 3.22 The apparent permeability (A) and efflux ratio (B) of 
methotrexate and me mitoxantrone in the absence and presence of 
hesperetin 
(A) Apparent permeability of methotrexate (black, white) and mitoxantrone (grey, 
red) In the presence and absence of hesperetin. (B) the efflux ratio of 
methotrexate (black, white) and hesperetin (yellow, red) in the presence and 








Glioblastomas are a common form of primary brain tumours which are known to 
affect 0.02% of the global population which constitutes to approximately 1.6 
million cases (Hanif and Muzaffar, 2017, Ersoz et al., 2019). Glioblastomas are 
considered rare, however, due to poor survival rates they represent a critical 
public health issue (Zhang et al., 2020). The standard treatment for glioblastoma 
is usually surgical removal of the tumour mass followed by chemotherapy 
treatment and/or radiotherapy. Yet, with a survival rate of less than 15 month, it’s 
clear that the current treatment regimens are not efficient enough (Bi and 
Beroukhim, 2014).  
 
Methotrexate has been used as a part of the treatment regime for  glioblastoma 
(Zhu et al., 2009, Sane et al., 2014) with studies reporting its limited distribution 
into the brain due to the role of BCRP at the BBB and BTB hindering access to 
GBM (Sane et al., 2014, Agarwal et al., 2010, Devineni et al., 1996).  On the other 
hand, mitoxantrone has been used in the treatment of glioblastoma (Ferroli and 
Broggi, 2006) and as a TRAIL sensitising agent in GBM (Senbabaoglu et al., 
2016). With studies corelating its MDR to the efflux function of BCRP (Doyle et 
al., 1998, Higgins, 1995, Miyata et al., 1999). 
 
Key to delivery of anticancer agents to gliomas, is the permeation across the 
BBB. Many anti-cancer agents such as mitoxantrone and methotrexate amongst 
others have limited permeability across the BBB due to the presence of ABC 
efflux transporters such as BCRP (Ni et al., 2010, Wijnholds et al., 2000, 
Cisternino et al., 2004, Breedveld et al., 2005, Toyoda et al., 2019). Breast cancer 
resistance protein (BCRP) itself is known to bind to and restrict the permeability 
of many CNS active anti-cancer agents, which leads to lowered therapeutic 
concentrations at the intended target (Dei et al., 2019). However, flavonoids from 
the phytochemicals group of chemicals, have emerged as potential novel agents 
possessing the ability to modulate the efflux function of BCRP and other ABC 
transporters (Kaur and Badhan, 2017, Zhang et al., 2004c, Gao et al., 2017b, An 
and Morris, 2010). 
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The results obtained from the previous chapter identified the ability of hesperetin 
to modulate the expression and function of BCRP in LN229 cells, in addition to 
hindering cellular migration, inducing ROS and activating Caspase-3/7 pathways. 
For this chapter we aimed to develop an in-vitro blood brain barrier model using 
primary PBMEC and asses the ability of hesperetin to permeate across the BBB 
model and to modulate the action of BCRP efflux transporter function to enhance 




The effects of using an appropriate extra cellular matrix as a coating surface on 
endothelial cell biology and integrity, cell adhesion and the cellular cytoskeleton 
have been well established (Carey et al., 2012, Levy-Mishali et al., 2009, Aurand 
et al., 2012, Antoine et al., 2014). 
 
Reports have noted that the extraction process of the collagen from an animal 
tissue affects the composition of fibrils of the collagen and subsequently would 
affect the interaction of cells with it when grown in-vitro (Kreger et al., 2010, 
Antoine et al., 2014). Type-1 rat tail collagen is a minimally crosslinked collagen 
usually sourced from tendons and is usually extracted by acid solubilisation 
(Antoine et al., 2014), while for highly crosslinked collagens from bovine and 
porcine, sourced from the dermis, the extraction process entails a mixture of 
neutral salt solution with proteolytic digestion (Walters and Stegemann, 2014, 
Parenteau-Bareil et al., 2010).  
Therefore, we decided to assess the impact of species-specific collagen using 
immortalised PBMEC/C12 cells, in order to conclude differences in TEER values 
under type-1 bovine collagen and  type-1 rat-tail collagen.  PBMEC/C12 cells 
were used rather than PBMEC for their rapid growth for initial screening. The 
results demonstrated that the use of bovine collagen resulted in higher TEER 
values throughout the study with a 1.8-fold higher mean TEER values for cells 
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grown on bovine coated inserts (P < 0.0001) (Figure 3.1).  Based on these 
studies, we adopted type-1 bovine collagen for all future studies when using the 




There is no consensus on a single best cellular model for use within in-vitro BBB 
research. A variety of cell lines are being utilised as BBB in-vitro models such as 
human cerebral cell line (hCMEC/D3) (Weksler et al., 2013), mouse models 
(bEND.5,b.END.3) (Schuhmann and Fluri, 2017) and bovine models (BCEC) 
(Helms et al., 2016). However, these produce suboptimal TEER values < 300 
Ω.cm2 (based on 12-well measurements) when the goal is to study drug transport 
(Weksler et al., 2013). Models such as IPSC-derived cells (Workman and 
Svendsen, 2020) can produce TEER values up to 3000 Ω.cm2, but the 
reproducibility of the model is poor due to the nature of stem cells and being cost 
ineffective (Gorecka et al., 2019, Liang and Zhang, 2013) 
 
Primary porcine brain microvascular endothelial cells (PBMEC) have been 
characterised and used in BBB in-vitro research for a number of years (Cantrill et 
al., 2012, Abbott, 2005, Patabendige et al., 2013, Elbakary and Badhan, 2020). 
The key benefits of using primary porcine cells are affordability, high yield, and 
maintenance of morphological and cellular characteristics after extraction 
(Patabendige et al., 2013). Pig brains are relatively easy to obtain shortly 
following slaughter, as they are a biproduct of the meat industry, therefore there 
is no need for a specialised animal breeding facility. In addition, porcine 
endothelial cells can retain crucial BBB feature after isolation and the rate of loss 
of BBB phenotypes is less than that of bovine or rodent (Deli et al., 2005). They 
can produce a tight BBB model with high TEER values (~800 Ω.cm2 ) based on 
12-well insert measurements (Patabendige et al., 2013).  Furthermore, the 
anatomy, genome and physiology of pigs reflect more closely to human than 
many established laboratory animals (Walters et al., 2011).  
 
PBMEC were isolated from brain hemispheres following a detailed method that 
was reported in (Patabendige et al., 2013). Cells were grown in bovine coated 
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flasks (50 µg/mL) and started growing in cluster formation (Figure 3.2.A), 
becoming confluent within 8-10 days (Figure 3.2.B).  The barrier integrity was 
enhanced by adding 250 μM CPT-cAMP, 17.5 μM RO20-1724 and 500 nM of 
hydrocortisone on day 3 post seeding which results in a spike in TEER values 
from 61.89 Ω.cm2 ± 6.8 Ω.cm2  to 1428.56 Ω.cm2 ± 270.4 Ω.cm2 (Figure 3.3).  
 
CMT-cAMP enhances intracellular cAMP which is known to enhance cell 
differentiation in different cell types (Tilling et al., 1998, Patabendige et al., 2013). 
The use of cAMP for this model is based on its use in a bovine model which 
resulted in enhancement in monolayer formation (Rubin et al., 1991). 
Furthermore, the addition of hydrocortisone is known to improve and sustain 
barrier tightness (Hoheisel et al., 1998, Förster et al., 2008) and is utilised by cell 
lines such as hCMEC/D3 cells to enhance barrier formation and increase TEER 
value (Weksler et al., 2013).  When combined with growing cells in a 50:50 
mixture of ACM, parodies the native endothelial/astrocyte basement membrane 
microenvironment (Haseloff et al., 2005). 
 
The highest TEER value obtained was 1428.6 Ω.cm2± 270.4 Ω.cm2 (Figure 3.3), 
which was higher than those reported by Patabendige et al. (Patabendige et al., 
2013), ~800 Ω.cm2. This may be a result of the use of bovine collagen due to the 
phylogenetic similarities sus scrofa have with bos taurus rather than rattus 
(Tejedor et al., 2011). However, there is a paucity in published studies comparing 
the interaction of porcine cells with bovine collagen.  
Nevertheless, using bovine collagen rather than rat tail collagen, significantly 
enhanced BBB formation and represents a novel extra cellular matrix enhancing 
cell proliferation, adhesion and polarity (Lu et al., 2011, Yue, 2014). To ensure 
barrier integrity and formation of tight junctions, the permeation of LY across the 
monolayer was used as a further marker and was detected at less than 1% 
(Figure 3.4). LY is routinely used as a paracellular permeability marker in testing 
barrier integrity and proper monolayer formation (Zhao et al., 2019b).  
 
We stained for tight junction protein ZO-1 on day 4, 24-hours following addition 
of barrier forming additives, and peak TEER value was recorded (Figure 3.5).  
We demonstrated complete cell-to-cell tight junction formation, which supports 
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the increase in TEER that was recorded. To ensure that actin is present within 
the cytoskeleton of the cells, we stained for F-actin (Figure 3.6). F-actin is a 
significant protein for maintenance of cell function and morphology (Dominguez 
and Holmes, 2011). The presence of F-actin is merely a confirmation of healthy 
viable morphologically correct cells which in turns would form a robust in-vitro 




In order to carry out transport studies, cellular toxicity studies were conducted to 
identity a non-toxic concentration range of hesperetin, methotrexate and 
mitoxantrone for use in the PBMEC model. Over the concentration range studied 
hesperetin displayed limited cellular toxicity, with the highest concentration (100 
µM) displaying 78% viability (Figure 3.9). Methotrexate demonstrated a greater 
degree of toxicity, where 100 µM exposure resulted in 64% cellular viability and 
an IC50 value of 138.6 µM (CI: 99.47-193.1) (Figure 3.7). Mitoxantrone 
demonstrated a higher IC50 of 243.3 µM (CI: 141.3- 496.5) (Figure 3.8). 
 
Previous reports have demonstrated limited toxicity of methotrexate at higher 
concentrations than those used in our studies, for example exposure to human 
renal cells to 100 µM of methotrexate after 24 hour exposure in serum free media 
resulted in ~80% viability (Caetano-Pinto et al., 2017). Whereas hesperetin has 
been reported to demonstrated an IC50 of 592 μM in human lymphoid cancer cells 
and IC50 of 500 μM in human myeloid cancer cells after 24 hours exposure (Sak, 
2014). Mitoxantrone was reported to have an IC50 of 139 μM when exposed to 
MCF-7 across a concentration range of 0-1000 μM for 24 hours (An and Morris, 
2010). 
 
In order in conduct further permeability studies using hesperetin in combination 
with methotrexate and mitoxantrone, the cytotoxic effects of the combinations on 
PBMEC were assessed. Methotrexate at 1,10 and 100 µM, was combined with 
50 µM hesperetin (Figure 3.10) with the viability remaining at 80.4% ± 2.3% at 
the highest methotrexate concentration. Mitoxantrone displayed similar toxicity 
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profile when combined with hesperetin (Figure 3.11), with cellular viability at 
70.3% ± 2.4% at 100 µM mitoxantrone.  
 
The combination of hesperetin with each anti-cancer agents resulted in slight 
changes in cellular viability, but this was not statistically significant. This may be 
due to the low concentrations used in the assays and consequently, their 
cytotoxic effect wasn’t fully realised. Additionally, this might suggest that 
hesperetin does not hinder the toxicity of the anti-cancer compounds at the BBB 
when it inhibits BCRP. Moreover, this would also suggest that hesperetin, much 
like other phytochemicals, has the ability to preserve normal healthy BBB cellular 
viability in the presence of anti-cancer agents, possibly due to the inherent anti-





Hesperetin has been demonstrated to modulate the efflux action of BCRP (Zhang 
et al., 2004c). When combining hesperetin with two anti-cancer agents that were 
reported to be effluxed by BCRP, namely methotrexate (Breedveld et al., 2004) 
and mitoxantrone (Mahringer et al., 2009). Here forth the aim was to enhance the 
permeability of these compound across the PBMEC in-vitro BBB model.   
 
The results demonstrated that hesperetin was able to permeate across the in-
vitro BBB model with reported Papp AB of 4.68 x10-6 cm/s ± 5.6 x10-7 cm/s and  
Papp BA of 4.59 x10-6 cm/s ± 4.73 x 10-7 cm/s (Figure 3.18).  
 
It is important to note that hesperetin has a high reported AB flux with a reported 
Papp AB value of 4.68 x10-6 cm/s ± 5.6 x10-7 cm/s (Figure 3.18), which is 29.4-fold 
higher than that of mitoxantrone (Figure 3.20) and 4.5-fold higher than that of 
methotrexate (Figure 3.17). The reported ER of hesperetin is 0.98, which is in 
line with other flavonoids which have been reported to have demonstrated an ER 
ranging over 0.8-1.5 (Shen et al., 2015, Youdim et al., 2004a, Fang et al., 2017).  
Furthermore, Papp values of more than or equal 5 x 10-6 cm/s indicate a high 
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permeability compound (Volpe et al., 2008) suggesting that hesperetin 
undergoes transcellular passive diffusion as it is the case of many flavonoid 
aglycons  (Nait Chabane et al., 2009, Nielsen et al., 2006, Shen et al., 2015). 
Other studies have also reported the permeability of hesperetin across the BBB 
in-vivo in rats brains when 50 mg/kg was administered intravenously (Tung-Hu 
and Mei-Chun, 2004).  
 
On the other hand, methotrexate demonstrated a lower AB flux and higher BA 
flux, with an efflux ratio of 1.6 (Figure 3.17). This is in line with a study reporting 
the ER of methotrexate in MDCK canine cells, ER=1.8, with a reported Papp AB of  
0.11 x10-6 cm/s ± 0.02 x10-6 cm/s and Papp BA of 0.2 x10-6 cm/s ± 0.02 x10-6 cm/s 
(Wang et al., 2005a). Under the combination of methotrexate with hesperetin, the 
resultant AB flux of methotrexate increased by1.8-fold, with a 1.9-fold reduction 
of ER was reported (Figure 3.22).  
 
The change in AB and BA flux may, in part, be due to the modulatory effect 
hesperetin on BCRP (Kaur and Badhan, 2017, Kaur and Badhan, 2015), in 
addition to its ability to modulate the action and downregulate the expression of 
BCRP in LN229 glioblastoma cells as demonstrated in the previous chapter.  
A study reported that hesperetin 30 µM had the greatest inhibitory effect when 
tested in MCF-7 cells and produced results similar to that of ko 143 10 µM but 
with far less toxicity(Cooray et al., 2004b).  Furthermore, hesperetin was able to 
modulate the action of BCRP in porcine cells PBMEC C1/2 cells at a 
concentration 1 µM and increase the intracellular accumulation of BCRP 
fluorescent substrate H33342 (Kaur and Badhan, 2017). 
 
When the apparent permeability of mitoxantrone was assessed in the PBMEC 
BBB model, the reported Papp AB was 1.59 x10-7 cm/s ± 3.5 x10-8 cm/s and Papp BA 
was 7.11 x10-7 cm/s ± 1.8 x10-8 cm/s (Figure 3.20). This suggests that 
mitoxantrone is a low permeability compound with a reported ER of 4.47. This is 
consistent with studies that reported the mitoxantrone was a low permeability 
compound with an Papp AB  of 0.49 x10-7  ± 0.3 x10-7 cm/s and  Papp BA = 1.04  x10-
8 ± 0.37 x10-8 cm/s with an efflux ratio of 2.19 assessed in Caco-2 cells (Li et al., 
2017). Furthermore, an ER of 2.65 was reported using MDCK canine cells, with 
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a reported Papp AB of 2.14   ×10−7 ± 0.81 ×10−7 cm/s and a Papp BA of 5.68  ×10−7 
± 0.86 ×10−7 cm/s   (An and Morris, 2010).  
 
When combining mitoxantrone with hesperetin, the reported AB flux increased by 
3.5-fold (Figure 3.21) and BA flux reduced by 1.5-fold in the presence of 
hesperetin, with a concomitant reduction in ER of 3.5-fold reduction (Figure 3.22) 
This is in accordance with a study that successfully utilised hesperetin amongst 
other flavonoids to enhance permeability of mitoxantrone in MCF-7 breast cancer 
cells (Zhang et al., 2004b). 
 
To summarise, we developed a primary PBMEC BBB in-vitro model which was 
validated as a model suitable for drug permeability studies by the recorded high 
TEER values, less than 1% LY leakage and the presence of tight junction protein 
ZO-1.  
 
Using this model, we were able to assess the ability of hesperetin to permeate 
across an in-vitro BBB model as well as its ability to modulate the efflux function 
of BCRP expressed in PBMECs and subsequently enhance the permeability of 
BCRP substrate anti-cancer agents methotrexate and mitoxantrone. combining 
hesperetin with methotrexate lead to a 2.7-fold increase in AB flux. More notably, 
combining hesperetin with mitoxantrone lead to a 3.5-fold increase in AB flux and 






To conclude, in this chapter hesperetin was used as a BCRP modulator in in-vitro 
PBMECs BBB model to enhance the permeability of BCRP substrate anti-cancer 
agents methotrexate and mitoxantrone. Our results demonstrated that hesperetin 
was able to permeate across an in-vitro BBB model, and was able to modulate 
the efflux action of BCRP and significantly increase the AB flux of both 
methotrexate and mitoxantrone and decrease the BA flux of mitoxantrone.  
Hesperetin is therefore a potentially viable candidate for use in further studies, in 
combination with BCRP substrate anti-cancer agents and may enhance 


































Chapter 4  
 
A dynamic perfusion-based in-vitro 


































This chapter has been published in the following manuscript: 
 
Elbakary, B. and R. K. S. Badhan (2020). "A dynamic perfusion based blood-
brain barrier model for cytotoxicity testing and drug permeation." Scientific 





The blood-brain barrier (BBB) represents a restrictive barrier for the delivery of 
therapeutic agents for a wide range of central nervous system (CNS) disorders.  
Penetration through the restrictive brain microvascular endothelial cell barrier is 
often hindered by the presence of a network of intra-cellular tight junction 
proteins, in addition to a network of membrane localised active transporter 
proteins and enzymatic metabolism processes. 
 
The development and maintenance of an appropriate restrictive in-vitro BBB 
model is critical when assessing the potential for small molecule transport.  
Despite the rise in the use of in-vivo models for assessing BBB structure and 
function, in-vitro models are still widely used and have been developed from a 
range of species.  However, a consensus on the most appropriate cellular system 
has still not been achieved, particularly in the context of assessing drug 
permeation and inherent barrier properties.  
 
For example, the human immortalised hCMEC/D3 cells, when grown in co-culture 
with astrocytes, yields low TEER values of approximately 140 Ω.cm2 (Hatherell 
et al., 2011) and those from primary endothelial cells from rodents yield TEER 
values of approximately 300 Ω.cm2 (Abbott et al., 2010). Higher TEER values 
have been obtained with stem cell-based systems (iPSC-derived endothelial 
cells) and neuronal progenitor cells, when exposed to chemical treatment to 
promote BBB formation, resulting in values of 3000-4000 Ω.cm2 (Lippmann et al., 
2015), however, these often require specialised and costly methods to culture.  
Although human brain tissue derived in-vitro BBB models are ideal for BBB 
studies, the lack of appropriate monolayer formation and reproducibility in-vitro 
has led to other cellular models being attractive options.  
 
The use of a porcine primary cell culture system, PBMEC, reporting high TEER 
without the need for co-culture with astrocytes, are a potentially viable high purity, 
high resistance and reproducible in-vitro blood brain barrier model (Cantrill et al., 




However, a critical feature of the BBB endothelium missing in many current in-
vitro models, is the exposure of cells to laminar shear stress. Shear stress is an 
indirect force caused by flow of blood across the surface of endothelial cells. This 
flow modulates upregulation/downregulation of genes, and that in turn impacts 
BBB characteristics and functions (Cucullo et al., 2011).  
 
When comparing gene analysis results from human brain microvascular 
endothelial cells (HBMEC) grown under static (traditional flask culture methods) 
and dynamic perfusion conditions (under constant media flow) have shown 
elevated RNA levels of tight junction proteins such as claudin-3, cadherins and 
zonula occludens-1 (ZO-1) under dynamic conditions (Schnittler, 1998). The 
importance of this response to shear stress is very evident in the structural 
integrity and tightness of the endothelial vascular bed. Endothelial cells cultured 
under flow formed a much tighter barrier (TEER » 700 W.cm2) in comparison to 
its static counterpart (TEER »100 W.Cm2). The ‘tightness’ of the barrier also 
affects its selectivity and consequently affects permeation of drug molecules 
(Cucullo et al., 2011). 
 
Brain endothelial cells are exposed to rapid blood perfusion (750 mL/min) to 
which they act in response by cellular re-alignment in the direction of the flow, 
rearrangement of cell fibres, in addition to functional remodelling (Ando and 
Yamamoto, 2009) and increased life span and proliferation (Cucullo et al., 2011, 
Di and Kerns, 2015). Further, there is an underrated mechanical stimulus that 
also affects endothelial cells in the brain, that stimulus is shear stress (Cucullo et 
al., 2011).  
 
Gene array analysis of key tight junction proteins showed that expression of 
proteins such as occludin, claudin-5 and cadherin-1 in flow models were 
upregulated compared to static models (Wong et al., 2013). Exposure to shear 
stress also increased the RNA expression levels of a range of ABC transporter 
proteins such as ABCB1, ABCC2, and ABCC5 (Doan et al., 2002) and CYPP450 
enzymes such as CYP1, CYP2 and CYP3 families (Dauchy et al., 2008a). 
Furthermore, shear stress also enhances response of pro-inflammatory stimuli 
by facilitating endothelial-leukocyte cross talk and T-lymphocyte migration by 
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upregulating expression levels of ICAM-1, VCAM-1 and PECAM-1 (Wong, 2007, 
Steiner et al., 2010).  Furthermore, shear stress stimulates the endothelial 
expression of ion channels and specialised transport systems such glucose 
transporter family (GLUT-1, GLUT-2, GLUT-3 and GLUT-5), Acetyl-CoA 
transporter (SLC33A1) and organic anions and cations transporters amongst 
many others (Cucullo et al., 2011). 
 
Modern dynamic cell culture in-vitro models can mimic the physiological 
interactions between tissues connected by bloodstream. These models have 
immense capabilities as they enable studies on specific organ-organ and tissue 
interactions. A range of approaches have been used to simulate shear stress 
across brain endothelial cells, from microfluidic systems (Wang et al., 2017, 
Brown et al., 2015) to hollow fibre constructs (Neuhaus et al., 2006). 
 
Recently, a novel cell culture flow-based chamber technology was developed and 
commercialised (Vozzi et al., 2008, Sbrana and Ahluwalia, 2012) this technology 
is called the QuasiVivoâ system (Kirstall, Sheffield, UK).  The QuasiVivoâ system 
utilises a flow model that is able to simulate blood flow between different cell 
culture chambers which represent tissues (Haycock, 2014). 
 
This novel perfusion cell culture system was designed to be used alongside 
permeable inserts (QV600 and QV900) often developed with in-vitro barrier 
models such as the lung (Chandorkar et al., 2017) and the  BBB (Elbakary and 
Badhan, 2020) and, for the first time, allowed direct modelling of the impact of 
perfusion on cell differentiation and barrier formation. The QV600 system allows 
for the application of various flow rates depending on the cell type which provides 
the cells with a constant nutrient return (Mazzei et al., 2010). The QV600 system 
consists of 1) PDSM chamber that is  15 mm in width and can hold up to 4 mL 
liquid, 2) connectors through which the chambers are linked, 3) a reservoir bottle 
that can hold up to 30 mL of media, 4) a peristaltic pump that can be housed in 
the incubator  (Figure 1.13). 
 
The advantages of using QV600 as opposed to other dynamic  in-vitro cell culture 
models are:  
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• Continuous use of media across all cell cultures  
• Easy to run and set up 
• Easy to clean (can be autoclave up to 3 times) 
• Steady level of liquid within the chamber- no risk of cells drying. 
 
 
The QV600 was successfully used in the development of in-vitro organ models. 
A 3D lung model to study fungal infection was developed using QV600. This study 
demonstrated that growing normal human bronchial cells NHBE under an air-
liquid interface (ALI) resulted in a significant increase in mucous production on 
day 7 in the perfusion model compared to day 21 under static conditions 
(Chandorkar et al., 2017).  
Furthermore, the QV600 system was used with epithelial Caco-2 cells. The 
results displayed an enhancement  of barrier integrity which was validated by an 
increase in the expression of tight junction protein ZO-1 as well as an increase in 
the reported TEER values 1800 Ω.cm2 after growing the cells under static 




 Aims and objectives 
 
The aim for this chapter was to assess the effect of shear stress on the in-vitro 
PBMEC BBB model cellular morphology and characteristics following the 
application of laminal flow using the QV600 system. 
 
In order to attain these aims, the objectives were to: 
• Create a blood brain barrier model using PBMEC grown in 24-well inserts 
for use in the QV600 chamber 
• Determine the optimal flow rate suitable for PBMEC growth   
• Examine the effect of shear stress on cell proliferation  
• Examine the effect of shear stress on TEER values  
• Examine the effect of shear stress on ZO-1 tight junction protein 
expression 
• Assess the permeability of mitoxantrone and hesperetin across the BBB 




 Materials:  
See section 3.3 for a list of materials. The Quasi Vivo® chamber, connectors and 
the peristaltic pump were obtained from Kirkstall (Rotherham, UK); all other 
chemicals were sourced from Sigma (Dorset, UK). 
Stock solutions of all test compounds were prepared in dimethyl sulfoxide 
(DMSO) and stored at -20°C until use. 
 
 Methods 
In order to examine the effect shear stress on the characteristics of an in-vitro 
BBB model, PBMEC were grown in permeable inserts and subjected to low and 








The PBMEC model was developed as described in Section 3.4.4. Here, we 
uitlised 24 well/0.33 cm2 permeable inserts (Greiner BioOne transparent 
ThinCerts® 24 well), a lower seeding density 3x104 cells/cm2 was used to 




To model dynamic perfusion of media within the cell culturing environment, the 
QV600 interconnected chamber system was utilised. This allows for the use of 
permeable inserts and coverslips within chambers. The QV600 consists of 
chambers, a media reservoir, a peristaltic pump and associated tubing 
connectors (Figure 4.1A). In order to utilise permeable inserts, the media level 
within each chamber was raised by increasing the height of the reservoir bottle 
by 5 cm with luer-locks sealing the upper chambers (Figure 4.1B). Prior to use, 
 
 159 
the QV600 system was sterilised by submerging in 70% v/v ethanol for 24 hours, 
followed by exposed to UV light for 6 hours and flushed for 1 hour with PBS 
supplemented with 1% v/v penicillin and streptomycin. 
 
Each peristaltic pump provided two independent channels, which were used with 
3 chambers each. To assess shear stress, we considered flow rates within a 
range of 0-600 µL/min (0-11.0 x10-6 Pa or 0-110 x10-6 dyne/cm2) or flow speed 
of 0-1.69 x10-6 m/s, with sheer stress (Pa) and flow speed (m/s) as described by 







Figure 4.1 Diagrammatical representation of the QuasiVivo® 600 
(A) The setup of the QV600 in the incubator showing peristatic pump, a raised 
reservoir bottle, two interconnected chambers were 24-well insets are fitted; (B) 
A schematic representation of the exposure to the raised coverslips to the flow 






Circular cover slips (13 mm) were coated with bovine collagen (50 µg/mL) and 
fibronectin (7.5 µg/mL) prior to seeding with 3 x104 cells (from passage 1) and 
grown in 24-well plates in PBMEC:ACM.  On day 3, coverslips were carefully 
transferred to QV600 chambers and raised by 10.5 mm using an inverted 
standing insert (Millicell, 12 mm insert) (Figure 4.1B), to match the height of the 
permeable insert membrane when seated within the QV600 chamber (Figure 
4.1A). 
 
Following optimisation of initial flow rates, cells were subjected to flow at 275 
µL/min and 550 µL/min for 48 hours. The choice of the flow rate was based on 
previous  findings that endothelial cells can withstand flow rates over 300 µL/min 
(Miranda-Azpiazu et al., 2018) 
 
Thereafter, cell morphology was assessed using light microscopy followed by 
assessment of tight junction formation through immunocytochemistry. Coverslips 
were washed with ice cold PBS three times and fixed in 4% w/v 
paraformaldehyde for 10 minutes. The coverslips were then washed three times 
with PBS and cells permeabilised using 0.02% w/v saponin for 10 minutes 
followed by a further cycle of washing in PBS three times. 
 
Cells were subsequently blocked with 6% v/v goat serum (Sigma, UK) for 5 hours, 
prior to incubation with the ZO-1 primary antibody (ZO-1 1A12 monoclonal) 
prepared in blocking buffer at a 1:100 dilution overnight at 4 °C. Thereafter, the 
coverslips were washed three times with ice cold PBS followed by the addition of 
the secondary antibody (0.5 µg/ml goat anti-mouse IgG H+L superclonal 
secondary Alexa 488®) for 2 hours at room temperature. The cells were then 
washed with ice cold PBS three times and mounted on a microscope slides using 
Fluoroshield (containing DAPI). Tight junction formation was subsequently 
assessed using an upright confocal microscope (Leica SP5 TCS II MP) and 
visualised with a 40× oil immersion objective. Images were acquired with an 





In order to assess the impact of shear stress on the viability of the cells, a 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was 
conducted using PBMEC grown on cover slips that were subjected to laminar 
flow for 48 hours (at an optimal flow rate determined previously) and under static 
conditions. Thereafter, the coverslips were placed in 24-well plates and washed 
once with pre-warmed PBS prior to being incubated with 0.5 mg/mL MTT for 4 
hours at 37 °C, 5% CO2. The resulting formazan crystals were dissolved in DMSO 
(100 µL/coverslip) for 15 minutes, before being transferred to a clear 96 well plate 
and with the UV-absorbance of the formazan crystals measured at 570 nm 
(Tecan Spark 10M®). 
 
 
PBMEC grown on 24-well permeable inserts intended for use in the QV600, were 
first seeded and grown on inserts under static conditions, within 24-well plates, 
and grown for 3 days prior to transfer into the QV600 chambers (n=20 inserts in 
total over 5 independent experiments). An acceptable monolayer formation under 
static and shear stress was determined using the TEER value (EVOM, World 
Precision Instruments, USA) and corrected for background resistance (coated 
inserts without cells) and by the surface area of the insert (0.33 cm2). TEER was 
assessed by transferring the inserts into 24-well plates for TEER measurement, 
before returning to the QV600 chambers. Furthermore, tight junction formation 





PBMECs were grown on permeable inserts and exposed to high flow (550 
µL/min) for 48 hours using the QV600.  Thereafter, inserts were removed and 
placed into a 24-well cell culture plate.  Mitoxantrone (50 µM) was prepared in 
serum free PBMEC media containing 25 mM HEPES and added to the apical (AB 
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flux) or basolateral (BA flux) compartments with sampling taking place from the 
opposite compartment, which contained serum free PBMEC media containing 25 
mM HEPES.   
 
Samples were taken at intervals between 15-90 minutes and replaced with equal 
amount fresh warm serum free PBMEC media containing 25 mM HEPES.  
Mitoxantrone concentrations were analysed using a fluorescent plate reader 
(Tecan Spark 10M®) at an excitation wavelength of 488 nm and emission 
wavelength of 670 nm. The apparent permeability (Papp) was calculated (Equation 




PBMECs were grown on permeable inserts and exposed to high flow (550 
µL/min) for 48 hours using the QV600.  Thereafter, inserts were removed and 
placed into a 24-well cell culture plate.  hesperetin (50 µM) was prepared in serum 
free PBMEC media containing 25 mM HEPES and added to the apical (AB flux) 
or basolateral (BA flux) compartments with sampling taking place from the 
opposite compartment, which contained serum free PBMEC media containing 25 
mM HEPES.   
 
The hesperetin transport assay and subsequent detection was detailed in 
Sections 3.4.6.1 and 3.6.8.2. 
 
 Statistical analysis 
 
All data is presented as mean ± standard deviation, with experiments being 
conducted in at least replicate independent experiment unless otherwise stated. 
Where appropriate, statistical analyses was performed in Graphpad Prism (La 
Jolla, California, USA), with t-tests used to determine differences between the 







In order to identify optimal sheer stress for use with PBMECs, coverslips were 
raised and exposed to low (275 µL/min) and high (550 µL/min) flow rates and 
compared to matching coverslips grown under static conditions and subsequently 
stained for ZO-1.  Under static conditions, limited cell-to-cell ZO-1 formation is 
evident (Figure 4.2).  When the flow rate was applied at low (275 µL/min) (Figure 
4.3) and high (550 µL/min) (Figure 4.4), cellular reorganisation was evident with 
the cell-to-cell ZO-1 protein formation.  However, the translocation of ZO-1 to the 










Figure 4.2 Immunocytochemistry images obtained following ZO-1 staining under static conditions on coverslips 
PBMEC grown on collagen (50 µg/mL) and fibronectin (7.5 µg/mL) coated coverslips under static conditions  Images were taken using 












Figure 4.3 Immunocytochemistry images obtained following ZO-1 staining following exposure to low flow rate on 
coverslips 
PBMECs grown on bovine collagen (50 µg/mL) and fibronectin (7.5 µg/mL) coated coverslips. PBMEC exposed to low flow (275 
µL/min) for 48 hours in the QV600 system. (A) for DAPI, (B) for ZO-1 and (C) for merged . Images were taken using a Leica SP5 TCS 
II MP confocal microscope. The white arrow indicates the direction of flow and the  yellow arrows indicate formation of tight junctions. 
 
  








Figure 4.4 Immunocytochemistry images obtained following ZO-1 staining following exposure to high flow rate on 
coverslips 
PBMECs grown on bovine collagen (50 µg/mL) and fibronectin (7.5 µg/mL) coated coverslips. PBMEC were exposed to  high flow 
(550 µL/min) for 48 hours using the QV600.  (A) for DAPI, (B) for ZO-1 and (C) for merged. Images were taken using a Leica SP5 
TCS II MP confocal microscope. The white arrow indicates the direction of flow and yellow arrows indicate formation of tight junctions.  
 
  





To assess the impact of shear stress on PBMEC cellular viability, high flow (550 
µL/min) was applied for 96 hours and cellular viability of PBMECs (grown on 
raised coverslips) was assessed using a MTT cellular viability assay. The 
presence of high flow for 4 days did not reduce the viability of PBMEC cells, with 




Figure 4.5 Cellular viability of PBMECs grown in static and dynamic 
conditions 
Cellular viability of PBMEC grown on coverslips under static media and dynamic 
high flow (550 µL/min) for 96 hours, using a MTT assay.  Dynamic results were 
normalised to the mean of the static results. n=9 coverslips in 3 independent 




To investigate the formation of a high resistance barrier, the TEER from 
monolayers of ‘60s’ grown on semi-permeable inserts (24-well, 0.33 cm2) were 




To assess whether shear stress is capable of inducing barrier formation, PBMEC 
were grown on semi-permeable inserts and subjected to flow at 550 µL/min, 
without the addition of any barrier forming additives. At 4 days post-seeding, 
inserts exposed to flow demonstrated a significantly higher TEER (35.7 Ω.cm2 ± 
5.1 Ω.cm2) compared by those maintained in static culture conditions (21 Ω.cm2 
± 1.5 Ω.cm2) (P ≤ 0.001), which was maintained through to day 7 post seeding 
(Figure 4.6A). 
 
To further assess the ability of shear stress to induce barrier formation, static and 
dynamic inserts were exposed to endothelial tight junction inducing agents on 
day 3 post seeding for 24 hours only. On day 4, TEER values significantly 
increased under both static media, to 306.3 Ω.cm2 ± 41.9 Ω.cm2, and dynamic 









Figure 4.6 TEER measurements under static and dynamic conditions 
TEER measured following growth of  PBMEC cells on permeable cell culture 
inserts (24-well, 0.33 cm2) under static and dynamic (550 µL/min) conditions.  
TEER of PBMEC were measured when grown on permeable inserts in the (A) 
absence and (B) presence of barrier forming additives.  * P ≤ 0.05, ** P ≤ 0.01, 








The expression of the tight junction protein ZO-1 was assessed using 
immunocytochemistry on semi-permeable inserts maintained in either static 
media or exposed to shear stress (550 µL/min).  In the absence (Figure 4.7) and 
presence (Figure 4.8 and 4.9) of shear stress, cellular labelling with ZO-1 
antibody demonstrated the ability of PBMECs to form tight junctions.  Under static 
conditions (Figure 4.7), the cellular morphology was indiscriminately organised 
with a discontinuous serrated pattern. However, under shear stress, linear 
realignment of the PBMECs was particularly visible following 24-hours (Figure 
4.8) and 48-hours (Figure 4.9) of shear stress exposure and was largely localised 










Figure 4.7 Immunocytochemistry images obtained following ZO-1 staining under static conditions in inserts 
Immunocytochemistry images obtained following PBMEC staining for (A) DAPI, (B) ZO-1 and (C) merged. PBMECs  were grown on 
permeable inserts under static media conditions. Images were taken using a Leica SP5 TCS II MP confocal microscope. The yellow 
arrows indicate disrupted tight junction. 
 







Figure 4.8 Immunocytochemistry images obtained following ZO-1 staining following exposure to high flow in inserts for 24 
hours 
Immunocytochemistry images obtained following PBMEC staining for (A) DAPI, (B) ZO-1 and (C) merged.  PBMECs  were grown on 
permeable inserts under high flow (550 µL/min) for 24 hours using the QV600.  Images were taken using a Leica SP5 TCS II MP 
confocal microscope. The white arrow indicates the direction of flow; and the yellow arrows indicate disrupted tight junction. 
 
  







Figure 4.9 Immunocytochemistry images obtained following ZO-1 staining following exposure to high flow in inserts for 48 
hours 
Immunocytochemistry images obtained following PBMEC staining for (A) DAPI, (B) ZO-1 and (C) merged. .  PBMECs were grown on 
permeable inserts under high flow  (550 µL/min) for 48 hours using the QV600.  Images were taken using a Leica SP5 TCS II MP 
confocal microscope. The white arrow indicates the direction of flow; and the yellow arrows indicate disrupted tight junction. 
 
 A                                                      B                                                        C  
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Furthermore, the ZO-1 junctional intensity was significantly higher following 48-
hours exposure to flow (1.52 ± 0.11 fold) than in static control (P ≤ 0.05). In 
addition, there was a statistically significant greater junctional intensity at 48-





Figure 4.10 ZO-1 junctional fluorescence intensity 
ZO-1 junctional fluorescence intensity as quantified by junctional regions and 





To demonstrate the functional impact of dynamic media flow on BBB properties, 
the permeability of the anti-cancer agent mitoxantrone was assessed across 
PBMECs grown on permeable inserts, in the absence (Figure 4.11A) and 




When compared to static conditions, the impact of shear stress resulted in a 
significant increase in the cumulative amount transported in the BA direction 
(Figure 4.11B) when compared to the AB direction (Figure 4.11A).  In the absence 
of flow, Papp AB was 0.84 x10-6 cm/s ± 0.16 x10-6 cm/s and Papp BA was 1.35 x10-6 
cm/s ± 0.23 x10-6 cm/s, resulting in an efflux ratio of 1.6.   
 
However, under the exposure of flow, there was a significant increase in efflux 
ratio to 3.6 with a significantly reduced Papp AB (0.48 x10-6 cm/s ± 0.09 x10-6 cm/s) 
(P ≤ 0.01) and significantly increased Papp BA (1.74 x10-6 cm/s ± 0.08 x10-6 cm/s) 







Figure 4.11 Mitoxantrone flux across PBMEC grown on permeable insets 
Mitoxantrone transport in apical-to-basolateral (AB) (circles) or basolateral-to-apical (BA) (squares) under (A) static media or (B) when 
exposed to high flow (550 µL/min) for 48 hours with associated apparent membrane permeability (Papp) values in the AB or BA 





To further confirm the ability of hesperetin to permeate across a physiologically 
relevant in-vitro BBB model, its permeability was assessed in the perfusion based 
PBMEC in-vitro model (Figure 4.12).  When compared to static conditions, the 
impact of shear stress resulted in an increase in the cumulative amount 
transported in the BA direction (Figure 4.12B) when compared to the AB direction 
(Figure 4.12A).  In the absence of flow, Papp AB was 4.67 x10-6 cm/s ± 1 x10-7 cm/s 
and Papp BA was 7.19 x10-6 cm/s ± 2 x10-7 cm/s, which resulted in an efflux ratio 
of 1.53.   
 
However, under the exposure of flow, there was a slight but insignificant increase 
in efflux ratio to 1.54 with increased Papp AB  of 4.89 x10-6 cm/s ± 1 x10-7 cm/s and 







   
 
 
Figure 4.12 Hesperetin flux across PBMEC grown on permeable inserts 
 
Hesperetin transport in apical-to-basolateral (AB) (circles) or basolateral-to-apical (BA) (squares) under (A) static media or (B) when 
exposed to high flow (550 µL/min) for 48 hours. with associated apparent membrane permeability (Papp) values in the AB or BA 


















































The development and maintenance of an in-vitro BBB model is critical when 
assessing the potential for small molecule transport, with the ability to form a 
coherent and robust barrier being paramount. Critical to the establishment of 
models, is the maintenance of appropriate in-vitro culturing conditions.  
A key component to the formation of the BBB in-vivo, is the presence of 
circumferential stress on the walls of the brain microvasculature, which plays an 
important role in the morphology and functional capacity of endothelial cells, 
along with governing signalling and transport processes within the neurovascular 
unit (Chien, 2007, Johnson et al., 2011, Conway and Schwartz, 2012, Krizanac-
Bengez et al., 2004, Cucullo et al., 2011). The average shear stress within the 
arterial circulation is 4–30 dyne cm2 and 1–4 dyne cm2 in the venous circulation 
(Wong et al., 2013). BBB models which have incorporated laminar shear stress 
have demonstrated the lowest permeability to sucrose and mannitol tracers, 
highlighting the critical role that laminar shear plays in stimulating a stable BBB 
phenotype (Santaguida et al., 2006, Stanness et al., 1997). 
Given the low TEER and complexity in culturing approaches, we adopted the use 
of a primary porcine brain microvascular endothelial cell culture system (PBMEC) 
reporting high TEER without the need for co-culture with astrocytes (Kaur and 
Badhan, 2017, Patabendige et al., 2013, Cantrill et al., 2012). 
 
We first aimed to assess the impact of shear stress on PBMEC when grown on 
coverslips and evaluated both changes in cellular morphology along with cellular 
viability. The location of the coverslip within the QV600 chamber is critical when 
assessing the impact of sheer stress on cellular viability, given that there is at 
least a 200 to 300-fold decrease in sheer stress when approaching the base of 
the chamber (Mazzei et al., 2010). Furthermore, the use of permeable inserts to 
develop a BBB monolayer places the cell layer within the vicinity of the chamber 
inlet/outlet (Wilkinson, 2017). To this end, PBMEC were seeded on coverslips 
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and raised to the equivalent height of the filter membrane of the permeable inserts 
(Figure 4.1B), prior to exposure to low (275 μL/min) and high (550 μL/min) flow 
rates.  
The impact of sheer stress on PBMECs morphology was evident at both low and 
high flow rates, with significant reorientation under flow in addition to improved 
clarity of cell-to-cell tight junction formation (Figure 4.3 and 4.4) when compared 
to cells grown under static conditions (Figure 4.2). 
Given that PBMEC have not been previously used within the QV system, the 
present study attempted to first identify an appropriate flow rate for use within 
PBMECs. Drawing on work conducted previously by Miranda-Azpiazu et al., we 
selected a flow rate of 550 μL/min to assess cellular viability. Miranda-Azpiazu et 
al. utilised a maximum flow rate of 300 μL/min and suggested higher flow rates 
are sustainable for endothelial cells within the same perfusion-based system we 
used. Furthermore, the flow rates chosen were within the range suggested to 
ensure laminar flow within the perfusion system (Mazzei et al., 2010). This would 
mimic the haemodynamic flow and forces within the broad linear regions of the 
endothelial structure as opposed to the branched regions where non-
linear/disturbed flow would be more apparent (Chiu and Chien, 2011). Given that 
morphological alterations were evident under both low and high flow rates (Figure 
4.3 and 4.4) we focussed upon the high flow rate (550 µL/min) for a comparison 
of cellular viability between static and dynamic conditions.  
This higher flow rate did not adversely affect cellular viability, but rather resulted 
in a 28.2 % increase (P = 0.031)  in viability when exposed for 4 days to high flow 
(Figure 4.5). The increase in viability reported herein was not to the same extent 
as those reported by Mazzei et al., > 50% increase, who utilised astrocytes 
cultured on coverslips and exposed to flow within the QV500 system without 
raising the height of the coverslips to achieve more representative shear stress 




Having established that higher flow rates can sustain the growth of PBMEC within 
the QV600 system, we next assessed the impact of sheer stress on barrier 
formulation when PBEMC were grown on permeable inserts. A benefit of the 
PBMEC system is the reproducible nature of the high TEER small vessels 
isolated from fresh porcine hemispheres (Patabendige et al., 2013, Cantrill et al., 
2012, Kaur and Badhan, 2017) which can reach in excess of 800 Ω.cm2 (in 1.1 
cm2, 12-well permeable inserts).  
In the absence of barrier forming additives, sheer stress resulted in a statistically 
significant (P < 0.05) increase in TEER throughout the study period of 7 days, 
when compared to inserts grown under static conditions (Figure 4.6A). A peak 
TEER of 35.7 Ω.cm2 ± 5.1 Ω.cm2 was determined when compared to that of static 
conditions, 21 Ω.cm2 ± 1.5 Ω.cm2 (P ≤ 0.001) highlighting the positive impact 
shear stress had on barrier formation, despite the absence of media 
supplementation.  
With the addition of supplementation, we noted a 12.8-fold increase in peak 
TEER under shear stress when compared to its absence, with TEER under shear 
stress significantly higher from day 5 onwards (Figure 4.6B). The peak TEER 
under flow, 448.1 Ω.cm
2 ± 11.3 Ω.cm
2
, is higher than those conducted in other 
cells lines (Daniels et al., 2013, Abbott, 2013, Lippmann et al., 2015). However, 
it should be noted that the QV600 accepts only 24-well multiplate inserts with a 
surface area of 0.33 cm
2
. PBMECs established in the previous chapter as well 
as by other groups typically utilise 12-well multiplate inserts (1.1 cm
2
) (Cantrill et 
al., 2012, Patabendige et al., 2013). 
In the QV600, the insert is used in such a way that the flow of media attempts to 
mimic human brain interstitial flow, reported to be <500 µL/min in human brain 
(Faghih and Sharp, 2018, Hladky and Barrand, 2014). The role of sheer stress 
under these conditions are difficult to conceptualise. However, it is known that 
shear stress can exert a mechanism strain and pressure effect on cells, impacting 
upon cell differentiation and growth (Gayer and Basson, 2009, Diresta et al., 
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2005, Sun et al., 2013). With flow in the basolateral side of the membrane , the 
porous nature of the membrane would allow this pressure differential, which 
would enhance both the transfer of small molecules such as oxygen and CO2 in 
addition to providing physical forces to the cell monolayer (Pörtner et al., 2005). 
This is critical as increased dissolved CO2 concentrations (Kimura, 1996, Gray et 
al., 1996) can reduce the intracellular pH and thereby affect cell metabolism 
(Madshus, 1988), in addition to high levels of dissolved CO2 reducing cellular 
growth rates (Pattison et al., 2000, Dezengotita et al., 1998). 
Furthermore, the increase in TEER may also be a direct result of the 
rearrangement of cellular morphology of the cells, which is commonplace and the 
defining feature of laminar flow within the vascular network. For example, within 
athlorsclerotic-prone regions of the endothelia, there is a strong correlation with 
the failure of endothelial cells to elongate and align (Davies et al., 1997, Davies, 
2009, Nerem, 1981, Flaherty et al., 1972, Wang et al., 2013). A similar increase 
in TEER was noted by others when using the QV600 to develop an in-vitro 
pulmonary model cultured on permeable inserts (Chandorkar et al., 2017).  
To examine morphological changes under flow, permeable inserts were 
subsequently assessed for the formation and localisation of tight junction protein 
marker ZO-1. Under static conditions, the localisation of ZO-1 was presented with 
a discontinuous pattern of formation (Figure 4.7). In the presence of shear stress, 
clear realignment of the cells was evident, with more pronounced TJ formation 
after 48-hours (Figure 4.9) rather than 24-hours (Figure 4.8) of exposure of shear 
stress. The fluorescent intensity of the junction protein expression was further 
assessed and demonstrated that 48 hours of exposure yielded statistically 
significant (P ≤ 0.05) higher levels of ZO-1 when compared to static PBMEC 
(Figure 4.10). Further, the solidity of the tight junctions was greater at 48-hours 
compared to 24-hours when compared to static conditions (P ≤ 0.05). Although 
the decrease in solidity at 24-hours, may be a result of realignment of junctional 
morphology (Figure 4.6). This increasing expression of tight junction markers has 
been previously demonstrated, albeit under higher shear stress in alternative 





In the scope of developing a BBB, the use of permeable inserts allows for the 
monitoring of monolayer formation and small molecular transport. To assess the 
impact of shear stress on these processes, we assess the permeation of the anti-
cancer agent mitoxantrone across PBMEC grown under static and shear stress-
exposed inserts. mitoxantrone undergoes active transport partly through ACBG2 
and ABCB1 (Ross et al., 1999, Morrow et al., 2006) and is classified as a low 
permeability compound (Volpe et al., 2008) 
Under static conditions, the resultant apparent permeability in the BA direction, 
when compared to the AB direction, (i.e. the efflux ratio) was 1.6-fold greater and 
statistically significant (P < 0.05) suggesting an active efflux process (Figure 
4.11A) However, in the presence of shear stress, this increased to 3.6-fold  
(Figure 4.11B) with a concomitant reduction in Papp AB suggesting a tighter barrier 
formation limiting mitoxantrone flux (Figure 4.11C). 
To further assess the impact of shear stress on the permeability of molecules, we 
assessed the permeability of hesperetin in this system. The changes noted in the 
absence and presence of shear stress were small but significant. A 4.7% 
decrease (** P ≤ 0.01) was recorded for A to B flux and 5.3% decrease (* P ≤ 
0.05) in B to A flux after exposure of the model to flow (Figure 4.12C).  
The insignificant changes obtained when assessing permeability of hesperetin in 
static and dynamic models may be due to the fact that hesperetin is a high 
permeability compound, and static PBMEC in-vitro blood brain barrier model 
produces a restrictive model and hence there wasn’t a significant change in flux 
or efflux. This further confirms the claim made in the previous chapter regarding 
the ability of hesperetin to permeate across the BBB since it was able to permeate 
across a more restrictive barrier formed as result of exposure to shear stress.  
To summarise, in the present study we applied the PBMEC model system 
(Patabendige et al., 2013) within the Kirkstall QuasiVivo® (Mazzei et al., 2010) 
interconnected chambers system QV600 (Figure 1.13) which can accommodate 
both cells grown on coverslips (13 mm diameter) and permeable inserts (24-well 
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plate, 13 mm diameter) in an attempt to determine whether the impact of localised 
perfusion on PBMECs would enhance barrier formation, as measured by the 
TEER (Patabendige et al., 2013, Nakagawa et al., 2007, Nakagawa et al., 
2009).The presence of hemodynamic shear stress is an important element within 
endothelial cells which is absent in cells cultured on inserts under static 
conditions and contributes to the polarisation of the brain endothelium structure 
as well as governing the expression and localisation of drug transporter systems 
(Björnmalm et al., 2016).  
The QV600 chambers are connected in series or parallel, with perfusion within 
all chambers from a central perfusion pump (Figure 4.1A). The key advantage is 
the rapid perfusion of media and oxygen transport. Whist the QuasiVivo® system 
has been used by other groups to assess the benefit of dynamic media flow within 
an interconnected system of chambers with different cell cultures (Miranda-
Azpiazu et al., 2018) its use with BBB cell types grown on permeable inserts has 
been limited, particularly with high TEER primary origin cell lines.  
Furthermore, whilst the use of human origin cells in microfluidic systems has 
gained traction, these remain a novel and niche research tool (Wang et al., 2017, 
Brown et al., 2015) which often fail to represent macroscale environments and 
make it difficult for research with established techniques, such as permeable 
insert barrier systems, to easily adopt such systems (Cucullo et al., 2011). 
 
 Conclusion 
To conclude, for the first time we have demonstrated the impact of the novel 
application of sheer stress to an easy to isolate, cost-effective and highly 
reproducible TEER BBB model derived from porcine brain micro- vascular 
endothelial cells (PBMEC) when grown on routinely utilised permeable inserts 
culturing system. The use of this well-established culturing approach provides an 
ability to incorporate, with ease, BBB in-vitro models into the commercially 
available QuasiVivo® perfusion system platform without the necessary 
complications of other perfusion-based systems, such as microfluidic platforms. 
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Microfluidic systems have gained some traction but still remain a niche research 
tool for perfusion based cell culture systems, given that the vast majority of 
research groups working on barrier models are still using permeable-inserts such 
as Transwell® systems (Ohshima et al., 2019, Bayir et al., 2019, Zhao et al., 
2019a, Puech et al., 2018, Oda et al., 2018) for assessment of the impact of 
perfusion on the functional activity of barrier due to commercial availability, high-
throughput potential and ease of use. Several well documented challenges and 
limitations have been reported with micro- fluidics systems, for example the lack 
of standardised parameters and critical experiment factors such as: (i) the use of 
an appropriate shear stress; (ii) defining an appropriate TEER cut-off for 
monolayer formation, which are typically low (<250 Ω.cm2) (Tang et al., 2018, 
Deosarkar et al., 2015) and (iii) appropriate application of paracellular 
permeability markers (Gastfriend et al., 2018, Helms et al., 2016, Musafargani et 
al., 2020). 
These limitations make comparison to well established BBB models such as, 
permeable insert models challenging. Further, the well cited scalability issues and 
specialised microfluidics fabrication equipment severely limit the use and 
validation of such models across the wider scientific community (Musafargani et 
al., 2020) In comparison, the proposed model system we implemented is 
commercially available and well validated, utilising existing and well-established 
permeable insert systems for barrier formation. Further, using a simplistic 
PBMEC system from porcine hemispheres, we were able to demonstrate 
significantly higher TEER in traditional inserts in addition to enhanced TEER 
using a commercially available perfusion system, with the benefits of being 
reproducible and requiring little technical knowledge when compared to 
microfluidic systems.  
The novelty herein is the fact that we have, for the first time, highlighted the 
application of the easy to isolate and cost-effective PBMEC BBB model within the 
QuasiVivo® system, which for the first time demonstrated a resultant impact on 
TEER and BBB phenotype enhancement. Further, we demonstrated higher 
TEER values in the absence or presence of perfusion, when compared to other 
microfluidic systems employing rodent or human derived BBB models, alongside 
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further demonstrated the functional consequence of shear stress on small-
molecule transport. Our results highlight an apparent change in both cellular 
morphology and enhanced barrier formation, providing a valuable research tool 
to assess both the neurotoxicity of molecules at the BBB but also their 







Chapter 5  
 




 Conclusion  
 
The overall aim of this work was to enhance permeability and drug delivery of 
anti-cancer agents into brain tumours by modulating the action of BCRP at the 
BBB and the BTB using phytochemical modulators, in addition to assessing the 
anti-cancer proprieties of phytochemicals as possible adjunct therapy with 
routinely used anti-cancer agents. 
 
The theory behind the order of the work presented within this thesis was to 
commence from the tumour site and progress towards the BBB. This was based 
on previous studies conducted by our group demonstrating that some 
phytochemicals are permeable across the BBB. Our goal was to screen 
phytocompounds for their anti-cancer proprieties and their ability to modulate 
BCRP expressed in the GMB in-vitro cell culture model LN229 cells, before 
examining their permeability through the BBB and their ability to modulate BCRP 
in the BBB and hence enhance the permeability of BCRP substrate anti-cancer 
drugs. 
 
In Chapter 2, a total of 13 modulators were assessed and screened, for the first 
time,  for their cytotoxicity and ability to modulate the efflux function of BCRP, in 
addition to their ability to reduce LN229 cellular migration and their effects on the 
expression of BCRP in LN229 cells. Based on the results obtained, two 
candidates were selected for further investigation, namely hesperetin and 
baicalin. Further studies assessed their ability to activate apoptosis through ROS 
production and the activation of caspase pathways, with both methotrexate and 
temozolomide used as reference compounds.  
 
Our findings highlighted that both hesperetin and baicalin were able to increase 
ROS production and activate caspase -3/7 in addition to their ability to modulate 
BCRP efflux function.  Furthermore, we demonstrated the action of hesperetin in 
downregulating the expression of BCRP in LN229 cells.  
 
Based on the findings we observed in the second chapter, we selected hesperetin 
for further testing using the primary PBMECs in-vitro BBB model. In Chapter 3, 
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we were able to develop an in-vitro BBB model using PBMECs.  This model 
possessed BBB characteristics comparable to published studies and achieved 
comparable TEER values along with the presence of ZO-1 tight junction proteins 
and F-actin expression. We demonstrated, for the first time, the ability of 
hesperetin to permeate across the PBMEC BBB model in addition to the 
permeability of methotrexate and mitoxantrone. Further, the impact of hesperetin 
in modulating BCRP at the BBB was demonstrated by an increase in both 
methotrexate and mitoxantrone Papp AB flux and reduced Papp BA flux when studied 
in combination with hesperetin.  
 
In order to provide more evidence on the ability of hesperetin to permeate across 
the BBB, in Chapter 4 we developed a more realistic perfusion based PBMEC in-
vitro BBB model which was determined to be a more restrictive model, displaying 
better BBB characteristics when compared to BBB models grown in static 
conditions. The impact of shear stress on the PBMEC in-vitro BBB model was 
assessed where, the cells responded to the flow by rearranging and changing in 
morphology. In addition, higher TEER values were recorded, and ZO-1 was 
formed with fewer interruptions which indicates the formation of a more restrictive 
model. Next, we assessed the permeability of hesperetin and mitoxantrone 
across the perfusion-based model compared to a static counterpart. In these 
studies, hesperetin demonstrated higher permeabilities when compared to those 
reported under static conditions, however, the permeability of mitoxantrone was 
significantly reduced.  
 
Limitations of this study were (I) using porcine cells instead of human cells to 
create a BBB model and (II) differences in transporter expression due to 
homologic differences between pigs and humans. This might become a 
hindrance when extrapolating the data obtained for human pharmacokinetics 
studies. That said, primary human brain cells are difficult to obtain and 
characterise, in addition, commercially available human cell lines express low 
TEER values (<250 Ω.cm2) and wouldn’t have been suitable for small molecule 
drug transport studies. Moreover, similar to human brain endothelial cells, BCRP 
in PBMECs was reported to be the most abundant efflux transporter. (III) some 
of the anti-cancer compounds and phytochemicals that were used might interact 
 
 190 
with other efflux transporters expressed in the cells that we utilised mainly P-gp. 
Nevertheless, in both PBMECs and LN229 cells, BCRP is more abundantly 
expressed than p-gp, therefore, the compounds used were likely to interact with 
BCRP over p-gp. However, in future studies using a P-gp modulator such as 
verapamil should be taken in consideration to ensure that any compounds used 
would only interact with BCRP. (IV) utilising a 2D cancer cell line. Using patient 
derived primary tumour cells in a 3D culture would have been a better 
representation of human in-vitro solid tumours. Still, using 2D cell lines remain a 
necessary preliminary step for screening of novel compounds before proceeding 
to using patient derived tumour cells and 3D culture as these more technically 
challenging and time consuming to optimise.  
 
To summarise, this thesis has identified hesperetin as being a viable candidate 
phytochemical agent which possess both pro-oxidant properties towards LN229 
human glioblastoma cells, in addition to being capable of inhibiting BCRP. It 
therefore represents a viable dual-purpose candidate for further studies to assess 






 Future work 
 
Whilst we examined some flavonoids, future work should examine other groups 
of flavonoids, more specifically phenolic acids and stilbenes for their modulatory 
effect on BCRP as well as P-gp and MRP-1 which were reported to be expressed 
in LN229 cells and their effect on cell migration and apoptosis. Further, evaluating 
the potential of using two or more flavonoids in combination, would allow for 
multiple avenues to explore such as the ability to modulate a range of drug 
transporter proteins and their resultant synergistic and/or antagonistic effects 




In Chapter 3, we explored the role of the ECM in enhancing barrier formation.  
This should further explore the impact and causes of bovine-specific ECM on in-
vitro cell growth and characteristics. However, due to the commercial 
unavailability of medical grade porcine collagen, a method could be devised to 
extract porcine collagen from porcine skin, in a similar fashion to that routinely 
conducted for rat tail collagen, in order to better assess its effect on BBB model 
formation Additionally, assessing the permeability of other flavonoids that 
displaying optimal anti-cancer properties and BCRP inhibitory effects in LN229 
cells. 
 
Moreover, throughout our cell culture models, we did not consider co-culturing 
with LN229 cells.  Future work should examine combining an in-vitro glioblastoma 
model with the already established PBMEC BBB in-vitro model to examine the 
effect the tumour cells may have on the integrity of the BBB model, and to assess 
the resulting impact on drug permeability across both the BBB and BTB. 
Furthermore, applying shear stress to the in-vitro glioblastoma model alone and 
in combination with the established in-vitro BBB perfusion model would allow an 
opportunity to study the effect of the tumour  formation and progression under an 
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